<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call January 28, 2026 8:00 AM EST<br><br>Company Participants<br><br>Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence<br>Richard Francis - President, CEO & Director<br>Eric Hughes - Executive VP of Global R&D and Chief Medical Officer<br>Eliyahu Kalif - Executive VP & CFO<br><br>Conference Call Participants<br><br>David Amsellem - Piper Sandler & Co., Research Division<br>Louise Chen - Scotiabank Global Banking and Markets, Research Division<br>Ashwani Verma - UBS Investment Bank, Research Division<br>Jason Gerberry - BofA Securities, Research Division<br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Umer Raffat - Evercore ISI Institutional Equities, Research Division<br>Leszek Sulewski - Truist Securities, Inc., Research Division<br>Yuchen Ding - Jefferies LLC, Research Division<br><br>Presentation<br><br>Operator<br><br>Hello, and welcome to the Teva Pharmaceuticals Industries Limited Q4 2025 Earnings Conference Call.</td><td>í…Œë°” íŒŒë§ˆìˆ˜í‹°ì»¬ ì¸ë”ìŠ¤íŠ¸ë¦¬ìŠ¤ ë¦¬ë¯¸í‹°ë“œ (TEVA) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 1ì›” 28ì¼ ì˜¤ì „ 8ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>í¬ë¦¬ìŠ¤í† í¼ ìŠ¤í…Œë³´ - íˆ¬ìì ê´€ê³„ ë° ê²½ìŸ ì¸í…”ë¦¬ì „ìŠ¤ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br>ë¦¬ì²˜ë“œ í”„ë€ì‹œìŠ¤ - ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br>ì—ë¦­ íœ´ì¦ˆ - ê¸€ë¡œë²Œ R&D ë‹´ë‹¹ ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³  ì˜ë£Œ ì±…ì„ì<br>ì—˜ë¦¬ì•¼í›„ ì¹¼ë¦¬í”„ - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ê°€ì<br><br>ë°ì´ë¹„ë“œ ì•”ì…€ë ˜ - íŒŒì´í¼ ìƒŒë“¤ëŸ¬ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë£¨ì´ì¦ˆ ì²¸ - ìŠ¤ì½”ìƒ¤ë±…í¬ ê¸€ë¡œë²Œ ë±…í‚¹ ì•¤ ë§ˆì¼“ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì•„ìŠˆì™€ë‹ˆ ë² ë¥´ë§ˆ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œì´ìŠ¨ ê±°ë² ë¦¬ - ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì‹œíë¦¬í‹°ì¦ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í¬ë¦¬ìŠ¤í† í¼ ì‡¼íŠ¸ - JPëª¨ê±´ ì²´ì´ìŠ¤ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìš°ë¨¸ ë¼íŒŒíŠ¸ - ì—ë²„ì½”ì–´ ISI ì¸ìŠ¤í‹°íŠœì…”ë„ ì—í€´í‹°ì¦ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë ˆì„¹ ìˆ ë ˆí”„ìŠ¤í‚¤ - íŠ¸ë£¨ì´ìŠ¤íŠ¸ ì‹œíë¦¬í‹°ì¦ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìœ ì²¸ ë”© - ì œí”„ë¦¬ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, í…Œë°” íŒŒë§ˆìˆ˜í‹°ì»¬ ì¸ë”ìŠ¤íŠ¸ë¦¬ìŠ¤ ë¦¬ë¯¸í‹°ë“œ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>My name is Alex, and I'll be coordinating today's call. [Operator Instructions] I'll now hand over to Chris Stevo, SVP, Investor Relations. Please go ahead. Christopher Stevo<br>Senior Vice President of Investor Relations & Competitive Intelligence<br><br>Thank you, Alex. Good morning, and good afternoon, everyone. Thank you for joining us on our fourth quarter call. Before I turn it over to our CEO, Richard Francis, I just want to remind everyone that we will be making forward-looking statements on this call. Any statements we make are only as of today, and we undertake no obligation to update those statements subsequently.</td><td>ì œ ì´ë¦„ì€ Alexì´ë©°, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­] ì´ì œ Chris Stevo íˆ¬ììê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ë¶€ì‚¬ì¥ë‹˜ê»˜ ì§„í–‰ì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ë§ì”€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>Christopher Stevo<br>íˆ¬ììê´€ê³„ ë° ê²½ìŸë ¥ ë¶„ì„ ë‹´ë‹¹ ìˆ˜ì„ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Alex. ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì—¬ëŸ¬ë¶„. 4ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. Richard Francis ëŒ€í‘œì´ì‚¬ë‹˜ê»˜ ì§„í–‰ì„ ë„˜ê¸°ê¸° ì „ì—, ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì„ í•˜ê²Œ ë  ê²ƒì„ì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤. ì €í¬ê°€ í•˜ëŠ” ëª¨ë“  ì§„ìˆ ì€ ì˜¤ëŠ˜ ê¸°ì¤€ì´ë©°, ì´í›„ í•´ë‹¹ ì§„ìˆ ë“¤ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ëŠ” ì—†ìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>And if you have any questions about our forward-looking statements, feel free to see the appropriate sections in our SEC Forms 10-K and 10-Q. With that, Richard Francis. Richard Francis<br>President, CEO & Director<br><br>Thank you, Chris. Good morning, good afternoon, everybody. Great to have you on the call. Also on the call with me today will be Dr. Eric Hughes, Head of R&D and Chief Medical Officer, who will be walking you through some exciting developments in our pipeline. And then Eli Kalif, my CFO, who will go through the Q4 and the full year results. So starting with, as I always do, the Pivot to Growth strategy and the progress we've made over the last 3 years.</td><td>ê·¸ë¦¬ê³  ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— ëŒ€í•´ ê¶ê¸ˆí•˜ì‹  ì ì´ ìˆìœ¼ì‹œë©´, SEC Form 10-K ë° 10-Qì˜ í•´ë‹¹ ì„¹ì…˜ì„ ì°¸ì¡°í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ëŸ¼ ë¦¬ì²˜ë“œ í”„ëœì‹œìŠ¤ ì‚¬ì¥ë‹˜ê»˜ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ë¦¬ì²˜ë“œ í”„ëœì‹œìŠ¤<br>ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br><br>í¬ë¦¬ìŠ¤, ê°ì‚¬í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„, ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤, ì¢‹ì€ ì˜¤í›„ì…ë‹ˆë‹¤. ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ ì—ë¦­ íœ´ì¦ˆ ë°•ì‚¬ë‹˜ì´ ì°¸ì„í•˜ì…¨ìŠµë‹ˆë‹¤. ì—°êµ¬ê°œë°œ ì±…ì„ìì´ì ìµœê³ ì˜ë£Œì±…ì„ìë¡œì„œ ì €í¬ íŒŒì´í”„ë¼ì¸ì˜ í¥ë¯¸ë¡œìš´ ê°œë°œ í˜„í™©ì„ ì„¤ëª…í•´ ì£¼ì‹¤ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¼ë¼ì´ ì¹¼ë¦¬í”„ CFOê°€ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì„ ì„¤ëª…ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ì œê°€ í•­ìƒ ê·¸ë ‡ë“¯ì´, ì„±ì¥ìœ¼ë¡œì˜ ì „í™˜(Pivot to Growth) ì „ëµê³¼ ì§€ë‚œ 3ë…„ê°„ ì´ë£¬ ì„±ê³¼ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As you know, the foundation is the 4 pillars: deliver on our growth engines, I think you'll see in the results that we continue to have great momentum around our innovative portfolio of AUSTEDO, UZEDY and AJOVY and some great progress on our innovation, so step-up innovation. You'll see that we filed olanzapine last year, completed the recruitment of the DARI study, dual-action rescue inhaler and started our Phase III study for duvakitug in UC and CD. And then sustained generics powerhouse, good progress. Our aim is to get this business back to stability, and we have done that. And now we see some exciting growth emerging from our biosimilars portfolio, and I'll talk a bit about that.</td><td>ì•„ì‹œë‹¤ì‹œí”¼, ê¸°ë°˜ì€ 4ê°€ì§€ í•µì‹¬ ì¶•ì…ë‹ˆë‹¤: ì„±ì¥ ì—”ì§„ ì‹¤í˜„, ì‹¤ì ì—ì„œ ë³´ì‹œê² ì§€ë§Œ AUSTEDO, UZEDY, AJOVY ë“± í˜ì‹ ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ê³„ì†í•´ì„œ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, í˜ì‹  ë¶€ë¬¸ì—ì„œë„ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì‘ë…„ì— ì˜¬ë€ìí•€ì„ ì‹ ì²­í–ˆê³ , DARI ì—°êµ¬(ì´ì¤‘ì‘ìš© êµ¬ê¸‰ í¡ì…ê¸°) ì„ìƒì‹œí—˜ ëª¨ì§‘ì„ ì™„ë£Œí–ˆìœ¼ë©°, ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼(UC)ê³¼ í¬ë¡ ë³‘(CD)ì— ëŒ€í•œ duvakitugì˜ 3ìƒ ì„ìƒì‹œí—˜ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ì† ê°€ëŠ¥í•œ ì œë„¤ë¦­ ì‚¬ì—… ë¶€ë¬¸ì—ì„œë„ ì¢‹ì€ ì§„ì „ì´ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ëª©í‘œëŠ” ì´ ì‚¬ì—…ì„ ì•ˆì •í™”ì‹œí‚¤ëŠ” ê²ƒì´ì—ˆê³ , ê·¸ê²ƒì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ì œ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ í¥ë¯¸ë¡œìš´ ì„±ì¥ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìœ¼ë©°, ì´ì— ëŒ€í•´ ì¢€ ë” ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And then focus the business. This is all about making sure we allocate capital to the correct areas to give the best return. And we'll walk you through a bit of the progress we've had on our transformation program, which is the aim is to have $700 million of net savings by 2027. We made excellent progress in '25, and we're on track to hit the 2/3 by the end of this year 2026. So now moving on to the actual results. So I'm pleased with these results. Now just to orientate you on this slide, the numbers on the left include the Sanofi milestones and the numbers on the right do not. So starting with the revenues. So a 5% increase in revenues at $17.3 billion. EBITDA grew 12% up to $5.3 billion.</td><td>ê·¸ë¦¬ê³  ì‚¬ì—…ì— ì§‘ì¤‘í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìµœê³ ì˜ ìˆ˜ìµì„ ì°½ì¶œí•˜ê¸° ìœ„í•´ ì˜¬ë°”ë¥¸ ì˜ì—­ì— ìë³¸ì„ ë°°ë¶„í•˜ëŠ” ê²ƒì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. 2027ë…„ê¹Œì§€ ìˆœ ì ˆê°ì•¡ 7ì–µ ë‹¬ëŸ¬ë¥¼ ëª©í‘œë¡œ í•˜ëŠ” êµ¬ì¡°ì¡°ì • í”„ë¡œê·¸ë¨ì˜ ì§„í–‰ ìƒí™©ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 2025ë…„ì— íƒì›”í•œ ì§„ì „ì„ ì´ë£¨ì—ˆìœ¼ë©°, ì˜¬í•´ 2026ë…„ ë§ê¹Œì§€ ëª©í‘œì˜ 3ë¶„ì˜ 2ë¥¼ ë‹¬ì„±í•  ê¶¤ë„ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ ì‹¤ì œ ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ì‹¤ì ì— ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ìŠ¬ë¼ì´ë“œë¥¼ ì„¤ëª…ë“œë¦¬ìë©´, ì™¼ìª½ì˜ ìˆ˜ì¹˜ëŠ” ì‚¬ë…¸í”¼ ë§ˆì¼ìŠ¤í†¤ì„ í¬í•¨í•˜ê³  ì˜¤ë¥¸ìª½ ìˆ˜ì¹˜ëŠ” í¬í•¨í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§¤ì¶œë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ë§¤ì¶œì€ 5% ì¦ê°€í•œ 173ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. EBITDAëŠ” 12% ì„±ì¥í•˜ì—¬ 53ì–µ ë‹¬ëŸ¬ì— ë‹¬í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>EPS grew 19% to $2.93 and free cash flow was up 16% to $2.4 billion. And our net debt to EBITDA is now at 2.5x, which is, as you know, our goal for 2027 is to 2x. So we're well on our way to do that. Now a slide that I've shown over the last 12 quarters actually, to show that our return to growth, which was our strategy, part of the Pivot to Growth strategy when we launched it in 2023. And as you see, we've consecutively done this. And we did that in Q4, where the growth was up 11%. Now that did include the milestone from Sanofi. If you take that away, we were slightly down at 1%. But let's look at it over a 3-year period.</td><td>EPSëŠ” 19% ì¦ê°€í•œ 2.93ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆê³ , ì‰ì—¬í˜„ê¸ˆíë¦„ì€ 16% ì¦ê°€í•œ 24ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìˆœë¶€ì±„ ëŒ€ EBITDA ë¹„ìœ¨ì€ í˜„ì¬ 2.5ë°° ìˆ˜ì¤€ì¸ë°, ì•„ì‹œë‹¤ì‹œí”¼ 2027ë…„ ëª©í‘œê°€ 2ë°°ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê·¸ ëª©í‘œë¥¼ í–¥í•´ ìˆœì¡°ë¡­ê²Œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì œê°€ ì§€ë‚œ 12ë¶„ê¸° ë™ì•ˆ ê³„ì† ë³´ì—¬ë“œë¦° ìŠ¬ë¼ì´ë“œì…ë‹ˆë‹¤. ì´ëŠ” 2023ë…„ Pivot to Growth ì „ëµì„ ì‹œì‘í•  ë•Œ ì „ëµì˜ ì¼ë¶€ì˜€ë˜ ì„±ì¥ íšŒë³µì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ëŠ” ì´ë¥¼ ì—°ì†ì ìœ¼ë¡œ ë‹¬ì„±í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  4ë¶„ê¸°ì—ë„ 11% ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ì´ë¥¼ ì´ì–´ê°”ìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì´ëŠ” ì‚¬ë…¸í”¼ë¡œë¶€í„°ì˜ ë§ˆì¼ìŠ¤í†¤ì´ í¬í•¨ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ë¥¼ ì œì™¸í•˜ë©´ 1% ì†Œí­ ê°ì†Œí–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 3ë…„ ê¸°ê°„ìœ¼ë¡œ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So over a 3-year period, these are impressive results, once again, reminding you that we had multiple years of sales decline. And so in 2023, we actually grew the business 4%, in '24, 11% and then last year, 2%. So we're well on track for our CAGR of mid-single digit, as you can see from the slide there. Now let's get into a bit of detail as to what's driving these good results. So on the next slide, you'll see the innovative performance is one of the key areas of growth for us. And AUSTEDO, UZEDY and AJOVY hit $3.1 billion for the year. This is up about 35%. So excellent results there.</td><td>3ë…„ ë™ì•ˆ ì´ëŸ¬í•œ ì¸ìƒì ì¸ ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ ìš°ë¦¬ëŠ” ì—¬ëŸ¬ í•´ ë™ì•ˆ ë§¤ì¶œ ê°ì†Œë¥¼ ê²ªì—ˆìŠµë‹ˆë‹¤. 2023ë…„ì—ëŠ” ì‹¤ì œë¡œ ì‚¬ì—…ì´ 4% ì„±ì¥í–ˆê³ , 2024ë…„ì—ëŠ” 11%, ê·¸ë¦¬ê³  ì‘ë…„ì—ëŠ” 2% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìŠ¬ë¼ì´ë“œì—ì„œ ë³´ì‹œëŠ” ë°”ì™€ ê°™ì´ ìš°ë¦¬ëŠ” ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ëŒ€ì˜ ì—°í‰ê·  ì„±ì¥ë¥ (CAGR) ëª©í‘œë¥¼ ìˆœì¡°ë¡­ê²Œ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì´ëŸ¬í•œ ì¢‹ì€ ì‹¤ì ì„ ê²¬ì¸í•˜ëŠ” ìš”ì¸ë“¤ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ë‹¤ìŒ ìŠ¬ë¼ì´ë“œì—ì„œ ë³´ì‹œë©´, í˜ì‹ ì ì¸ ì„±ê³¼ê°€ ìš°ë¦¬ì˜ í•µì‹¬ ì„±ì¥ ì˜ì—­ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. AUSTEDO, UZEDY, AJOVYê°€ ì—°ê°„ 31ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•½ 35% ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë§¤ìš° ìš°ìˆ˜í•œ ì‹¤ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And I'm really pleased to tell you that in Q4, we surpassed $1 billion for our innovative portfolio that you see on the screen here. But in a bit more detail, AUSTEDO grew at 34% at $2.26 billion. UZEDY was up 63% at $191 million, and AJOVY continues to perform, was up 30% at $673 million. Our generics business was flat, worth noting this excludes Japan from these numbers. Now I've talked a lot about moving from a pure-play generics company to a biopharma company. I think these results show we clearly have done that. And now it's a question of just how much we can keep driving this innovative portfolio and the pipeline that comes through. Now moving on to a bit more detail.</td><td>ê·¸ë¦¬ê³  4ë¶„ê¸°ì— ì—¬ê¸° í™”ë©´ì— ë³´ì´ëŠ” í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ê°€ 10ì–µ ë‹¬ëŸ¬ë¥¼ ëŒíŒŒí–ˆë‹¤ëŠ” ì†Œì‹ì„ ì „í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ë©´, AUSTEDOëŠ” ì „ë…„ ëŒ€ë¹„ 34% ì„±ì¥í•˜ì—¬ 22ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. UZEDYëŠ” 63% ì¦ê°€í•œ 1ì–µ 9,100ë§Œ ë‹¬ëŸ¬, AJOVYëŠ” ì§€ì†ì ìœ¼ë¡œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ë©° 30% ì¦ê°€í•œ 6ì–µ 7,300ë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì œë„¤ë¦­ ì‚¬ì—…ë¶€ëŠ” ë³´í•©ì„¸ë¥¼ ìœ ì§€í–ˆëŠ”ë°, ì´ ìˆ˜ì¹˜ì—ëŠ” ì¼ë³¸ì´ ì œì™¸ë˜ì–´ ìˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤. ì €ëŠ” ìˆœìˆ˜ ì œë„¤ë¦­ ê¸°ì—…ì—ì„œ ë°”ì´ì˜¤íŒŒë§ˆ ê¸°ì—…ìœ¼ë¡œì˜ ì „í™˜ì— ëŒ€í•´ ë§ì´ ë§ì”€ë“œë ¤ ì™”ìŠµë‹ˆë‹¤. ì´ë²ˆ ì‹¤ì ì€ ìš°ë¦¬ê°€ ë¶„ëª…íˆ ê·¸ ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŒì„ ë³´ì—¬ì¤€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ì œëŠ” ì´ í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ì™€ íŒŒì´í”„ë¼ì¸ì„ ì–¼ë§ˆë‚˜ ë” ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆëŠëƒì˜ ë¬¸ì œì…ë‹ˆë‹¤. ì´ì œ ì¢€ ë” ìƒì„¸í•œ ë‚´ìš©ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I wanted to talk to you a bit about AUSTEDO. So AUSTEDO had a really strong quarter in quarter 4, as you can see, $725 million, up 40% for the quarter. And for the full year, $2.2 billion, up 35%. And this was delivered with good underlying growth. As you can see, TRx is 10%, and there's a 19% rise in milligram volume. This is driven by both new patients and better adherence. It's worth noting that AUSTEDO XR now accounts for 60% of new patients. Now -- very impressive results here. Now we did have in Q4, these numbers did reflect some year-end inventory stocking and some favorable gross to net. And Eli will talk a bit more detail about that.</td><td>AUSTEDOì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. AUSTEDOëŠ” 4ë¶„ê¸°ì— ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ 7ì–µ 2,500ë§Œ ë‹¬ëŸ¬ë¡œ ì „ ë¶„ê¸° ëŒ€ë¹„ 40% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—°ê°„ìœ¼ë¡œëŠ” 22ì–µ ë‹¬ëŸ¬ë¡œ 35% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê²¬ê³ í•œ ê¸°ì € ì„±ì¥ìœ¼ë¡œ ë‹¬ì„±ë˜ì—ˆìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ì´ ì²˜ë°©ê±´ìˆ˜(TRx)ëŠ” 10% ì¦ê°€í–ˆê³ , ë°€ë¦¬ê·¸ë¨ ë³¼ë¥¨ì€ 19% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹ ê·œ í™˜ì ì¦ê°€ì™€ ë³µì•½ ìˆœì‘ë„ ê°œì„  ëª¨ë‘ì— ì˜í•´ ê²¬ì¸ë˜ì—ˆìŠµë‹ˆë‹¤. ì£¼ëª©í•  ë§Œí•œ ì ì€ AUSTEDO XRì´ í˜„ì¬ ì‹ ê·œ í™˜ìì˜ 60%ë¥¼ ì°¨ì§€í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë§¤ìš° ì¸ìƒì ì¸ ê²°ê³¼ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” ì´ëŸ¬í•œ ìˆ˜ì¹˜ì— ì¼ë¶€ ì—°ë§ ì¬ê³  í™•ë³´(inventory stocking)ì™€ ìœ ë¦¬í•œ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œ(gross to net) íš¨ê³¼ê°€ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” Eliê°€ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>But if you actually take that out, then we still grew at 20% in Q4. So once again, the underlying growth of this product is very strong. And because of that, we're giving the guidance of $2.4 billion to $2.55 billion for 2025 (sic) [ 2026 ]. I think it's worth noting that if we do hit the upper end of that, then that means we've hit the $2.5 billion a year ahead of schedule. But we'll talk in a bit more detail of the puts and takes to that range. Now moving on to UZEDY. UZEDY also had another strong quarter, $55 million, up 28% and for the full year, up an impressive 63% to $191 million. TRx volume grew an impressive 123% year-over-year.</td><td>í•˜ì§€ë§Œ ê·¸ ë¶€ë¶„ì„ ì œì™¸í•˜ë©´, 4ë¶„ê¸°ì—ë„ ì—¬ì „íˆ 20% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ ì œí’ˆì˜ ê¸°ì € ì„±ì¥ì„¸ëŠ” ë§¤ìš° ê°•ë ¥í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì´ìœ ë¡œ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ 24ì–µ ë‹¬ëŸ¬ì—ì„œ 25ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ë¡œ ì œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§Œì•½ ê°€ì´ë˜ìŠ¤ ìƒë‹¨ì„ ë‹¬ì„±í•œë‹¤ë©´, ì´ëŠ” 25ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆì •ë³´ë‹¤ 1ë…„ ì•ë‹¹ê²¨ ë‹¬ì„±í•˜ëŠ” ê²ƒì´ë¼ëŠ” ì ì„ ì£¼ëª©í•  í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. ì´ ë²”ìœ„ì— ëŒ€í•œ ê¸ì •ì  ìš”ì¸ê³¼ ë¶€ì •ì  ìš”ì¸ì— ëŒ€í•´ì„œëŠ” ì¡°ê¸ˆ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ì´ì œ UZEDYë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. UZEDY ì—­ì‹œ ë˜ í•œ ë²ˆ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. 5,500ë§Œ ë‹¬ëŸ¬ë¡œ 28% ì¦ê°€í–ˆìœ¼ë©°, ì—°ê°„ìœ¼ë¡œëŠ” 63%ë¼ëŠ” ì¸ìƒì ì¸ ì„±ì¥ë¥ ì„ ë³´ì´ë©° 1ì–µ 9,100ë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ ì²˜ë°© ê±´ìˆ˜ëŠ” ì „ë…„ ëŒ€ë¹„ 123%ë¼ëŠ” ë†€ë¼ìš´ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And it's worth noting that more than 83% of the NBRx generated -- was generated by patients transitioning from oral therapies or treatment naive, which confirms that UZEDY is expanding the long-acting injectable market, not just taking share. Now another impressive fact on UZEDY is it's the fastest-growing long-acting injectable in its category. And because of this momentum, our guidance reflects this. And as you see, we have a guidance of $250 million to $280 million for 2026. Now moving on to AJOVY. AJOVY had a strong quarter as well, up 43% year-on-year at $211 million. And for the full year, it's $673 million, up 30%.</td><td>ê·¸ë¦¬ê³  ì£¼ëª©í•  ë§Œí•œ ì ì€ ì‹ ê·œ ì²˜ë°©(NBRx)ì˜ 83% ì´ìƒì´ ê²½êµ¬ ì¹˜ë£Œì œì—ì„œ ì „í™˜í•˜ê±°ë‚˜ ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ìë“¤ë¡œë¶€í„° ë°œìƒí–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” UZEDYê°€ ë‹¨ìˆœíˆ ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì ¸ê°€ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì§€ì†í˜• ì£¼ì‚¬ì œ ì‹œì¥ ìì²´ë¥¼ í™•ëŒ€í•˜ê³  ìˆìŒì„ í™•ì¸ì‹œì¼œ ì¤ë‹ˆë‹¤. UZEDYì˜ ë˜ ë‹¤ë¥¸ ì¸ìƒì ì¸ ì‚¬ì‹¤ì€ í•´ë‹¹ ì¹´í…Œê³ ë¦¬ì—ì„œ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ê³  ìˆëŠ” ì§€ì†í˜• ì£¼ì‚¬ì œë¼ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë©˜í…€ìœ¼ë¡œ ì¸í•´ ìš°ë¦¬ì˜ ê°€ì´ë˜ìŠ¤ì—ë„ ì´ê²ƒì´ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ 2026ë…„ ê°€ì´ë˜ìŠ¤ëŠ” 2ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ 8ì²œë§Œ ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ì´ì œ AJOVYë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. AJOVY ì—­ì‹œ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ê¸°ë¡í–ˆìœ¼ë©°, ì „ë…„ ëŒ€ë¹„ 43% ì¦ê°€í•œ 2ì–µ 1,100ë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” 6ì–µ 7,300ë§Œ ë‹¬ëŸ¬ë¡œ 30% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So once again, for a product that's fairly mature, really strong growth. AJOVY continues to be #1 preventative anti-CGRP injectable in the top U.S. headache centers, and it leads in 30 markets across Europe and international. And this continued growth is driven by, I think, our commercial excellence, our ability to continue to take market share to manage the pricing and the payer environment in the U.S. and to continue to expand in new geographies. And because of this strength, we're giving a guidance of $750 million to $790 million. Now moving on to the pipeline.</td><td>ìƒë‹¹íˆ ì„±ìˆ™í•œ ì œí’ˆì„ì—ë„ ë¶ˆêµ¬í•˜ê³  ë‹¤ì‹œ í•œë²ˆ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. AJOVYëŠ” ë¯¸êµ­ ì£¼ìš” ë‘í†µ ì„¼í„°ì—ì„œ 1ìœ„ ì˜ˆë°©ìš© í•­-CGRP ì£¼ì‚¬ì œë¡œ ìë¦¬ë§¤ê¹€í•˜ê³  ìˆìœ¼ë©°, ìœ ëŸ½ê³¼ í•´ì™¸ 30ê°œ ì‹œì¥ì—ì„œ ì„ ë‘ë¥¼ ë‹¬ë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì§€ì†ì ì¸ ì„±ì¥ì€ ìš°ìˆ˜í•œ ìƒì—…ì  ì—­ëŸ‰, ì§€ì†ì ì¸ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ ëŠ¥ë ¥, ë¯¸êµ­ ë‚´ ê°€ê²© ë° ë³´í—˜ì‚¬ í™˜ê²½ ê´€ë¦¬ ëŠ¥ë ¥, ê·¸ë¦¬ê³  ì‹ ê·œ ì§€ì—­ìœ¼ë¡œì˜ ì§€ì†ì ì¸ í™•ì¥ì— ê¸°ì¸í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ì ì„ ë°”íƒ•ìœ¼ë¡œ 7ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 7ì–µ 9ì²œë§Œ ë‹¬ëŸ¬ì˜ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ íŒŒì´í”„ë¼ì¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So we talked about the products we have in the market and the excellent progress we made on those, but the pipeline is really exciting here. And I do want to mention this, even though I know Eric will talk a bit about it. The things I always remind people about this slide is every product we're going to launch has a potential of over $1 billion. The size of the markets we're entering into are significant and our entry points into these markets are in the short term. And if you look at the total, the total of the portfolio can be over $10 billion of peak sales.</td><td>ì €í¬ê°€ ì‹œì¥ì— ë‚´ë†“ì€ ì œí’ˆë“¤ê³¼ ê·¸ ì œí’ˆë“¤ì—ì„œ ê±°ë‘” íƒì›”í•œ ì„±ê³¼ì— ëŒ€í•´ ë§ì”€ë“œë ¸ì§€ë§Œ, íŒŒì´í”„ë¼ì¸ì´ ì •ë§ í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. Ericì´ ì´ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦´ ì˜ˆì •ì´ì§€ë§Œ, ì €ëŠ” ì´ ì ì„ ê¼­ ì–¸ê¸‰í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì œê°€ ì´ ìŠ¬ë¼ì´ë“œì— ëŒ€í•´ í•­ìƒ ì‚¬ëŒë“¤ì—ê²Œ ìƒê¸°ì‹œí‚¤ëŠ” ê²ƒì€ ì €í¬ê°€ ì¶œì‹œí•  ëª¨ë“  ì œí’ˆì´ 10ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì €í¬ê°€ ì§„ì…í•˜ê³  ìˆëŠ” ì‹œì¥ì˜ ê·œëª¨ëŠ” ìƒë‹¹í•˜ë©°, ì´ëŸ¬í•œ ì‹œì¥ìœ¼ë¡œì˜ ì§„ì… ì‹œì ì€ ë‹¨ê¸°ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì´í•©ì„ ë³´ì‹œë©´, ìµœê³  ë§¤ì¶œ ê¸°ì¤€ìœ¼ë¡œ 100ì–µ ë‹¬ëŸ¬ ì´ìƒì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>There's an addition to this slide that some of you may not have seen, which is we will be announcing 2 new indications for duvakitug later this year, once again, highlighting that is a pipeline in a product. Now moving on to our generics business. Our generics business, our aim was to get this back to stability, and we've done that. And the generics business was flat in 2025 versus 2024. Now one of the things that I do always highlight is you need to look at the generics business over a multiyear period because of the fact that some years, you have more launches than others. That's just part of the business. And as you see here, our 2-year CAGR is 6%. But for 2025, the U.S.</td><td>ì´ ìŠ¬ë¼ì´ë“œì— ì¶”ê°€ëœ ë‚´ìš©ì´ ìˆëŠ”ë°, ì—¬ëŸ¬ë¶„ ì¤‘ ì¼ë¶€ëŠ” ë³´ì§€ ëª»í•˜ì…¨ì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë§ì— ë“€ë°”í‚¤íˆ­(duvakitug)ì— ëŒ€í•œ 2ê°œì˜ ìƒˆë¡œìš´ ì ì‘ì¦ì„ ë°œí‘œí•  ì˜ˆì •ì´ë©°, ì´ëŠ” ë‹¤ì‹œ í•œë²ˆ ì´ê²ƒì´ í•˜ë‚˜ì˜ ì œí’ˆ ì•ˆì— íŒŒì´í”„ë¼ì¸ì´ ìˆë‹¤ëŠ” ê²ƒì„ ê°•ì¡°í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ì œ ì œë„¤ë¦­ ì‚¬ì—…ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì œë„¤ë¦­ ì‚¬ì—…ì˜ ëª©í‘œëŠ” ì•ˆì •ì„±ì„ íšŒë³µí•˜ëŠ” ê²ƒì´ì—ˆê³ , ìš°ë¦¬ëŠ” ê·¸ê²ƒì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì œë„¤ë¦­ ì‚¬ì—…ì€ 2024ë…„ ëŒ€ë¹„ 2025ë…„ì— ë³´í•©ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì œê°€ í•­ìƒ ê°•ì¡°í•˜ëŠ” ì  ì¤‘ í•˜ë‚˜ëŠ” ì œë„¤ë¦­ ì‚¬ì—…ì„ ë‹¤ë…„ê°„ì˜ ê¸°ê°„ì— ê±¸ì³ ì‚´í´ë´ì•¼ í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì–´ë–¤ í•´ì—ëŠ” ë‹¤ë¥¸ í•´ë³´ë‹¤ ë” ë§ì€ ì‹ ì œí’ˆ ì¶œì‹œê°€ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ê²ƒì€ ì‚¬ì—…ì˜ ì¼ë¶€ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ ë³´ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ì˜ 2ê°œë…„ ì—°í‰ê·  ì„±ì¥ë¥ (CAGR)ì€ 6%ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ 2025ë…„ ë¯¸êµ­ ì‹œì¥ì˜ ê²½ìš°...</td></tr>
<tr><td>grew at 2%, international markets, 1% and Europe declined 2%. Now we continue to see good performance from our biosimilars business, and I think I'll move on to that now to talk you through that. And where we started with biosimilars over the last 3 years, we've made tremendous progress. It's worth noting that we now have 10 assets in the market globally, and we're going to launch 6 additional between now and the end of 2027. Then we have another 10 assets that are going to start launching from '28 and beyond. So some impressive numbers here. So the aim was to build a world-leading portfolio, and we've done that.</td><td>2% ì„±ì¥í–ˆê³ , êµ­ì œ ì‹œì¥ì€ 1%, ìœ ëŸ½ì€ 2% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì‚¬ì—…ì—ì„œëŠ” ê³„ì†í•´ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, ì´ì œ ê·¸ ë¶€ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§€ë‚œ 3ë…„ê°„ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ë¶„ì•¼ì—ì„œ ìš°ë¦¬ëŠ” ì—„ì²­ë‚œ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ 10ê°œì˜ ìì‚°ì„ ì‹œì¥ì— ì¶œì‹œí–ˆë‹¤ëŠ” ì ì„ ì£¼ëª©í•  í•„ìš”ê°€ ìˆìœ¼ë©°, ì§€ê¸ˆë¶€í„° 2027ë…„ ë§ê¹Œì§€ 6ê°œë¥¼ ì¶”ê°€ë¡œ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  2028ë…„ ì´í›„ë¶€í„° ì¶œì‹œë¥¼ ì‹œì‘í•  10ê°œì˜ ìì‚°ì´ ë” ìˆìŠµë‹ˆë‹¤. ìƒë‹¹íˆ ì¸ìƒì ì¸ ìˆ˜ì¹˜ë“¤ì…ë‹ˆë‹¤. ìš°ë¦¬ì˜ ëª©í‘œëŠ” ì„¸ê³„ ìµœê³  ìˆ˜ì¤€ì˜ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í•˜ëŠ” ê²ƒì´ì—ˆê³ , ìš°ë¦¬ëŠ” ê·¸ê²ƒì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In fact, I think we have the second largest portfolio of biosimilars now in the industry, and we've launched the most biosimilars since 2020. And because of this, we're well on track to grow our biosimilars business by $400 million by 2027. Now to close out, as you've seen by some of the numbers we've talked about, we're well on track to hit our 2027 guidance. The CAGR, I talked about, we currently stand at 6%. The operating margin will go into a bit more detail, but with the success of our innovative portfolio, we're very confident about 30%. Net debt to EBITDA at 2x, we're already at 2.5x and cash to earnings is 80%, Eli will walk you through a bit more detail on that.</td><td>ì‹¤ì œë¡œ ì €í¬ëŠ” í˜„ì¬ ì—…ê³„ì—ì„œ ë‘ ë²ˆì§¸ë¡œ í° ë°”ì´ì˜¤ì‹œë°€ëŸ¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, 2020ë…„ ì´í›„ ê°€ì¥ ë§ì€ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ë¥¼ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ 2027ë…„ê¹Œì§€ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì‚¬ì—…ì„ 4ì–µ ë‹¬ëŸ¬ ì„±ì¥ì‹œí‚¬ ê³„íšì„ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë§ˆë¬´ë¦¬í•˜ë©´ì„œ ë§ì”€ë“œë¦¬ìë©´, ì•ì„œ ì–¸ê¸‰í•œ ìˆ˜ì¹˜ë“¤ì—ì„œ ë³´ì…¨ë“¯ì´ ì €í¬ëŠ” 2027ë…„ ê°€ì´ë˜ìŠ¤ ë‹¬ì„±ì„ ìœ„í•´ ìˆœì¡°ë¡­ê²Œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦° ì—°í‰ê·  ì„±ì¥ë¥ (CAGR)ì€ í˜„ì¬ 6%ì…ë‹ˆë‹¤. ì˜ì—…ì´ìµë¥ ì— ëŒ€í•´ì„œëŠ” ì¢€ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦¬ê² ì§€ë§Œ, í˜ì‹ ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì„±ê³µìœ¼ë¡œ 30% ë‹¬ì„±ì„ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìˆœë¶€ì±„ ëŒ€ë¹„ EBITDA ë¹„ìœ¨ì€ 2ë°°ë¥¼ ëª©í‘œë¡œ í•˜ê³  ìˆìœ¼ë©°, í˜„ì¬ 2.5ë°° ìˆ˜ì¤€ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜„ê¸ˆ ëŒ€ë¹„ ì´ìµ ë¹„ìœ¨ì€ 80%ì¸ë°, ì´ì— ëŒ€í•´ì„œëŠ” Eliê°€ ì¢€ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦´ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>But with that, I'll hand you over to Eric to talk about our exciting pipeline. Eric Hughes<br>Executive VP of Global R&D and Chief Medical Officer<br><br>Thank you, Richard. Starting with the slide that Richard went over briefly. One of the things about this pipeline is there's 3 Phase III programs and 2 burgeoning Phase II programs. And the market potential is big, like Richard mentioned. But more importantly, it's the unmet medical need that we take pride in and what we're potentially going to address. And finally, I'd like to say that we planned over 5 years for submissions. So we're very proud of the fact that we've turned around this innovative pipeline and moved it forward so quickly.</td><td>í•˜ì§€ë§Œ ì´ì œ Ericì—ê²Œ ë„˜ê²¨ì„œ ì €í¬ì˜ í¥ë¯¸ì§„ì§„í•œ íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>Eric Hughes<br>ê¸€ë¡œë²Œ R&D ë¶€ë¬¸ ë¶€ì‚¬ì¥ ê²¸ ìµœê³ ì˜ë£Œì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Richard. Richardê°€ ê°„ëµíˆ ì„¤ëª…í•œ ìŠ¬ë¼ì´ë“œë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì´ íŒŒì´í”„ë¼ì¸ì˜ íŠ¹ì§• ì¤‘ í•˜ë‚˜ëŠ” 3ê°œì˜ 3ìƒ í”„ë¡œê·¸ë¨ê³¼ 2ê°œì˜ ì„±ì¥í•˜ê³  ìˆëŠ” 2ìƒ í”„ë¡œê·¸ë¨ì´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Richardê°€ ì–¸ê¸‰í•œ ê²ƒì²˜ëŸ¼ ì‹œì¥ ì ì¬ë ¥ì´ í½ë‹ˆë‹¤. í•˜ì§€ë§Œ ë” ì¤‘ìš”í•œ ê²ƒì€, ì €í¬ê°€ ìë¶€ì‹¬ì„ ê°–ê³  ìˆê³  ì ì¬ì ìœ¼ë¡œ í•´ê²°í•˜ê³ ì í•˜ëŠ” ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì €í¬ëŠ” 5ë…„ ì´ìƒì— ê±¸ì³ ì œì¶œì„ ê³„íší–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ê°€ ì´ í˜ì‹ ì ì¸ íŒŒì´í”„ë¼ì¸ì„ ì „í™˜í•˜ê³  ì´ë ‡ê²Œ ë¹ ë¥´ê²Œ ì§„ì „ì‹œí‚¨ ê²ƒì— ëŒ€í•´ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>But I first want to highlight olanzapine LAI. We got the submission in on December 9, and we're looking forward to the EU submission in the second quarter of this year. We've shown that this olanzapine LAI that can address an unmet medical need in schizophrenia has great safety and efficacy, and we want to discuss that with the health authorities and hopefully get that approval at the end of this year. So something very exciting to look forward to. Next, on our DARI program, our dual-action rescue inhaler, we're very proud of the fact that we finished the targeted enrollment of this study at the end of 2025.</td><td>ë¨¼ì € ì˜¬ë€ìí•€ LAIì— ëŒ€í•´ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. 12ì›” 9ì¼ì— ì œì¶œì„ ì™„ë£Œí–ˆìœ¼ë©°, ì˜¬í•´ 2ë¶„ê¸° ì¤‘ EU ì œì¶œì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°í˜„ë³‘ì˜ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•  ìˆ˜ ìˆëŠ” ì´ ì˜¬ë€ìí•€ LAIê°€ ìš°ìˆ˜í•œ ì•ˆì „ì„±ê³¼ ìœ íš¨ì„±ì„ ë³´ì—¬ì£¼ì—ˆìœ¼ë©°, ë³´ê±´ ë‹¹êµ­ê³¼ ì´ì— ëŒ€í•´ ë…¼ì˜í•˜ì—¬ ì˜¬í•´ ë§ ìŠ¹ì¸ì„ ë°›ê¸°ë¥¼ í¬ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ê¸°ëŒ€ë˜ëŠ” ì¼ì…ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, ì´ì¤‘ì‘ìš© êµ¬ê¸‰ í¡ì…ì œì¸ DARI í”„ë¡œê·¸ë¨ì— ëŒ€í•´ì„œëŠ”, 2025ë…„ ë§ì— ì´ ì—°êµ¬ì˜ ëª©í‘œ ë“±ë¡ì„ ì™„ë£Œí•œ ê²ƒì„ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And in fact, we're going to continue enrolling it to accelerate the back end of the study. And the most important thing about that enrollment, one of the things that's most difficult is the fact it has pediatrics, adolescents and adult patients. So I think that the opportunity here for a differentiated product of a dry powder inhaler and the fact that we have the potential to have adolescents and pediatrics in the label is a true differentiator for this program, addressing a large unmet medical need in asthma. And then moving on to duvakitug, a very exciting brand-new biologic class that's in development.</td><td>ì‚¬ì‹¤ ìš°ë¦¬ëŠ” ì„ìƒì‹œí—˜ í›„ë°˜ë¶€ë¥¼ ê°€ì†í™”í•˜ê¸° ìœ„í•´ ê³„ì†í•´ì„œ í™˜ì ë“±ë¡ì„ ì§„í–‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ í™˜ì ë“±ë¡ì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ ì  ì¤‘ í•˜ë‚˜ëŠ”, ê°€ì¥ ì–´ë ¤ìš´ ë¶€ë¶„ì´ê¸°ë„ í•œë°, ì†Œì•„, ì²­ì†Œë…„ ë° ì„±ì¸ í™˜ìë¥¼ ëª¨ë‘ í¬í•¨í•œë‹¤ëŠ” ì‚¬ì‹¤ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê±´ì¡°ë¶„ë§í¡ì…ê¸°ë¼ëŠ” ì°¨ë³„í™”ëœ ì œí’ˆì˜ ê¸°íšŒì™€ í•¨ê»˜ ì œí’ˆ ë¼ë²¨ì— ì²­ì†Œë…„ ë° ì†Œì•„ ì ì‘ì¦ì„ í¬í•¨í•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì€ ì´ í”„ë¡œê·¸ë¨ì˜ ì§„ì •í•œ ì°¨ë³„í™” ìš”ì†Œì´ë©°, ì²œì‹ ë¶„ì•¼ì˜ í° ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì–´ì„œ ë‘ë°”í‚¤íˆ­(duvakitug)ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ê°œë°œ ì¤‘ì¸ ë§¤ìš° í¥ë¯¸ë¡œìš´ ì™„ì „íˆ ìƒˆë¡œìš´ ìƒë¬¼í•™ì  ì œì œ ê³„ì—´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>A year ago, we showed really exciting Phase II data in both ulcerative colitis and Crohn's disease, posting very good numbers in both with a nice dose response. But now we're excited to be looking forward to the maintenance data in the first half of this year. And the important thing about the maintenance data is that we will show hopefully the durability of response. And that's really what people need in ulcerative colitis and Crohn's disease. These are chronic diseases that people frequently fail on their advanced therapies and need more. So durability in the long term is most important.</td><td>1ë…„ ì „, ìš°ë¦¬ëŠ” ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ê³¼ í¬ë¡ ë³‘ ëª¨ë‘ì—ì„œ ë§¤ìš° ê³ ë¬´ì ì¸ 2ìƒ ì„ìƒ ë°ì´í„°ë¥¼ ë°œí‘œí–ˆìœ¼ë©°, ë‘ ì§ˆí™˜ ëª¨ë‘ì—ì„œ ìš°ìˆ˜í•œ ìˆ˜ì¹˜ì™€ í•¨ê»˜ ì–‘í˜¸í•œ ìš©ëŸ‰ ë°˜ì‘ì„ ë³´ì—¬ë“œë ¸ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì œ ìš°ë¦¬ëŠ” ì˜¬í•´ ìƒë°˜ê¸°ì— ë‚˜ì˜¬ ìœ ì§€ìš”ë²• ë°ì´í„°ë¥¼ ê¸°ëŒ€í•˜ë©° ì•ì„ ë°”ë¼ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìœ ì§€ìš”ë²• ë°ì´í„°ì˜ ì¤‘ìš”í•œ ì ì€ ë°˜ì‘ì˜ ì§€ì†ì„±ì„ ë³´ì—¬ì¤„ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ê³¼ í¬ë¡ ë³‘ í™˜ìë“¤ì—ê²Œ ì •ë§ í•„ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. ì´ë“¤ì€ ë§Œì„± ì§ˆí™˜ìœ¼ë¡œ, í™˜ìë“¤ì´ ê¸°ì¡´ì˜ ì§„ë³´ëœ ì¹˜ë£Œë²•ì—ì„œ ìì£¼ ì‹¤íŒ¨í•˜ê³  ë” ë§ì€ ì¹˜ë£Œ ì˜µì…˜ì„ í•„ìš”ë¡œ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì¥ê¸°ì ì¸ ì§€ì†ì„±ì´ ê°€ì¥ ì¤‘ìš”í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And just a review, this represents 58 weeks of exposure, looking at 2 different doses given subcutaneously every 4 weeks. And Richard also mentioned that we started our Phase III programs with our partner, Sanofi, the SUNSCAPE and STARSCAPE, started right on time, and we're accelerating those programs and executing very well, and we'll be looking forward to new indications this year. And then moving on to anti-IL-15. We had a very exciting announcement at JPMorgan that Royalty Pharma provided funding for our program in vitiligo for a Phase II/III program.</td><td>ê·¸ë¦¬ê³  ê°„ë‹¨íˆ ê²€í† í•˜ìë©´, ì´ëŠ” 4ì£¼ë§ˆë‹¤ í”¼í•˜ íˆ¬ì—¬ë˜ëŠ” 2ê°€ì§€ ìš©ëŸ‰ì„ ì‚´í´ë³¸ 58ì£¼ê°„ì˜ ë…¸ì¶œ ë°ì´í„°ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Richardê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì €í¬ëŠ” íŒŒíŠ¸ë„ˆì‚¬ì¸ Sanofiì™€ í•¨ê»˜ Phase III í”„ë¡œê·¸ë¨ì¸ SUNSCAPEì™€ STARSCAPEë¥¼ ì •ì‹œì— ì‹œì‘í–ˆìœ¼ë©°, ì´ëŸ¬í•œ í”„ë¡œê·¸ë¨ë“¤ì„ ê°€ì†í™”í•˜ê³  ë§¤ìš° ì˜ ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ìƒˆë¡œìš´ ì ì‘ì¦ë“¤ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  anti-IL-15ë¡œ ë„˜ì–´ê°€ë©´, JPMorgan ì»¨í¼ëŸ°ìŠ¤ì—ì„œ Royalty Pharmaê°€ ë°±ë°˜ì¦(vitiligo) Phase II/III í”„ë¡œê·¸ë¨ì— ìê¸ˆì„ ì œê³µí•œë‹¤ëŠ” ë§¤ìš° í¥ë¯¸ë¡œìš´ ë°œí‘œê°€ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is really great external validation of our program, what we will -- what we believe is a very differentiated product to address a number of unmet medical needs. First, in vitiligo, this is something that systemic therapies are needed for, and that results will be available in the first half of this year. But also celiac disease, we're running our second proof-of-concept study with a biopsy endpoint that will be available in the second half of this year. But in addition to that, alopecia areata, atopic dermatitis and eosinophilic esophagitis are all possible targets for this very important cytokine. And then on to emrusolmin.</td><td>ì´ëŠ” ìš°ë¦¬ í”„ë¡œê·¸ë¨ì— ëŒ€í•œ ë§¤ìš° í›Œë¥­í•œ ì™¸ë¶€ ê²€ì¦ì´ë©°, ìš°ë¦¬ê°€ ë¯¿ê¸°ë¡œëŠ” ì—¬ëŸ¬ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•  ìˆ˜ ìˆëŠ” ë§¤ìš° ì°¨ë³„í™”ëœ ì œí’ˆì…ë‹ˆë‹¤. ì²«ì§¸, ë°±ë°˜ì¦ì˜ ê²½ìš°, ì „ì‹  ì¹˜ë£Œì œê°€ í•„ìš”í•œ ì§ˆí™˜ì´ë©°, ì˜¬í•´ ìƒë°˜ê¸°ì— ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. ë˜í•œ ì…€ë¦¬ì•…ë³‘ì˜ ê²½ìš°, ìƒê²€ í‰ê°€ë³€ìˆ˜ë¥¼ ì‚¬ìš©í•œ ë‘ ë²ˆì§¸ ê°œë…ì¦ëª… ì—°êµ¬ë¥¼ ì§„í–‰ ì¤‘ì´ë©° ì˜¬í•´ í•˜ë°˜ê¸°ì— ê²°ê³¼ê°€ ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. ì´ ì™¸ì—ë„ ì›í˜• íƒˆëª¨ì¦, ì•„í† í”¼ í”¼ë¶€ì—¼, í˜¸ì‚°êµ¬ì„± ì‹ë„ì—¼ ëª¨ë‘ ì´ ë§¤ìš° ì¤‘ìš”í•œ ì‚¬ì´í† ì¹´ì¸ì˜ ê°€ëŠ¥í•œ ì ì‘ì¦ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì— ë£¨ì†”ë¯¼ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>One of the things I've been very impressed with is the rate at which we've been enrolling this study. This is a Phase II study looking at critical endpoints of an important unmet medical need. I always like to remind people the mean survival in this disease after diagnosis is 6 to 10 years. So this is a very important unmet medical need. We are working hard to make sure that this study not only enrolls quickly, but we will over-enroll to make sure that this Phase II program is as pristine as powerful as possible, really potentially capitalizing on the ability to accelerate this approval. And before I get on to my last slide, I just wanted to do a shout out for the AJOVY team at Teva.</td><td>ì œê°€ ë§¤ìš° ì¸ìƒ ê¹Šê²Œ ë³¸ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ì´ ì„ìƒì‹œí—˜ì˜ í™˜ì ë“±ë¡ ì†ë„ì…ë‹ˆë‹¤. ì´ê²ƒì€ ì¤‘ìš”í•œ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ì˜ í•µì‹¬ í‰ê°€ë³€ìˆ˜ë¥¼ ì‚´í´ë³´ëŠ” 2ìƒ ì„ìƒì‹œí—˜ì…ë‹ˆë‹¤. ì €ëŠ” í•­ìƒ ì‚¬ëŒë“¤ì—ê²Œ ì´ ì§ˆí™˜ì˜ ì§„ë‹¨ í›„ í‰ê·  ìƒì¡´ê¸°ê°„ì´ 6ë…„ì—ì„œ 10ë…„ì´ë¼ëŠ” ì ì„ ìƒê¸°ì‹œí‚¤ê³  ì‹¶ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•œ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ ì„ìƒì‹œí—˜ì´ ì‹ ì†í•˜ê²Œ ë“±ë¡ë  ë¿ë§Œ ì•„ë‹ˆë¼, ì´ 2ìƒ í”„ë¡œê·¸ë¨ì´ ê°€ëŠ¥í•œ í•œ ì™„ë²½í•˜ê³  ê°•ë ¥í•˜ë„ë¡ ì´ˆê³¼ ë“±ë¡í•  ê²ƒì´ë©°, ì‹¤ì œë¡œ ìŠ¹ì¸ ê°€ì†í™” ê°€ëŠ¥ì„±ì„ í™œìš©í•  ìˆ˜ ìˆë„ë¡ ì—´ì‹¬íˆ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ ìŠ¬ë¼ì´ë“œë¡œ ë„˜ì–´ê°€ê¸° ì „ì—, Tevaì˜ AJOVY íŒ€ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>They've done a great job in generating data in migraine, and it's very satisfying to see our innovation is recognized by the New England Journal of Medicine with a publication this month. This is great work by the team and really got that sort of the approval for the only and first CGRP antagonist to be approved for pediatrics with episodic migraine. So very proud and great work and kudos to the team. But finally, I just want to go over something that we take with great pride. We have a very exciting 2026 coming up with many different milestones in the R&D organization. The duvakitug data, as I mentioned, will come out in the first half.</td><td>ê·¸ë“¤ì€ í¸ë‘í†µ ë¶„ì•¼ì—ì„œ ë°ì´í„°ë¥¼ ìƒì„±í•˜ëŠ” ë° í›Œë¥­í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìœ¼ë©°, ì´ë²ˆ ë‹¬ ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„(New England Journal of Medicine)ì— ê²Œì¬ëœ ë…¼ë¬¸ì„ í†µí•´ ìš°ë¦¬ì˜ í˜ì‹ ì´ ì¸ì •ë°›ëŠ” ê²ƒì„ ë³´ë‹ˆ ë§¤ìš° ë¿Œë“¯í•©ë‹ˆë‹¤. ì´ëŠ” íŒ€ì˜ í›Œë¥­í•œ ì„±ê³¼ì´ë©°, ì†Œì•„ ì‚½í™”ì„± í¸ë‘í†µ(episodic migraine)ì— ëŒ€í•´ ìŠ¹ì¸ëœ ìœ ì¼í•˜ê³  ìµœì´ˆì˜ CGRP ê¸¸í•­ì œë¡œì„œ ìŠ¹ì¸ì„ ë°›ì•˜ë‹¤ëŠ” ì ì—ì„œ ì •ë§ ì˜ë¯¸ê°€ ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ìë‘ìŠ¤ëŸ½ê³  í›Œë¥­í•œ ì„±ê³¼ì´ë©° íŒ€ì—ê²Œ ì°¬ì‚¬ë¥¼ ë³´ëƒ…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ê°€ í° ìë¶€ì‹¬ì„ ê°€ì§€ê³  ìˆëŠ” ë¶€ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. R&D ì¡°ì§ì—ì„œ ë‹¤ì–‘í•œ ë§ˆì¼ìŠ¤í†¤ì„ ì•ë‘ê³  ìˆëŠ” ë§¤ìš° í¥ë¯¸ì§„ì§„í•œ 2026ë…„ì´ ë‹¤ê°€ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´ ë‘ë°”í‚¤íˆ­(duvakitug) ë°ì´í„°ëŠ” ìƒë°˜ê¸°ì— ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>For anti-IL-15, vitiligo data in the first half and celiac data in the second half of 2026. We'll be looking for that final event in the asthma exacerbation study of DARI by the end of the year, which would be completing the Phase III study. The emrusolmin will be targeting a futility analysis at the end of this year, even in the face of accelerating and increasing the enrollment in that Phase II study. And obviously, we're looking for the anticipated approval of olanzapine LAI at the end of the year, and we'll be talking about our first human data for our anti-PD-1 IL-2. So a really exciting year full of catalysts. We're looking forward to all these milestones.</td><td>í•­-IL-15ì˜ ê²½ìš°, 2026ë…„ ìƒë°˜ê¸°ì— ë°±ë°˜ì¦ ë°ì´í„°ê°€, í•˜ë°˜ê¸°ì— ì…€ë¦¬ì•…ë³‘ ë°ì´í„°ê°€ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. DARIì˜ ì²œì‹ ì•…í™” ì—°êµ¬ì—ì„œëŠ” ì—°ë§ê¹Œì§€ ìµœì¢… ì´ë²¤íŠ¸ë¥¼ í™•ì¸í•  ì˜ˆì •ì´ë©°, ì´ë¡œì¨ 3ìƒ ì„ìƒì‹œí—˜ì´ ì™„ë£Œë  ê²ƒì…ë‹ˆë‹¤. ì— ë£¨ì†”ë¯¼ì˜ ê²½ìš°, 2ìƒ ì„ìƒì‹œí—˜ì˜ ë“±ë¡ì„ ê°€ì†í™”í•˜ê³  í™•ëŒ€í•˜ëŠ” ê°€ìš´ë° ì˜¬í•´ ë§ ë¬´ìµì„± ë¶„ì„(futility analysis)ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ì˜¬ë€ìí•€ LAIì˜ ìŠ¹ì¸ì´ ì—°ë§ì— ì˜ˆìƒë˜ë©°, í•­-PD-1 IL-2ì— ëŒ€í•œ ì²« ì¸ì²´ ë°ì´í„°ë„ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì •ë§ ë§ì€ ì´‰ë§¤ì œë“¤ë¡œ ê°€ë“í•œ í¥ë¯¸ì§„ì§„í•œ í•œ í•´ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ì´ ëª¨ë“  ë§ˆì¼ìŠ¤í†¤ë“¤ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And with that, I'm going to pass it off to Eli Kalif. Eliyahu Kalif<br>Executive VP & CFO<br><br>Thank you, Eric, and good morning and good afternoon to everyone. I will review our 2025 financial results, focusing on our fourth quarter performance, followed by our outlook for 2026. I would like to start with the following key messages that highlight our consistent execution throughout 2025. First, we delivered solid Q4 and full year results, driven once again by our fast-growing innovative portfolio, which is also driving a meaningful shift in our margin profile. This was our third consecutive year of growth since we launched our Pivot to Growth strategy.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, Eric. ê·¸ëŸ¼ Eli Kalifì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Eliyahu Kalif<br>ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>Eric, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. 2025ë…„ ì¬ë¬´ ì‹¤ì ì„ ê²€í† í•˜ê² ìœ¼ë©°, 4ë¶„ê¸° ì‹¤ì ì— ì¤‘ì ì„ ë‘ê³ , ì´ì–´ì„œ 2026ë…„ ì „ë§ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € 2025ë…„ ë‚´ë‚´ ìš°ë¦¬ì˜ ì¼ê´€ëœ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì£¼ëŠ” ë‹¤ìŒì˜ í•µì‹¬ ë©”ì‹œì§€ë¡œ ì‹œì‘í•˜ê³ ì í•©ë‹ˆë‹¤.<br><br>ì²«ì§¸, ìš°ë¦¬ëŠ” ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ì— í˜ì…ì–´ ê²¬ê³ í•œ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ë˜í•œ ìš°ë¦¬ì˜ ë§ˆì§„ êµ¬ì¡°ì— ì˜ë¯¸ ìˆëŠ” ë³€í™”ë¥¼ ì´ëŒì–´ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì„±ì¥ ì „í™˜(Pivot to Growth) ì „ëµì„ ì‹œì‘í•œ ì´í›„ 3ë…„ ì—°ì† ì„±ì¥ì„ ê¸°ë¡í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Second, we continue to strengthen our balance sheet with a net debt reduced to approximately $13 billion and a net debt-to-EBITDA ratio of 2.5x, well on track to achieve our target of 2x and our journey to investment-grade ratings. Third, we made significant progress on our transformation programs, achieving $70 million of our planned savings in 2025, staying on track to deliver approximately $700 million savings by 2027, achieving our 30% non-GAAP operating margin targets. And lastly, with our performance in 2025 and outlook for 2026, we are well positioned to achieve our long-term financial targets for 2030. Now moving to Slide 28.</td><td>ë‘˜ì§¸, ìš°ë¦¬ëŠ” ìˆœë¶€ì±„ë¥¼ ì•½ 130ì–µ ë‹¬ëŸ¬ë¡œ ê°ì¶•í•˜ê³  ìˆœë¶€ì±„/EBITDA ë¹„ìœ¨ì„ 2.5ë°°ë¡œ ë‚®ì¶”ë©° ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ëª©í‘œì¸ 2ë°° ë‹¬ì„±ê³¼ íˆ¬ìë“±ê¸‰ íšë“ì„ í–¥í•œ ì—¬ì •ì—ì„œ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì…‹ì§¸, ìš°ë¦¬ëŠ” í˜ì‹  í”„ë¡œê·¸ë¨ì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì–´ 2025ë…„ ê³„íšëœ ì ˆê°ì•¡ ì¤‘ 7ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, 2027ë…„ê¹Œì§€ ì•½ 7ì–µ ë‹¬ëŸ¬ì˜ ì ˆê°ì•¡ì„ ì‹¤í˜„í•˜ê³  non-GAAP ì˜ì—…ì´ìµë¥  30% ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•œ ê¶¤ë„ë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2025ë…„ ì‹¤ì ê³¼ 2026ë…„ ì „ë§ì„ ë°”íƒ•ìœ¼ë¡œ ìš°ë¦¬ëŠ” 2030ë…„ ì¥ê¸° ì¬ë¬´ ëª©í‘œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 28ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Before I start with the results, I would like to remind everyone that in the fourth quarter of 2025, Teva initiated a Phase III of UC and Crohn's indication for our duvakitug program. As per the collaboration agreement with Sanofi, we received $500 million in Q4 of 2025 for this development milestone. This payment positively contributed $500 million to both our revenue and free cash flow and had a positive contribution to our adjusted EBITDA of approximately $410 million. During this presentation, I will be discussing our results for the quarter and for the full year of 2025, excluding the impact of these milestone payments.</td><td>ë°œí‘œë¥¼ ì‹œì‘í•˜ê¸° ì „ì—, 2025ë…„ 4ë¶„ê¸°ì— Tevaê°€ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ë° í¬ë¡ ë³‘ ì ì‘ì¦ì— ëŒ€í•œ duvakitug í”„ë¡œê·¸ë¨ì˜ 3ìƒ ì„ìƒì‹œí—˜ì„ ê°œì‹œí–ˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. Sanofiì™€ì˜ í˜‘ë ¥ ê³„ì•½ì— ë”°ë¼, ë‹¹ì‚¬ëŠ” ì´ ê°œë°œ ë§ˆì¼ìŠ¤í†¤ì— ëŒ€í•´ 2025ë…„ 4ë¶„ê¸°ì— 5ì–µ ë‹¬ëŸ¬ë¥¼ ìˆ˜ë ¹í–ˆìŠµë‹ˆë‹¤. ì´ ì§€ê¸‰ê¸ˆì€ ë‹¹ì‚¬ì˜ ë§¤ì¶œê³¼ ì‰ì—¬í˜„ê¸ˆíë¦„ì— ê°ê° 5ì–µ ë‹¬ëŸ¬ì”© ê¸ì •ì ìœ¼ë¡œ ê¸°ì—¬í–ˆìœ¼ë©°, ì¡°ì • EBITDAì—ëŠ” ì•½ 4ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ì˜ ê¸ì •ì  ê¸°ì—¬ë¥¼ í–ˆìŠµë‹ˆë‹¤. ë³¸ ë°œí‘œì—ì„œëŠ” ì´ëŸ¬í•œ ë§ˆì¼ìŠ¤í†¤ ì§€ê¸‰ê¸ˆì˜ ì˜í–¥ì„ ì œì™¸í•œ 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In addition to these payments, I will also be excluding any contribution from the Japan business venture, which we divested on March 31, 2025, to help to provide you with a like-to-like comparison of our financial results. Now starting with our Q4 GAAP performance. Our Q4 revenue were approximately $4.2 billion, up 2% in U.S. dollars or down 1% in local currency year-over-year. Our key innovative products, AUSTEDO, AJOVY and UZEDY continued strong momentum, all meeting or exceeding our guidance for the full year. This strong growth in our innovative portfolio and stable generics was offset by lower proceeds from the sale of certain product rights compared to Q4 2024.</td><td>ì´ëŸ¬í•œ ì§€ê¸‰ê¸ˆ ì™¸ì—ë„, ì¬ë¬´ ì‹¤ì ì˜ ë™ì¼ ê¸°ì¤€ ë¹„êµë¥¼ ì œê³µí•˜ê¸° ìœ„í•´ 2025ë…„ 3ì›” 31ì¼ ë§¤ê°í•œ ì¼ë³¸ ì‚¬ì—… ë²¤ì²˜ì˜ ê¸°ì—¬ë¶„ë„ ì œì™¸í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ì œ 4ë¶„ê¸° GAAP ì‹¤ì ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë§¤ì¶œì€ ì•½ 42ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë¯¸êµ­ ë‹¬ëŸ¬ ê¸°ì¤€ 2% ì¦ê°€, í˜„ì§€í†µí™” ê¸°ì¤€ 1% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì£¼ìš” í˜ì‹  ì œí’ˆì¸ AUSTEDO, AJOVY, UZEDYëŠ” ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë³´ì´ë©° ëª¨ë‘ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ì¶©ì¡±í•˜ê±°ë‚˜ ì´ˆê³¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì´ëŸ¬í•œ ê°•ë ¥í•œ ì„±ì¥ê³¼ ì•ˆì •ì ì¸ ì œë„¤ë¦­ ì˜ì•½í’ˆ ì‹¤ì ì€ 2024ë…„ 4ë¶„ê¸° ëŒ€ë¹„ íŠ¹ì • ì œí’ˆ ê¶Œë¦¬ ë§¤ê° ìˆ˜ìµ ê°ì†Œë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>GAAP net income and EPS were $480 million and $0.41, respectively, including the payments for the development milestones. Now looking to our non-GAAP performance. Our non-GAAP gross margin increased by 80 basis points year-over-year to 56.2% and resulted in our full year gross margin at 54.7%, well above the top end of our guidance range. This increase was mainly driven by a stronger-than-expected growth in our key innovative products, mainly AUSTEDO. Non-GAAP operating margin decreased by approximately 120 basis points year-over-year to 26.7%, mainly because of the higher planned investment in OpEx to support our innovative growth.</td><td>GAAP ê¸°ì¤€ ìˆœì´ìµê³¼ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ ê°ê° 4ì–µ 8ì²œë§Œ ë‹¬ëŸ¬ì™€ 0.41ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ê°œë°œ ë§ˆì¼ìŠ¤í†¤ ê´€ë ¨ ì§€ê¸‰ì•¡ì´ í¬í•¨ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ì œ non-GAAP ì‹¤ì ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. Non-GAAP ë§¤ì¶œì´ì´ìµë¥ ì€ ì „ë…„ ëŒ€ë¹„ 80bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) ì¦ê°€í•œ 56.2%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ì— ë”°ë¼ ì—°ê°„ ë§¤ì¶œì´ì´ìµë¥ ì€ 54.7%ë¡œ ê°€ì´ë˜ìŠ¤ ìƒë‹¨ì„ í¬ê²Œ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¦ê°€ëŠ” ì£¼ë¡œ í•µì‹¬ í˜ì‹  ì œí’ˆ, íŠ¹íˆ AUSTEDOì˜ ì˜ˆìƒë³´ë‹¤ ê°•ë ¥í•œ ì„±ì¥ì— ê¸°ì¸í•©ë‹ˆë‹¤. Non-GAAP ì˜ì—…ì´ìµë¥ ì€ ì „ë…„ ëŒ€ë¹„ ì•½ 120bp ê°ì†Œí•œ 26.7%ë¥¼ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ í˜ì‹ ì  ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•œ ìš´ì˜ë¹„(OpEx) íˆ¬ì ê³„íš ì¦ê°€ ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Overall, we ended the quarter with a non-GAAP earnings per share of $0.68 compared to $0.70 in Q4 2024. Total non-GAAP adjustments in Q4 were $649 million. This included impairment charge of $77.3 million, mainly related to a manufacturing facility in Europe. Our free cash flow in Q4 was approximately $800 million and $1.9 billion for the full year, coming at the higher end of our guidance range, excluding the development milestones related to duvakitug. Moving to Slide 29. We are making significant progress in our Teva transformation programs to deliver targeted savings of approximately $700 million by 2027 through a well-defined and planned efforts.</td><td>ì „ë°˜ì ìœ¼ë¡œ ë‹¹ì‚¬ëŠ” ì´ë²ˆ ë¶„ê¸° ë¹„GAAP ì£¼ë‹¹ìˆœì´ìµ 0.68ë‹¬ëŸ¬ë¡œ ë§ˆê°í–ˆìœ¼ë©°, ì´ëŠ” 2024ë…„ 4ë¶„ê¸° 0.70ë‹¬ëŸ¬ì™€ ë¹„êµë©ë‹ˆë‹¤. 4ë¶„ê¸° ì´ ë¹„GAAP ì¡°ì •ì•¡ì€ 6ì–µ 4,900ë§Œ ë‹¬ëŸ¬ì˜€ìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì£¼ë¡œ ìœ ëŸ½ ì œì¡°ì‹œì„¤ê³¼ ê´€ë ¨ëœ 7,730ë§Œ ë‹¬ëŸ¬ì˜ ì†ìƒì°¨ì†ì´ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì‰ì—¬í˜„ê¸ˆíë¦„ì€ ì•½ 8ì–µ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì—°ê°„ìœ¼ë¡œëŠ” 19ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ë‘ë°”í‚¤íˆ¬ê·¸ ê´€ë ¨ ê°œë°œ ë§ˆì¼ìŠ¤í†¤ì„ ì œì™¸í•˜ê³  ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ ìƒë‹¨ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 29ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ëª…í™•í•˜ê²Œ ì •ì˜ë˜ê³  ê³„íšëœ ë…¸ë ¥ì„ í†µí•´ 2027ë…„ê¹Œì§€ ì•½ 7ì–µ ë‹¬ëŸ¬ì˜ ëª©í‘œ ì ˆê°ì•¡ì„ ë‹¬ì„±í•˜ê¸° ìœ„í•œ í…Œë°” í˜ì‹  í”„ë¡œê·¸ë¨ì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>During 2025, we achieved $70 million of initial savings, demonstrating solid momentum and execution and continue to expect roughly 2/3 of our total savings target to be realized by the end of 2026. These transformation efforts, along with the ongoing portfolio shift towards high-growth and high-margin innovative products provide a clear path to achieving our 30% operating margin target by 2027, even as we continue to invest in our business for long-term growth. Now let me turn to our 2026 outlook. As I mentioned earlier, 2025 was a year of a strong progress on our Pivot to Growth strategy.</td><td>2025ë…„ ë™ì•ˆ ìš°ë¦¬ëŠ” 7ì²œë§Œ ë‹¬ëŸ¬ì˜ ì´ˆê¸° ì ˆê°ì•¡ì„ ë‹¬ì„±í•˜ì—¬ ê²¬ê³ í•œ ëª¨ë©˜í…€ê³¼ ì‹¤í–‰ë ¥ì„ ì…ì¦í–ˆìœ¼ë©°, 2026ë…„ ë§ê¹Œì§€ ì „ì²´ ì ˆê° ëª©í‘œì˜ ì•½ 2/3ê°€ ì‹¤í˜„ë  ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í˜ì‹  ë…¸ë ¥ì€ ê³ ì„±ì¥ ë° ê³ ë§ˆì§„ í˜ì‹  ì œí’ˆìœ¼ë¡œì˜ ì§€ì†ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ì „í™˜ê³¼ í•¨ê»˜, ì¥ê¸° ì„±ì¥ì„ ìœ„í•œ ì‚¬ì—… íˆ¬ìë¥¼ ì§€ì†í•˜ë©´ì„œë„ 2027ë…„ê¹Œì§€ ì˜ì—…ì´ìµë¥  30% ëª©í‘œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ëª…í™•í•œ ê²½ë¡œë¥¼ ì œì‹œí•©ë‹ˆë‹¤. ì´ì œ 2026ë…„ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, 2025ë…„ì€ ìš°ë¦¬ì˜ ì„±ì¥ ì „í™˜(Pivot to Growth) ì „ëµì—ì„œ ê°•ë ¥í•œ ì§„ì „ì„ ì´ë£¬ í•œ í•´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We delivered revenue growth, expanded profits and margin, invested in our innovative products and pipeline and made significant progress towards our journey to investment-grade ratings. In 2026, we remain focused on continuing this momentum and executing on accelerate growth path to our strategy. Starting with our revenue guidance for 2026. We expect full year revenue of $16.4 billion to $16.8 billion. This represents a range of approximately 1% growth to 2% decline compared to 2025 on a normal base, excluding the $500 million development milestone payments and $75 million contribution in 2025 for the Japan business venture.</td><td>ìš°ë¦¬ëŠ” ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆê³ , ìˆ˜ìµê³¼ ë§ˆì§„ì„ í™•ëŒ€í–ˆìœ¼ë©°, í˜ì‹ ì ì¸ ì œí’ˆê³¼ íŒŒì´í”„ë¼ì¸ì— íˆ¬ìí–ˆê³ , íˆ¬ìë“±ê¸‰ ì‹ ìš©ë“±ê¸‰ íšë“ì„ í–¥í•œ ì—¬ì •ì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. 2026ë…„ì—ë„ ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ëª¨ë©˜í…€ì„ ì§€ì†í•˜ê³  ì„±ì¥ ê°€ì†í™” ì „ëµì„ ì‹¤í–‰í•˜ëŠ” ë° ì§‘ì¤‘í•  ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—°ê°„ ë§¤ì¶œì´ 164ì–µ ë‹¬ëŸ¬ì—ì„œ 168ì–µ ë‹¬ëŸ¬ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŠ” 5ì–µ ë‹¬ëŸ¬ì˜ ê°œë°œ ë§ˆì¼ìŠ¤í†¤ ì§€ê¸‰ì•¡ê³¼ 2025ë…„ ì¼ë³¸ ì‚¬ì—… ë²¤ì²˜ì˜ 7,500ë§Œ ë‹¬ëŸ¬ ê¸°ì—¬ë¶„ì„ ì œì™¸í•œ ì •ìƒ ê¸°ì¤€ìœ¼ë¡œ, 2025ë…„ ëŒ€ë¹„ ì•½ 1% ì„±ì¥ì—ì„œ 2% ê°ì†Œ ë²”ìœ„ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>This revenue guidance is consistent with our previous communication and reflects continued strong momentum in our innovative portfolio, including AUSTEDO, AJOVY and UZEDY combined with a low single-digit growth in global generics business. It's expected to largely offset revenue headwinds of approximately $1.1 billion from generic Revlimid in 2026. We expect non-GAAP gross margin in 2026 to be in the range of 54.5% to 55.5%, showing a further improvement over a strong 2025, driven again by the ongoing positive shift in our portfolio mix and the cost savings from our ongoing transformation programs.</td><td>ì´ëŸ¬í•œ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ëŠ” ê¸°ì¡´ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ê³¼ ì¼ê´€ë˜ë©°, AUSTEDO, AJOVY, UZEDYë¥¼ í¬í•¨í•œ í˜ì‹ ì  í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ëª¨ë©˜í…€ê³¼ ê¸€ë¡œë²Œ ì œë„¤ë¦­ ì‚¬ì—…ì˜ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì´ ê²°í•©ëœ ê²ƒì„ ë°˜ì˜í•©ë‹ˆë‹¤. ì´ëŠ” 2026ë…„ ì œë„¤ë¦­ Revlimidë¡œ ì¸í•œ ì•½ 11ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œ ì—­í’ì„ ëŒ€ë¶€ë¶„ ìƒì‡„í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. 2026ë…„ non-GAAP ë§¤ì¶œì´ì´ìµë¥ ì€ 54.5%ì—ì„œ 55.5% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ê°•ë ¥í–ˆë˜ 2025ë…„ ëŒ€ë¹„ ì¶”ê°€ì ì¸ ê°œì„ ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒìœ¼ë¡œ, í¬íŠ¸í´ë¦¬ì˜¤ ë¯¹ìŠ¤ì˜ ì§€ì†ì ì¸ ê¸ì •ì  ë³€í™”ì™€ ì§„í–‰ ì¤‘ì¸ í˜ì‹  í”„ë¡œê·¸ë¨ì„ í†µí•œ ë¹„ìš© ì ˆê°ì— ì˜í•´ ì£¼ë„ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As a result, and as previously communicated, we expected our non-GAAP operating income and adjusted EBITDA to both growth in absolute dollars and as a percentage of revenue compared to 2025. Our operating expenses are expected to be in the range of 27% to 28% of revenue with a higher impact of the transformation program cost savings in the second half of the year. We expect finance expenses to be approximately $800 million in 2026, lower than 2025, reflecting the reduced debt levels and ongoing deleveraging.</td><td>ê·¸ ê²°ê³¼, ê·¸ë¦¬ê³  ì´ì „ì— ê³µì§€í•œ ë°”ì™€ ê°™ì´, ë‹¹ì‚¬ëŠ” 2026ë…„ ë¹„GAAP ì˜ì—…ì´ìµê³¼ ì¡°ì • EBITDAê°€ 2025ë…„ ëŒ€ë¹„ ì ˆëŒ€ ê¸ˆì•¡ ê¸°ì¤€ê³¼ ë§¤ì¶œ ëŒ€ë¹„ ë¹„ìœ¨ ëª¨ë‘ì—ì„œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì˜ì—…ë¹„ìš©ì€ ë§¤ì¶œì˜ 27%ì—ì„œ 28% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, êµ¬ì¡°ì¡°ì • í”„ë¡œê·¸ë¨ì˜ ë¹„ìš© ì ˆê° íš¨ê³¼ëŠ” í•˜ë°˜ê¸°ì— ë” í¬ê²Œ ë‚˜íƒ€ë‚  ê²ƒì…ë‹ˆë‹¤. ê¸ˆìœµë¹„ìš©ì€ 2026ë…„ì— ì•½ 8ì–µ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ë¶€ì±„ ìˆ˜ì¤€ ê°ì†Œì™€ ì§€ì†ì ì¸ ë””ë ˆë²„ë¦¬ì§•ì„ ë°˜ì˜í•˜ì—¬ 2025ë…„ë³´ë‹¤ ë‚®ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our non-GAAP tax rate is expected to be in the range of 16% to 19%, slightly higher than 2025, which benefited partially from IP-related integration plans and the recognition of certain U.S. tax attributes. This brings us to expected non-GAAP earnings per share range of $2.57 to $2.77. Our 2026 free cash flow is expected to be in the range of $2 billion to $2.4 billion, representing a strong ongoing improvement in our cash conversion profile and consistent with our long-term targets. Now lastly, let me provide you with some directions on how we think about quarterly progression in 2026.</td><td>ë‹¹ì‚¬ì˜ ë¹„-GAAP ì„¸ìœ¨ì€ 16%ì—ì„œ 19% ë²”ìœ„ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” IP ê´€ë ¨ í†µí•© ê³„íšê³¼ íŠ¹ì • ë¯¸êµ­ ì„¸ë¬´ ì†ì„± ì¸ì‹ìœ¼ë¡œ ë¶€ë¶„ì ì¸ í˜œíƒì„ ë°›ì•˜ë˜ 2025ë…„ ëŒ€ë¹„ ì†Œí­ ë†’ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì˜ˆìƒ ë¹„-GAAP ì£¼ë‹¹ìˆœì´ìµì€ 2.57ë‹¬ëŸ¬ì—ì„œ 2.77ë‹¬ëŸ¬ ë²”ìœ„ê°€ ë©ë‹ˆë‹¤. 2026ë…„ ì‰ì—¬í˜„ê¸ˆíë¦„ì€ 20ì–µ ë‹¬ëŸ¬ì—ì„œ 24ì–µ ë‹¬ëŸ¬ ë²”ìœ„ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ë‹¹ì‚¬ì˜ í˜„ê¸ˆì „í™˜ìœ¨ í”„ë¡œíŒŒì¼ì—ì„œ ê°•ë ¥í•˜ê³  ì§€ì†ì ì¸ ê°œì„ ì„ ë‚˜íƒ€ë‚´ë©° ì¥ê¸° ëª©í‘œì™€ë„ ì¼ì¹˜í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2026ë…„ ë¶„ê¸°ë³„ ì§„í–‰ ìƒí™©ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ì „ë§ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect revenue to gradually increase over the course of the year with the revenue in the second half of 2026 slightly higher than the first half. Q1 is expected to be light, mainly due to the following: First, a year-over-year decline in our U.S. generics revenue, mainly because of approximately $300 million in generic Revlimid revenue from Q1 of 2025 that is going away. Second, on AUSTEDO, during Q4 of 2025, on top of AUSTEDO's strong underlying performance, we had the benefit of a year-end inventory build and a onetime gross to net of approximately $100 million.</td><td>2026ë…„ í•œ í•´ ë™ì•ˆ ë§¤ì¶œì´ ì ì§„ì ìœ¼ë¡œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, 2026ë…„ í•˜ë°˜ê¸° ë§¤ì¶œì´ ìƒë°˜ê¸°ë³´ë‹¤ ì†Œí­ ë†’ì„ ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. 1ë¶„ê¸°ëŠ” ë‹¤ìŒê³¼ ê°™ì€ ì´ìœ ë¡œ ë¶€ì§„í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì²«ì§¸, ë¯¸êµ­ ì œë„¤ë¦­ ì˜ì•½í’ˆ ë§¤ì¶œì˜ ì „ë…„ ëŒ€ë¹„ ê°ì†Œì¸ë°, ì´ëŠ” ì£¼ë¡œ 2025ë…„ 1ë¶„ê¸°ì— ë°œìƒí–ˆë˜ ì•½ 3ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì œë„¤ë¦­ Revlimid ë§¤ì¶œì´ ì‚¬ë¼ì§€ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë‘˜ì§¸, AUSTEDOì˜ ê²½ìš°, 2025ë…„ 4ë¶„ê¸°ì— AUSTEDOì˜ ê°•ë ¥í•œ ê¸°ì € ì‹¤ì ì— ë”í•´ ì—°ë§ ì¬ê³  í™•ë³´ íš¨ê³¼ì™€ ì•½ 1ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì¼íšŒì„± ì´ì•¡-ìˆœì•¡ ì¡°ì • íš¨ê³¼ê°€ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>While we expect a strong year-over-year growth for AUSTEDO in Q1 2026, we expect Q1 revenue to reflect the sequential impact of these onetime benefits. We also expect AUSTEDO revenue in Q4 '26 to be potentially down year-over-year due to a different purchasing patterns and pricing environment ahead of the IRA implementation in January 2027. Our non-GAAP margins are also expected to be gradually ramped up over the course of the year, in line with the revenue trajectory as well as savings from the ongoing transformation programs. The onetime revenue dynamics that I just talked about will also impact gross margin in Q1 beyond the normal seasonality we see going from Q4 to Q1.</td><td>2026ë…„ 1ë¶„ê¸°ì— AUSTEDOì˜ ì „ë…„ ëŒ€ë¹„ ê°•ë ¥í•œ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆì§€ë§Œ, 1ë¶„ê¸° ë§¤ì¶œì€ ì´ëŸ¬í•œ ì¼íšŒì„± í˜œíƒì˜ ìˆœì°¨ì  ì˜í–¥ì„ ë°˜ì˜í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë˜í•œ 2027ë…„ 1ì›” IRA ì‹œí–‰ì„ ì•ë‘ê³  ë‹¬ë¼ì§„ êµ¬ë§¤ íŒ¨í„´ê³¼ ê°€ê²© í™˜ê²½ìœ¼ë¡œ ì¸í•´ 2026ë…„ 4ë¶„ê¸° AUSTEDO ë§¤ì¶œì´ ì „ë…„ ëŒ€ë¹„ ê°ì†Œí•  ê°€ëŠ¥ì„±ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ë¹„-GAAP ë§ˆì§„ì€ ë§¤ì¶œ ì¶”ì´ì™€ ì§„í–‰ ì¤‘ì¸ í˜ì‹  í”„ë¡œê·¸ë¨ì„ í†µí•œ ë¹„ìš© ì ˆê°ì— ë§ì¶° ì—°ì¤‘ ì ì§„ì ìœ¼ë¡œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë°©ê¸ˆ ë§ì”€ë“œë¦° ì¼íšŒì„± ë§¤ì¶œ ì—­í•™ì€ 4ë¶„ê¸°ì—ì„œ 1ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ë©´ì„œ ë‚˜íƒ€ë‚˜ëŠ” ì •ìƒì ì¸ ê³„ì ˆì„± ìš”ì¸ì„ ë„˜ì–´ 1ë¶„ê¸° ë§¤ì¶œì´ì´ìµë¥ ì—ë„ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Free cash flow is also expected to ramp up over the course of the year. Now on the next slide, I would like to highlight the strong free cash flow trajectory that we are on. There are 3 main elements that are going to continue to drive incremental free cash flow, going from approximately $1.9 billion in 2025, excluding duvakitug milestone payments to more than $3.5 billion by 2030. First, our innovative portfolio is uniquely positioned to continue to grow strongly, driving higher margins and free cash flow. In addition, we are on track to achieve $700 million savings from transformation programs by 2027. We don't stop here, and we'll continue to drive modernization of Teva beyond 2027.</td><td>ì‰ì—¬í˜„ê¸ˆíë¦„ë„ ì—°ì¤‘ ì ì§„ì ìœ¼ë¡œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë‹¤ìŒ ìŠ¬ë¼ì´ë“œì—ì„œëŠ” ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ê°•ë ¥í•œ ì‰ì—¬í˜„ê¸ˆíë¦„ ê¶¤ì ì„ ê°•ì¡°í•˜ê³ ì í•©ë‹ˆë‹¤. 2025ë…„ ë‘ë°”í‚¤íˆ­ ë§ˆì¼ìŠ¤í†¤ ì§€ê¸‰ì•¡ì„ ì œì™¸í•œ ì•½ 19ì–µ ë‹¬ëŸ¬ì—ì„œ 2030ë…„ê¹Œì§€ 35ì–µ ë‹¬ëŸ¬ ì´ìƒìœ¼ë¡œ ì¦ê°€í•˜ëŠ” ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì§€ì†ì ìœ¼ë¡œ ê²¬ì¸í•  ì„¸ ê°€ì§€ ì£¼ìš” ìš”ì†Œê°€ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, ìš°ë¦¬ì˜ í˜ì‹ ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì„±ì¥ì„ ì´ì–´ê°€ë©° ë” ë†’ì€ ë§ˆì§„ê³¼ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” ë…ë³´ì ì¸ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ë˜í•œ, ìš°ë¦¬ëŠ” 2027ë…„ê¹Œì§€ í˜ì‹  í”„ë¡œê·¸ë¨ì„ í†µí•´ 7ì–µ ë‹¬ëŸ¬ì˜ ë¹„ìš© ì ˆê°ì„ ë‹¬ì„±í•  ê³„íšëŒ€ë¡œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—¬ê¸°ì„œ ë©ˆì¶”ì§€ ì•Šê³  2027ë…„ ì´í›„ì—ë„ í…Œë°”ì˜ í˜„ëŒ€í™”ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì¶”ì§„í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Second, we continue to strengthen our balance sheet through working capital and CapEx optimization. And lastly, we continue to deleverage, reduction in our debt expected to result in lower finance expenses by approximately 50% by 2030, and we expect to see a reduction in our legal payments over time. Now turning to the next slide on capital allocation. Our capital allocation strategy is focused on driving our Pivot to Growth strategy. This means keep investing in our key growth drivers and our world-class innovative pipeline. We are also making significant progress towards our target of 2x net debt-to-EBITDA and an investment-grade credit ratings.</td><td>ë‘˜ì§¸, ìš°ë¦¬ëŠ” ìš´ì „ìë³¸ê³¼ ìë³¸ì ì§€ì¶œ ìµœì í™”ë¥¼ í†µí•´ ì¬ë¬´êµ¬ì¡°ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ë¶€ì±„ë¥¼ ì¶•ì†Œí•˜ê³  ìˆìœ¼ë©°, ë¶€ì±„ ê°ì¶•ìœ¼ë¡œ 2030ë…„ê¹Œì§€ ê¸ˆìœµë¹„ìš©ì´ ì•½ 50% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³ , ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë²•ë¥  ê´€ë ¨ ì§€ê¸‰ê¸ˆë„ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì´ì œ ë‹¤ìŒ ìŠ¬ë¼ì´ë“œì˜ ìë³¸ë°°ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ìë³¸ë°°ë¶„ ì „ëµì€ ì„±ì¥ ì¤‘ì‹¬ ì „í™˜(Pivot to Growth) ì „ëµì„ ì¶”ì§„í•˜ëŠ” ë° ì§‘ì¤‘ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í•µì‹¬ ì„±ì¥ë™ë ¥ê³¼ ì„¸ê³„ ìµœê³  ìˆ˜ì¤€ì˜ í˜ì‹ ì ì¸ íŒŒì´í”„ë¼ì¸ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•œë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ìˆœë¶€ì±„/EBITDA ë°°ìˆ˜ 2ë°° ëª©í‘œì™€ íˆ¬ìë“±ê¸‰ ì‹ ìš©ë“±ê¸‰ ë‹¬ì„±ì„ í–¥í•´ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This progress is recognized consistently by the major credit rating agencies, including the recent upgrade by S&P and an improved outlook by Moody's. With the progress we have been making, I expect to see us achieving these goals in not-too-distant future, which also position us very well to thoughtfully evaluate additional ways of returning capital to our shareholders. Finally, before I conclude my review of our 2025 performance, I would like to reiterate our long-term targets. We are clearly on the journey to be a leading innovative biopharma company.</td><td>ì´ëŸ¬í•œ ì§„ì „ì€ ìµœê·¼ S&Pì˜ ì‹ ìš©ë“±ê¸‰ ìƒí–¥ ì¡°ì •ê³¼ Moody'sì˜ ì „ë§ ê°œì„ ì„ í¬í•¨í•˜ì—¬ ì£¼ìš” ì‹ ìš©í‰ê°€ê¸°ê´€ë“¤ë¡œë¶€í„° ì§€ì†ì ìœ¼ë¡œ ì¸ì •ë°›ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì´ë£¨ì–´ì˜¨ ì§„ì „ì„ ê³ ë ¤í•  ë•Œ, ì €ëŠ” ë¨¸ì§€ì•Šì€ ë¯¸ë˜ì— ì´ëŸ¬í•œ ëª©í‘œë“¤ì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ë©°, ì´ëŠ” ë˜í•œ ì£¼ì£¼ë“¤ì—ê²Œ ìë³¸ì„ í™˜ì›í•˜ëŠ” ì¶”ê°€ì ì¸ ë°©ë²•ë“¤ì„ ì‹ ì¤‘í•˜ê²Œ ê²€í† í•  ìˆ˜ ìˆëŠ” ë§¤ìš° ìœ ë¦¬í•œ ìœ„ì¹˜ë¥¼ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2025ë…„ ì‹¤ì  ê²€í† ë¥¼ ë§ˆë¬´ë¦¬í•˜ê¸° ì „ì— ë‹¹ì‚¬ì˜ ì¥ê¸° ëª©í‘œë¥¼ ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ê³ ì í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¶„ëª…íˆ ì„ ë„ì ì¸ í˜ì‹  ë°”ì´ì˜¤ì œì•½ ê¸°ì—…ì´ ë˜ê¸° ìœ„í•œ ì—¬ì •ì„ ê±¸ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With our growing innovative mix, a number of key pipeline developments this year and our free cash flow trajectory, we are confident about the directions we are on to achieve our 2027 and 2030 financial targets. With that, I will now hand it back to Richard for his closing remarks. Richard Francis<br>President, CEO & Director<br><br>Thank you, Eli, and thank you, Eric. So the next slide I'm going to go on to here is the one Eric showed, but I think it's one that's worthy of being repeated. A really exciting year here for Teva with regards to milestones on our innovative portfolio. We have 7 milestones here on this slide. So very proud of that, very proud of what the team has achieved.</td><td>í˜ì‹ ì ì¸ ì œí’ˆ ë¯¹ìŠ¤ì˜ ì„±ì¥, ì˜¬í•´ ì—¬ëŸ¬ ì£¼ìš” íŒŒì´í”„ë¼ì¸ ê°œë°œ ì„±ê³¼, ê·¸ë¦¬ê³  ì‰ì—¬í˜„ê¸ˆíë¦„ ê¶¤ì ì„ ê³ ë ¤í•  ë•Œ, ìš°ë¦¬ëŠ” 2027ë…„ê³¼ 2030ë…„ ì¬ë¬´ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•œ ë°©í–¥ì„±ì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Richardì—ê²Œ ë§ˆë¬´ë¦¬ ë°œì–¸ì„ ìœ„í•´ ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Richard Francis<br>ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br><br>Eli, Eric, ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ìŒ ìŠ¬ë¼ì´ë“œëŠ” Ericì´ ë³´ì—¬ë“œë ¸ë˜ ê²ƒì´ì§€ë§Œ, ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•  ê°€ì¹˜ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ì˜ ë§ˆì¼ìŠ¤í†¤ê³¼ ê´€ë ¨í•˜ì—¬ Tevaì—ê²Œ ì •ë§ í¥ë¶„ë˜ëŠ” í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ì´ ìŠ¬ë¼ì´ë“œì— 7ê°œì˜ ë§ˆì¼ìŠ¤í†¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ë©°, íŒ€ì´ ì´ë£¬ ì„±ê³¼ì— ëŒ€í•´ ë§¤ìš° ìë‘ìŠ¤ëŸ½ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Obviously, we have some exciting data around vitiligo and anti-IL-15 and celiac disease. We have the olanzapine launch later this year. We have the duvakitug maintenance data, the futility analysis, which could accelerate our ability to get to market with emrusolmin treating this very serious disease. So lots of opportunity here to continue this transition to a world-class biopharma company. Congratulations once again to the R&D team for moving this through so quickly. In just 3 years, we progressed this pipeline at record speed.</td><td>ë°±ë°˜ì¦ê³¼ í•­IL-15, ê·¸ë¦¬ê³  ì…€ë¦¬ì•…ë³‘ì— ëŒ€í•œ í¥ë¯¸ë¡œìš´ ë°ì´í„°ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ í•˜ë°˜ê¸°ì—ëŠ” ì˜¬ë€ìí•€ ì¶œì‹œê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‘ë°”í‚¤íˆ­ì˜ ìœ ì§€ìš”ë²• ë°ì´í„°ì™€ ë¬´ìµì„± ë¶„ì„(futility analysis)ì´ ìˆëŠ”ë°, ì´ëŠ” ì´ ë§¤ìš° ì‹¬ê°í•œ ì§ˆí™˜ ì¹˜ë£Œì œì¸ ì— ë£¨ì†”ë¯¼ì˜ ì‹œì¥ ì§„ì…ì„ ê°€ì†í™”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì„¸ê³„ì  ìˆ˜ì¤€ì˜ ë°”ì´ì˜¤ì œì•½ ê¸°ì—…ìœ¼ë¡œì˜ ì „í™˜ì„ ì§€ì†í•  ìˆ˜ ìˆëŠ” ë§ì€ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ ì´ë ‡ê²Œ ì‹ ì†í•˜ê²Œ ì¶”ì§„í•œ R&D íŒ€ì—ê²Œ ë‹¤ì‹œ í•œë²ˆ ì¶•í•˜ë¥¼ ì „í•©ë‹ˆë‹¤. ë‹¨ 3ë…„ ë§Œì— ìš°ë¦¬ëŠ” ì´ íŒŒì´í”„ë¼ì¸ì„ ê¸°ë¡ì ì¸ ì†ë„ë¡œ ì§„ì „ì‹œì¼°ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now it's because of this pipeline, it's because of the continued strong performance we have in our innovative portfolio that I mentioned earlier and Eli also mentioned, is why we're confident about the opportunity to continue to grow Teva top and bottom line and why we think it's an attractive investment opportunity. Because as you can see here, not only do we have significant headroom for AUSTEDO, AJOVY, we have the LAI franchise with UZEDY performing well, but olanzapine about to join it this year. I highlighted the amount of biosimilars that will be launched over the next few years. And then as we look forward, that pipeline, the readouts I just mentioned will start to come to fruition.</td><td>ì´ëŸ¬í•œ íŒŒì´í”„ë¼ì¸ê³¼ ì œê°€ ì•ì„œ ë§ì”€ë“œë ¸ê³  Elië„ ì–¸ê¸‰í–ˆë˜ í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ì„±ê³¼ ë•ë¶„ì—, ìš°ë¦¬ëŠ” Tevaì˜ ë§¤ì¶œê³¼ ìˆ˜ìµì„ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆëŠ” ê¸°íšŒì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ë°”ë¡œ ë§¤ë ¥ì ì¸ íˆ¬ì ê¸°íšŒë¼ê³  ìƒê°í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ë³´ì‹œë‹¤ì‹œí”¼, AUSTEDOì™€ AJOVYì˜ ìƒë‹¹í•œ ì„±ì¥ ì—¬ë ¥ë¿ë§Œ ì•„ë‹ˆë¼, UZEDYê°€ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆëŠ” LAI í”„ëœì°¨ì´ì¦ˆê°€ ìˆê³ , ì˜¬í•´ ì˜¬ë€ìí•€ì´ í•©ë¥˜í•  ì˜ˆì •ì…ë‹ˆë‹¤. í–¥í›„ ëª‡ ë…„ê°„ ì¶œì‹œë  ë°”ì´ì˜¤ì‹œë°€ëŸ¬ì˜ ê·œëª¨ë„ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ì„ ë‚´ë‹¤ë³´ë©´, ì œê°€ ë°©ê¸ˆ ì–¸ê¸‰í•œ íŒŒì´í”„ë¼ì¸ì˜ ì„ìƒê²°ê³¼ë“¤ì´ ê²°ì‹¤ì„ ë§ºê¸° ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So we'll be able to continue this momentum going forward. To move on to my final slide, just to conclude. Our growth journey continues. We have 3 years of consecutive growth. We have a 6% CAGR. Our innovative brands are growing at double digit, and they have headroom to keep growing. We have near-term milestone readouts, 7 in '26. And we have a stable outlook for our generics business, and we continue to focus on accelerating our Pivot to Growth journey. And with that, I'll open the floor to questions. Thank you.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ë§ˆì§€ë§‰ ìŠ¬ë¼ì´ë“œë¡œ ë„˜ì–´ê°€ì„œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ì €í¬ì˜ ì„±ì¥ ì—¬ì •ì€ ê³„ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. 3ë…„ ì—°ì† ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì—°í‰ê·  ì„±ì¥ë¥ (CAGR)ì€ 6%ì…ë‹ˆë‹¤. í˜ì‹  ë¸Œëœë“œë“¤ì€ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•˜ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ê³„ì† ì„±ì¥í•  ì—¬ë ¥ì´ ì¶©ë¶„í•©ë‹ˆë‹¤. ë‹¨ê¸°ì ìœ¼ë¡œëŠ” 2026ë…„ì— 7ê±´ì˜ ì¤‘ìš”í•œ ì„ìƒ ê²°ê³¼ ë°œí‘œê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì œë„¤ë¦­ ì‚¬ì—…ì€ ì•ˆì •ì ì¸ ì „ë§ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì €í¬ëŠ” 'ì„±ì¥ìœ¼ë¡œì˜ ì „í™˜(Pivot to Growth)' ì—¬ì •ì„ ê°€ì†í™”í•˜ëŠ” ë° ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ìƒìœ¼ë¡œ ë°œí‘œë¥¼ ë§ˆì¹˜ê³ , ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Teva Pharmaceutical Q4 2025 ì‹¤ì  ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼<br>- **ë§¤ì¶œ 173ì–µ ë‹¬ëŸ¬ (5% ì¦ê°€)**, EBITDA 53ì–µ ë‹¬ëŸ¬ (12% ì¦ê°€), EPS $2.93 (19% ì¦ê°€), ì‰ì—¬í˜„ê¸ˆíë¦„ 24ì–µ ë‹¬ëŸ¬ (16% ì¦ê°€)<br>- **ìˆœë¶€ì±„/EBITDA ë¹„ìœ¨ 2.5ë°°**ë¡œ ê°œì„ ë˜ì–´ 2027ë…„ ëª©í‘œì¸ 2ë°° ë‹¬ì„± ê¶¤ë„ ì§„ì…<br>- **í˜ì‹  ì œí’ˆêµ° ë§¤ì¶œ 31ì–µ ë‹¬ëŸ¬ (35% ì¦ê°€)**: AUSTEDO $22.6ì–µ (34% ì¦ê°€), UZEDY $1.91ì–µ (63% ì¦ê°€), AJOVY $6.73ì–µ (30% ì¦ê°€)<br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ë§¤ì¶œ 164~168ì–µ ë‹¬ëŸ¬, EPS $2.57~2.77, ì‰ì—¬í˜„ê¸ˆíë¦„ 20~24ì–µ ë‹¬ëŸ¬<br><br>## ê²½ì˜ì§„ í†¤ ë° ì „ëµ<br>- **ê¸ì •ì ì´ê³  ìì‹ ê° ìˆëŠ” í†¤**: 3ë…„ ì—°ì† ì„±ì¥ ë‹¬ì„±ê³¼ í˜ì‹  ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ ê°•ì¡°<br>- **"Pivot to Growth" ì „ëµ ìˆœì¡°ë¡­ê²Œ ì§„í–‰**: ì œë„¤ë¦­ ì¤‘ì‹¬ì—ì„œ ë°”ì´ì˜¤íŒŒë§ˆë¡œì˜ ì „í™˜ ì„±ê³µì ìœ¼ë¡œ ì§„í–‰ ì¤‘<br>- **íŒŒì´í”„ë¼ì¸ ê°•ì¡°**: 7ê°œ ì£¼ìš” ë§ˆì¼ìŠ¤í†¤ ì˜ˆì • (duvakitug ìœ ì§€ìš”ë²• ë°ì´í„°, olanzapine LAI ì¶œì‹œ, ì²œì‹ ì¹˜ë£Œì œ DARI ë“±)<br><br>## ì£¼ìš” ë¦¬ìŠ¤í¬ ë° ê°•ì <br>- **ë¦¬ìŠ¤í¬**: Revlimid</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Christopher Stevo: Senior Vice President of Investor Relations & Competitive Intelligence Thanks, Richard. Alex, before you line up the question queue, I just want to remind callers, please limit yourself to one question and one follow-up. And if time permits, we will be more than happy to answer additional questions from you if you get back in the queue. Thank you.</td><td>**Christopher Stevo:** ê°ì‚¬í•©ë‹ˆë‹¤, Richard. Alex, ì§ˆë¬¸ ëŒ€ê¸°ì—´ì„ ì •ë¦¬í•˜ì‹œê¸° ì „ì— ì°¸ì—¬ì ì—¬ëŸ¬ë¶„ê»˜ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì´ ìˆìŠµë‹ˆë‹¤. ì§ˆë¬¸ì€ í•œ ë¶„ë‹¹ í•œ ê°œì™€ í›„ì† ì§ˆë¬¸ í•œ ê°œë¡œ ì œí•œí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì‹œê°„ì´ í—ˆë½í•œë‹¤ë©´, ë‹¤ì‹œ ëŒ€ê¸°ì—´ì— ë“¤ì–´ì˜¤ì…”ì„œ ì¶”ê°€ ì§ˆë¬¸ì„ ì£¼ì‹œë©´ ê¸°êº¼ì´ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] Our first question for today comes from David Amsellem of Piper Sandler.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì˜¤ëŠ˜ ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ íŒŒì´í¼ ìƒŒë“¤ëŸ¬ì˜ ë°ì´ë¹„ë“œ ì•”ì…€ë ˜ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Amsellem: Piper Sandler & Co., Research Division So I have one question on AUSTEDO and one on UZEDY. So helpful color on the guide, but I wanted to dig more deeply into the various pushes and pulls regarding AUSTEDO in 2026. Can you talk about net pricing dynamics and what's baked into your assumptions ex the gross to net favorability in 4Q and ex stocking? How should we be thinking about what your assumptions are regarding net pricing as we move through the year? And then how should we be thinking about what your assumptions are regarding volume growth, particularly on a per milligram basis. So that's number one. And on UZEDY, kind of a similar question. There's a lot of volume growth, obviously, but there's obviously significant government exposure, particularly Medicaid. So how should we be thinking about net pricing there? And what kind of assumptions you baked into your UZEDY guidance?</td><td>**David Amsellem:** ë¨¼ì € AUSTEDO 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìˆœê°€ê²© ì—­í•™(net pricing dynamics)ê³¼ ê´€ë ¨í•´ì„œëŠ”, 4ë¶„ê¸° ì´ì•¡ ëŒ€ë¹„ ìˆœì•¡(gross-to-net) ê°œì„  íš¨ê³¼ì™€ ì¬ê³  íš¨ê³¼ë¥¼ ì œì™¸í•˜ê³  ë³´ë©´, ìš°ë¦¬ëŠ” ì—°ì¤‘ ë¹„êµì  ì•ˆì •ì ì¸ ìˆœê°€ê²© í™˜ê²½ì„ ê°€ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì‹œì¥ ì—­í•™ì— ë”°ë¥¸ ì¼ë°˜ì ì¸ ë³€ë™ì„±ì€ ìˆê² ì§€ë§Œ, í° í­ì˜ ê°€ê²© ì••ë°•ì€ ì˜ˆìƒí•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°€ë¦¬ê·¸ë¨ë‹¹ ê¸°ì¤€ ë¬¼ëŸ‰ ì„±ì¥(volume growth)ê³¼ ê´€ë ¨í•´ì„œëŠ”, í™˜ì ìˆ˜ ì¦ê°€ì™€ í•¨ê»˜ ê¸°ì¡´ í™˜ìë“¤ì˜ ìš©ëŸ‰ ìµœì í™”ê°€ ê³„ì†ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ í—ŒíŒ…í„´ë³‘(Huntington's disease)ê³¼ ì§€ì—°ì„± ìš´ë™ì´ìƒì¦(tardive dyskinesia) ì‹œì¥ ëª¨ë‘ì—ì„œ ì¹¨íˆ¬ìœ¨(penetration)ì´ ë†’ì•„ì§€ë©´ì„œ ê²¬ê³ í•œ ë¬¼ëŸ‰ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>UZEDYì˜ ê²½ìš° ë§ì”€í•˜ì‹  ëŒ€ë¡œ ìƒë‹¹í•œ ë¬¼ëŸ‰ ì„±ì¥ì„ ë³´ê³  ìˆëŠ” ê²ƒì´ ë§ìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ(Medicaid)ë¥¼ í¬í•¨í•œ ì •ë¶€ ë¶€ë¬¸ ë…¸ì¶œë„ê°€ ë†’ì€ ê²ƒë„ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ì´ëŠ” ì¡°í˜„ë³‘(schizophrenia) ì¹˜ë£Œì œ ì‹œì¥ì˜ íŠ¹ì„±ìƒ ì˜ˆìƒëœ ë¶€ë¶„ì´ë©°, ìš°ë¦¬ ê°€ì´ë˜ìŠ¤ì—ëŠ” ì´ëŸ¬í•œ í˜ì´ì–´ ë¯¹ìŠ¤(payer mix)ê°€ ì´ë¯¸ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì •ë¶€ ì±„ë„ì˜ ê°€ê²© ì••ë°•ì„ ê³ ë ¤í•˜ë”ë¼ë„, ê°•ë ¥í•œ ë¬¼ëŸ‰ ì„±ì¥ì´ ì „ì²´ì ì¸ ë§¤ì¶œ ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. ìˆœê°€ê²©(net pricing)ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  UZEDY ê°€ì´ë˜ìŠ¤ì—ëŠ” ì–´ë–¤ ê°€ì •ë“¤ì„ ë°˜ì˜í•˜ì…¨ë‚˜ìš”?</td></tr>
<tr><td>Richard Francis: President, CEO & Director David, thanks for the questions. So let me start with AUSTEDO. I think the main point to highlight first here is we're really pleased with the momentum we have with the TRx growth we have, with the adoption of XR and the continued growth of the milligrams, as you saw there at 19%. So the fundamentals are really strong. We see a huge opportunity to continue to grow this from a TRx point of view with the amount of patients who are still untreated. So that fundamental is really strong. I think when it comes to the pricing, I think as we communicated last year, our aim has always been to make sure we get value and access. And so we've been very diligent about that for this year. And so obviously, it has got more competitive, but we've taken a very disciplined approach to that. And so I think we've maintained that value and access. So I don't think you could think of that as anything that's -- anything of any significance there. And I think the thing to think about with AUSTEDO is what we've finished 2025 with some really strong growth, both on our top line as well as on our milligrams and TRx. And as I said, if you back out that inventory build and the gross to net is still very strong performance. And so if you look at how we're performing across this range, I think we have a very strong range here. It does take into account some expectation that there may be some destocking in Q4 in 2026, but we'll see how that plays out. But probably the final thing I'll say on AUSTEDO, just to help give some clarity. If you do look at the range we've got and you back out the inventory build that we had in Q4, the growth of the brand is about -- the range is from 11% to 18%. So very strong growth on what is a lot bigger base. So I think that helps answer your question on AUSTEDO. On UZEDY, then as you've seen, very strong growth on UZEDY, really strong growth on TRx and continued really good change in the dynamics of this market that shows the quality of the product. But to your question, I think it's always important to understand that we have Medicaid and Medicare. And so we have that mix. And obviously, we know one is more profitable than the other. And how that mix plays out we've taken into account with our guidance and our range. But we see this product continued momentum, particularly as you look at the TRx being so high. So I think this product, we have a lot of enthusiasm around, but that's the fundamentals around the pricing. We factored them in, and it really comes down to those 2 channels. Thanks for the question, David.</td><td>**Richard Francis:** ë°ì´ë¹„ë“œ, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € AUSTEDOë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°€ì¥ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì ì€ í˜„ì¬ ìš°ë¦¬ê°€ ê°€ì§„ ëª¨ë©˜í…€ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. TRx ì„±ì¥ì„¸, XRì˜ ì±„íƒë¥ , ê·¸ë¦¬ê³  ë³´ì‹œë‹¤ì‹œí”¼ 19%ì— ë‹¬í•˜ëŠ” ë°€ë¦¬ê·¸ë¨ì˜ ì§€ì†ì ì¸ ì„±ì¥ ëª¨ë‘ ê¸ì •ì ì…ë‹ˆë‹¤. í€ë”ë©˜í„¸ì´ ì •ë§ íƒ„íƒ„í•©ë‹ˆë‹¤. ì•„ì§ ì¹˜ë£Œë°›ì§€ ëª»í•œ í™˜ì ìˆ˜ë¥¼ ê³ ë ¤í•˜ë©´ TRx ê´€ì ì—ì„œ ê³„ì† ì„±ì¥í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ì—„ì²­ë‚©ë‹ˆë‹¤. ì´ ê¸°ë³¸ì ì¸ ë¶€ë¶„ì´ ì •ë§ ê°•ë ¥í•©ë‹ˆë‹¤. <br><br>ê°€ê²© ì±…ì •ê³¼ ê´€ë ¨í•´ì„œëŠ”, ì‘ë…„ì— ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìš°ë¦¬ì˜ ëª©í‘œëŠ” í•­ìƒ ê°€ì¹˜ì™€ ì ‘ê·¼ì„±ì„ í™•ë³´í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¬í•´ë„ ì´ ë¶€ë¶„ì— ëŒ€í•´ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í•´ì™”ìŠµë‹ˆë‹¤. ê²½ìŸì´ ë” ì¹˜ì—´í•´ì§„ ê²ƒì€ ë¶„ëª…í•˜ì§€ë§Œ, ìš°ë¦¬ëŠ” ë§¤ìš° ê·œìœ¨ ìˆëŠ” ì ‘ê·¼ ë°©ì‹ì„ ì·¨í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ê·¸ ê°€ì¹˜ì™€ ì ‘ê·¼ì„±ì„ ìœ ì§€í•´ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ ì¤‘ìš”í•œ ì˜ë¯¸ê°€ ìˆëŠ” ê²ƒìœ¼ë¡œ ìƒê°í•˜ì‹¤ í•„ìš”ëŠ” ì—†ìŠµë‹ˆë‹¤. AUSTEDOì™€ ê´€ë ¨í•´ì„œ ìƒê°í•˜ì…”ì•¼ í•  ì ì€, ìš°ë¦¬ê°€ 2025ë…„ì„ ë§¤ì¶œê³¼ ë°€ë¦¬ê·¸ë¨, ì²˜ë°© ê±´ìˆ˜(TRx) ëª¨ë‘ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ìœ¼ë¡œ ë§ˆë¬´ë¦¬í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì¬ê³  ì¦ê°€ë¶„ì„ ì œì™¸í•˜ë”ë¼ë„ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œ(gross to net)ì€ ì—¬ì „íˆ ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì´ ë²”ìœ„ ì „ë°˜ì— ê±¸ì³ ì–´ë–»ê²Œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆëŠ”ì§€ ë³´ì‹œë©´, ë§¤ìš° ê²¬ê³ í•œ ë²”ìœ„ë¥¼ ê°€ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ëŠ” 2026ë…„ 4ë¶„ê¸°ì— ì¼ë¶€ ì¬ê³  ê°ì†Œê°€ ìˆì„ ìˆ˜ ìˆë‹¤ëŠ” ì˜ˆìƒì„ ë°˜ì˜í•œ ê²ƒì´ì§€ë§Œ, ì‹¤ì œë¡œ ì–´ë–»ê²Œ ì „ê°œë ì§€ëŠ” ì§€ì¼œë´ì•¼ í•  ê²ƒì…ë‹ˆë‹¤. AUSTEDOì— ëŒ€í•´ ë§ˆì§€ë§‰ìœ¼ë¡œ ë§ì”€ë“œë¦¬ìë©´, ì¢€ ë” ëª…í™•í•˜ê²Œ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ê°€ ì œì‹œí•œ ë²”ìœ„ë¥¼ ë³´ì‹œê³  4ë¶„ê¸° ì¬ê³  ì¦ê°€ë¶„ì„ ì œì™¸í•˜ë©´, ë¸Œëœë“œ ì„±ì¥ë¥ ì€ ì•½ 11%ì—ì„œ 18% ë²”ìœ„ì…ë‹ˆë‹¤. í›¨ì”¬ ë” í° ê¸°ì €ì—ì„œ ë‚˜ì˜¨ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì…ë‹ˆë‹¤. ì´ê²ƒì´ AUSTEDOì— ëŒ€í•œ ì§ˆë¬¸ì— ë‹µì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>UZEDYì˜ ê²½ìš°, ë³´ì‹œë‹¤ì‹œí”¼ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆê³ , ì´ ì²˜ë°©(TRx)ì—ì„œë„ ì •ë§ ê°•í•œ ì„±ì¥ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì œí’ˆì˜ ìš°ìˆ˜ì„±ì„ ë³´ì—¬ì£¼ëŠ” ì‹œì¥ ì—­í•™ì˜ ì§€ì†ì ì¸ ê¸ì •ì  ë³€í™”ê°€ ìˆìŠµë‹ˆë‹¤. ì§ˆë¬¸í•˜ì‹  ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ”, ì €í¬ê°€ ë©”ë””ì¼€ì´ë“œ(Medicaid)ì™€ ë©”ë””ì¼€ì–´(Medicare)ë¥¼ ëª¨ë‘ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ì´í•´í•˜ëŠ” ê²ƒì´ í•­ìƒ ì¤‘ìš”í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ë¯¹ìŠ¤ê°€ ìˆëŠ” ê²ƒì´ê³ , ë‹¹ì—°íˆ ë‘˜ ì¤‘ í•˜ë‚˜ê°€ ë‹¤ë¥¸ ê²ƒë³´ë‹¤ ìˆ˜ìµì„±ì´ ë” ë†’ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ë¯¹ìŠ¤ê°€ ì–´ë–»ê²Œ ì „ê°œë ì§€ëŠ” ì €í¬ ê°€ì´ë˜ìŠ¤ì™€ ë²”ìœ„ì— ì´ë¯¸ ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ íŠ¹íˆ TRxê°€ ë§¤ìš° ë†’ì€ ìˆ˜ì¤€ì¸ ì ì„ ê³ ë ¤í•˜ë©´, ì´ ì œí’ˆì˜ ì§€ì†ì ì¸ ëª¨ë©˜í…€ì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ì œí’ˆì— ëŒ€í•´ì„œëŠ” ìƒë‹¹í•œ ê¸°ëŒ€ë¥¼ ê°–ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ê°€ê²© ì±…ì •ì˜ ê¸°ë³¸ ì›ì¹™ì€ ëª…í™•í•©ë‹ˆë‹¤. ì´ë¯¸ ì´ë¥¼ ë°˜ì˜í–ˆê³ , ê²°êµ­ ë‘ ê°€ì§€ ì±„ë„ë¡œ ê·€ê²°ë©ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, David.</td></tr>
<tr><td>Operator: Our next question comes from Louise Chen of Scotiabank.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ìŠ¤ì½”ìƒ¤ë±…í¬ì˜ ë£¨ì´ì¦ˆ ì²¸ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Louise Chen: Scotiabank Global Banking and Markets, Research Division Congrats on the quarter. So my first question was, I wanted to ask you where you see the greatest disconnect between what you're excited about in your pipeline and what the Street is really missing on those products? And then second one, just a follow-up on AUSTEDO, I wanted to ask you how we should think about modeling 2027 in light of IRA and any other pushes and pulls you see here?</td><td>**Louise Chen:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ì€, ê·€ì‚¬ì˜ íŒŒì´í”„ë¼ì¸ì—ì„œ ê°€ì¥ ê¸°ëŒ€í•˜ê³  ê³„ì‹  ë¶€ë¶„ê³¼ ì‹œì¥ì´ ì‹¤ì œë¡œ ë†“ì¹˜ê³  ìˆëŠ” ì œí’ˆë“¤ ì‚¬ì´ì˜ ê°€ì¥ í° ê´´ë¦¬ê°€ ì–´ë””ì— ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” AUSTEDO ê´€ë ¨ ì¶”ê°€ ì§ˆë¬¸ì¸ë°ìš”, IRAì™€ ê¸°íƒ€ ì˜í–¥ ìš”ì¸ë“¤ì„ ê³ ë ¤í•  ë•Œ 2027ë…„ì„ ì–´ë–»ê²Œ ëª¨ë¸ë§í•´ì•¼ í• ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Richard Francis: President, CEO & Director Okay. Thanks for the questions there. So the pipeline, I'll probably tag team this a bit with Eric. What -- look, I'll never say anybody is missing anything because everybody is very experienced in this business. I do think that our pipeline has come along very fast, think of fast side, maybe that's caught people unaware. But I think the quality of our antibodies, the quality of anti-TL1, the quality of duvakitug, I think, will show out in the data. So I think probably what's going to happen, I'd anticipate is as we turn over these cards and we see the data, then I think Teva will get recognized for what is a world-class pipeline. But it's probably a bit surprising for people to see just the quality of the pipeline that's emerged in such a short space of time. But maybe I'll hand it to Eric to give his view on that.</td><td>**Richard Francis:** ì¢‹ìŠµë‹ˆë‹¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ì„œëŠ” Ericê³¼ í•¨ê»˜ ë‹µë³€ì„ ë‚˜ëˆ ì„œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ëˆ„êµ°ê°€ ë­”ê°€ë¥¼ ë†“ì¹˜ê³  ìˆë‹¤ê³  ë§í•˜ì§€ëŠ” ì•Šê² ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ ì—…ê³„ì— ê³„ì‹  ë¶„ë“¤ì€ ëª¨ë‘ ê²½í—˜ì´ í’ë¶€í•˜ì‹œë‹ˆê¹Œìš”. ë‹¤ë§Œ ì €í¬ íŒŒì´í”„ë¼ì¸ì´ ì •ë§ ë¹ ë¥´ê²Œ ë°œì „í•´ì™”ë‹¤ëŠ” ì , ì´ ì†ë„ê°ì´ ì‹œì¥ì—ì„œ ì˜ˆìƒí•˜ì§€ ëª»í–ˆì„ ìˆ˜ë„ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ í•­ì²´ì˜ í’ˆì§ˆ, anti-TL1ì˜ í’ˆì§ˆ, duvakitugì˜ í’ˆì§ˆì€ ë°ì´í„°ë¡œ ì…ì¦ë  ê²ƒì…ë‹ˆë‹¤. <br><br>ì•ìœ¼ë¡œ ì €í¬ê°€ ì¹´ë“œë¥¼ í•˜ë‚˜ì”© ê³µê°œí•˜ê³  ë°ì´í„°ë¥¼ ë³´ì—¬ë“œë¦¬ë©´, Tevaê°€ ì„¸ê³„ì  ìˆ˜ì¤€ì˜ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ì¸ì •ë°›ê²Œ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¤ë§Œ ì´ë ‡ê²Œ ì§§ì€ ê¸°ê°„ì— ì´ ì •ë„ í’ˆì§ˆì˜ íŒŒì´í”„ë¼ì¸ì´ êµ¬ì¶•ëœ ê²ƒ ìì²´ê°€ ì‹œì¥ì—ëŠ” ë‹¤ì†Œ ë†€ë¼ìš´ ì¼ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ” ì—ë¦­ì´ ì˜ê²¬ì„ ì œì‹œí•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eric Hughes: Executive VP of Global R&D and Chief Medical Officer Yes. Thank you, Richard, and thank you, Louise, for the question. I would emphasize something Richard said. I think the speed at which we turn around the innovative portfolio is quite honestly caught people by surprise. We've turned on a brand-new biologic for duvakitug, which is probably the best-in-class product for TL1A. We've launched or we will launch, hopefully, olanzapine LAI this year. But don't take our word for it. We've had external validation on 4 of these 5 programs. Olanzapine LAI got Royalty Pharma funding. Duvakitug was partnered with Sanofi, who saw the value. The DARI program was acknowledged by Abingworth. The anti-IL-15 program was recently acknowledged again by Royalty Pharma. And even emrusolmin, we've received Fast Track designation and an orphan designation. So across the entire innovative pipeline, we've accelerated them, I think, a little bit to the surprise of investors. But just look at the external validation that we've had in the pipeline and take that into consideration of your valuation.</td><td>**Eric Hughes:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Richard. ê·¸ë¦¬ê³  Louise, ì§ˆë¬¸ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. Richardê°€ ë§ì”€í•˜ì‹  ë¶€ë¶„ì„ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ê°€ í˜ì‹  í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì „í™˜í•œ ì†ë„ê°€ ì‚¬ëŒë“¤ì„ ë†€ë¼ê²Œ í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. TL1A íƒ€ê²Ÿì—ì„œ ì•„ë§ˆë„ ìµœê³  ìˆ˜ì¤€ì˜ ì œí’ˆì¸ ë“€ë°”í‚¤íˆ¬ê·¸(duvakitug)ë¼ëŠ” ì™„ì „íˆ ìƒˆë¡œìš´ ë°”ì´ì˜¤ë¡œì§ì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ì˜¬ë€ìí•€ LAI(olanzapine LAI)ë¥¼ ì¶œì‹œí–ˆê±°ë‚˜ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ ë§ë§Œ ë¯¿ì§€ ë§ˆì‹­ì‹œì˜¤. ì´ 5ê°œ í”„ë¡œê·¸ë¨ ì¤‘ 4ê°œì— ëŒ€í•´ ì™¸ë¶€ ê²€ì¦ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì˜¬ë€ìí•€ LAIëŠ” ë¡œì—´í‹° íŒŒë§ˆ(Royalty Pharma)ë¡œë¶€í„° í€ë”©ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ë“€ë°”í‚¤íˆ¬ê·¸ëŠ” ê·¸ ê°€ì¹˜ë¥¼ ì¸ì •í•œ ì‚¬ë…¸í”¼(Sanofi)ì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºì—ˆìŠµë‹ˆë‹¤. DARI í”„ë¡œê·¸ë¨ì€ ì•„ë¹™ì›ŒìŠ¤(Abingworth)ë¡œë¶€í„° ì¸ì •ë°›ì•˜ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•­-IL-15 í”„ë¡œê·¸ë¨ì€ ìµœê·¼ ë‹¤ì‹œ ë¡œì—´í‹° íŒŒë§ˆë¡œë¶€í„° ì¸ì •ë°›ì•˜ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì— ë£¨ì†”ë¯¼(emrusolmin)ì˜ ê²½ìš°ì—ë„ ì‹ ì†ì‹¬ì‚¬ì§€ì •(Fast Track designation)ê³¼ í¬ê·€ì˜ì•½í’ˆ ì§€ì •(orphan designation)ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì „ì²´ í˜ì‹  íŒŒì´í”„ë¼ì¸ì— ê±¸ì³ ìš°ë¦¬ëŠ” ê°œë°œ ì†ë„ë¥¼ ê°€ì†í™”í–ˆëŠ”ë°, íˆ¬ììë“¤ê»˜ì„œëŠ” ë‹¤ì†Œ ë†€ë¼ì…¨ì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ íŒŒì´í”„ë¼ì¸ì´ ë°›ì€ ì™¸ë¶€ ê²€ì¦ë“¤ì„ ë³´ì‹œê³ , ì´ë¥¼ ê¸°ì—…ê°€ì¹˜ í‰ê°€ì— ë°˜ì˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thank you, Eric. And then moving on to your final question about -- I think it was sort of asking for guidance on AUSTEDO in 2027, which I'm not going to give. Obviously, we've said we're going to do $2.5 billion for AUSTEDO in 2027. We remain very committed to that. As you see in our range that we have announced today, there's a potential that we will hit $2.5 billion in 2026. So we'll have to see how this plays out. I think the most important thing for AUSTEDO is to keep reminding everybody that 85% of people who suffer from tardive dyskinesia are still not treated. And so the opportunity to keep helping these patients to bring these patients in and give them therapy, I think, is a significant growth driver for AUSTEDO. So we also have the work we're doing on making sure that people can benefit from AUSTEDO XR. And as you can see there, 60% of new patients go on to AUSTEDO XR, and we know that helps with compliance and adherence, which obviously also in turn increases value. So I think we have a lot of value drivers for AUSTEDO, but I really don't want to get drawn into 2027 guidance at this moment. I think what I'm hoping people would see is what we have great momentum from '25. We're carrying that into '26, and we'll talk about '27 maybe this time next year.</td><td>**Richard Francis:** ê°ì‚¬í•©ë‹ˆë‹¤, Eric. ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ ì§ˆë¬¸ì´ì—ˆë˜ 2027ë…„ AUSTEDO ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ì„œëŠ” ì œê³µí•˜ì§€ ì•Šê² ìŠµë‹ˆë‹¤. ë‹¤ë§Œ ëª…í™•íˆ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” 2027ë…„ AUSTEDO ë§¤ì¶œ 25ì–µ ë‹¬ëŸ¬ ë‹¬ì„±ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìœ¼ë©°, ì´ ëª©í‘œì— ëŒ€í•œ ì˜ì§€ëŠ” í™•ê³ í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œí•œ ì „ë§ ë²”ìœ„ë¥¼ ë³´ì‹œë©´ 2026ë…„ì— 25ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í•  ê°€ëŠ¥ì„±ë„ ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ìƒí™©ì„ ì§€ì¼œë´ì•¼ í•  ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>AUSTEDOì™€ ê´€ë ¨í•´ì„œ ê°€ì¥ ì¤‘ìš”í•œ ì ì€, ì§€ë°œì„± ìš´ë™ì´ìƒì¦(tardive dyskinesia)ì„ ì•“ê³  ìˆëŠ” í™˜ìì˜ 85%ê°€ ì—¬ì „íˆ ì¹˜ë£Œë¥¼ ë°›ì§€ ëª»í•˜ê³  ìˆë‹¤ëŠ” ì‚¬ì‹¤ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ í™˜ìë“¤ì„ ì§€ì†ì ìœ¼ë¡œ ë•ê³ , ì¹˜ë£Œë¥¼ ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒì´ AUSTEDOì˜ ì¤‘ìš”í•œ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë˜í•œ í™˜ìë“¤ì´ AUSTEDO XRì˜ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ì‘ì—…ë„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ì‹ ê·œ í™˜ìì˜ 60%ê°€ AUSTEDO XRì„ ë³µìš©í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ìˆœì‘ë„ì™€ ì§€ì†ì„± í–¥ìƒì— ë„ì›€ì´ ëœë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‹¹ì—°íˆ ê°€ì¹˜ ì¦ëŒ€ë¡œ ì´ì–´ì§€ì£ . AUSTEDOì˜ ê°€ì¹˜ ë™ì¸ì´ ë§ë‹¤ê³  ìƒê°í•˜ì§€ë§Œ, ì§€ê¸ˆ ì‹œì ì—ì„œ 2027ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ê¹Šì´ ë“¤ì–´ê°€ê³  ì‹¶ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì œê°€ ë°”ë¼ëŠ” ê²ƒì€ 25ë…„ì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ í™•ì¸í•˜ì‹œëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ 26ë…„ìœ¼ë¡œ ì´ì–´ê°€ê³  ìˆê³ , 27ë…„ì— ëŒ€í•´ì„œëŠ” ë‚´ë…„ ì´ë§˜ë•Œì¯¤ ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Ash Verma of UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Ash Vermaë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ashwani Verma: UBS Investment Bank, Research Division Congrats on all the progress. So maybe just first one, how are you thinking about funding the R&D? So increasingly seeing more royalties and/or profit share. Just when you think about it strategically, how do you balance not giving away attractive economics to your partner versus seeing a meaningful increase in your internal R&D spend as you fund the growing pipeline? And then secondly, on the TL1A upcoming maintenance data, we've seen some competitors that the maintenance data versus the induction sort of went up on efficacy measures by high single digit to mid-teens in terms of percentage points. Is that a fair expectation to have as you look towards your upcoming results?</td><td>**Ashwani Verma:** ì—°êµ¬ê°œë°œ íˆ¬ì ì§„ì „ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë¨¼ì € ì²« ë²ˆì§¸ ì§ˆë¬¸ìœ¼ë¡œ, R&D ìê¸ˆ ì¡°ë‹¬ì„ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ìµœê·¼ ë¡œì—´í‹°ë‚˜ ì´ìµ ê³µìœ  ë°©ì‹ì´ ì ì  ëŠ˜ì–´ë‚˜ê³  ìˆëŠ”ë°ìš”. ì „ëµì  ê´€ì ì—ì„œ íŒŒíŠ¸ë„ˆì—ê²Œ ë§¤ë ¥ì ì¸ ê²½ì œì  ê°€ì¹˜ë¥¼ ë„˜ê²¨ì£¼ì§€ ì•ŠëŠ” ê²ƒê³¼ íŒŒì´í”„ë¼ì¸ ì„±ì¥ì„ ìœ„í•œ ë‚´ë¶€ R&D ì§€ì¶œì„ ì˜ë¯¸ ìˆê²Œ ëŠ˜ë¦¬ëŠ” ê²ƒ ì‚¬ì´ì˜ ê· í˜•ì„ ì–´ë–»ê²Œ ë§ì¶”ê³  ê³„ì‹ ê°€ìš”? <br><br>ë‘ ë²ˆì§¸ë¡œ TL1A ìœ ì§€ìš”ë²• ë°ì´í„° ê´€ë ¨í•´ì„œìš”. ê²½ìŸì‚¬ë“¤ì˜ ê²½ìš° ìœ ì§€ìš”ë²• ë°ì´í„°ê°€ ë„ì…ìš”ë²• ëŒ€ë¹„ íš¨ëŠ¥ ì§€í‘œì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ 10% ì¤‘ë°˜ëŒ€ê¹Œì§€ í¼ì„¼íŠ¸ í¬ì¸íŠ¸ ìƒìŠ¹í•˜ëŠ” ê²ƒì„ ë´¤ìŠµë‹ˆë‹¤. ë‹¤ê°€ì˜¤ëŠ” ê·€ì‚¬ ê²°ê³¼ë¥¼ ë³´ì‹¤ ë•Œ ì´ ì •ë„ê°€ í•©ë¦¬ì ì¸ ê¸°ëŒ€ì¹˜ë¼ê³  ë³´ì‹œë‚˜ìš”?</td></tr>
<tr><td>Richard Francis: President, CEO & Director Ash, thanks for the question. I'll tag team this with Eric again. But on the R&D funding, I think the question was, how are you going to fund this? Are you going to be giving away value if you keep doing these partnerships? So I think the way we think about it is we have a big late-stage pipeline. We have a lot of opportunities to drive significant value creation. And when you have a good pipeline, in my experience and my belief is it's about moving it faster to the market to have patients benefit from it and to get revenue. And so we're moving a big pipeline really quickly here. Now how does it impact the economics? It really doesn't impact the economics in any meaningful way for a couple of reasons. One is these -- all these brands will be above $1 billion. Some of them will be multiple billion brands. The second thing is, which is an interesting fact that I think people miss on Teva is we're starting with a company with a very different gross margin than many other biopharma companies. So every time we launch an innovative product, it transforms our gross margin, which transforms our ability to drive EBITDA to drive EPS and cash flow. So as I said, the fact that these are not in any way giving away value in the broadest sense. But even with regard to Teva, they don't because of where we actually start this journey. The other thing I'd also like to highlight on this, we are launching so many products over such a short period of time that, that is the focus we're on. And we're going to have a potential to launch 4 products in 5 years, and we're going to actually announce more and more indications. So I think the pipeline is about making sure we move it quickly to the market. But in no way are we giving away value. I'd say we're accelerating value because of the speed we're moving. And then with regard to the key to the TL1A maintenance data, what are our expectations? I'll hand it over to Eric to answer, and then I'll conclude.</td><td>**Richard Francis:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ Ericê³¼ í•¨ê»˜ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. R&D ìê¸ˆ ì¡°ë‹¬ì— ê´€í•œ ì§ˆë¬¸ì´ì…¨ëŠ”ë°, ì–´ë–»ê²Œ ìê¸ˆì„ ì¡°ë‹¬í•  ê²ƒì´ë©°, ì´ëŸ¬í•œ íŒŒíŠ¸ë„ˆì‹­ì„ ê³„ì† ì§„í–‰í•˜ë©´ ê°€ì¹˜ë¥¼ í¬ê¸°í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆëƒëŠ” ë‚´ìš©ì´ì—ˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ìƒê°í•˜ëŠ” ë°©ì‹ì€ ì´ë ‡ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ëŒ€ê·œëª¨ í›„ê¸° ë‹¨ê³„ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒë‹¹í•œ ê°€ì¹˜ ì°½ì¶œì„ ì´ëŒì–´ë‚¼ ìˆ˜ ìˆëŠ” ë§ì€ ê¸°íšŒë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì¢‹ì€ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆì„ ë•Œ, ì œ ê²½í—˜ê³¼ ì‹ ë…ìœ¼ë¡œëŠ” í™˜ìë“¤ì´ í˜œíƒì„ ë°›ê³  ë§¤ì¶œì„ ì°½ì¶œí•  ìˆ˜ ìˆë„ë¡ ë” ë¹ ë¥´ê²Œ ì‹œì¥ì— ì¶œì‹œí•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì§€ê¸ˆ ëŒ€ê·œëª¨ íŒŒì´í”„ë¼ì¸ì„ ë§¤ìš° ë¹ ë¥´ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ê²ƒì´ ê²½ì œì„±ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ëŠëƒê³ ìš”? ì‹¤ì œë¡œëŠ” ì˜ë¯¸ ìˆëŠ” ë°©ì‹ìœ¼ë¡œ ê²½ì œì„±ì— ì˜í–¥ì„ ì£¼ì§€ ì•ŠìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ ì´ìœ ê°€ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, ì´ ëª¨ë“  ë¸Œëœë“œë“¤ì€ 10ì–µ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ ì¤‘ ì¼ë¶€ëŠ” ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë¸Œëœë“œê°€ ë  ê²ƒì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ í¥ë¯¸ë¡œìš´ ì‚¬ì‹¤ì€, ë§ì€ ë¶„ë“¤ì´ í…Œë°”ì— ëŒ€í•´ ê°„ê³¼í•˜ì‹œëŠ” ë¶€ë¶„ì¸ë°, ìš°ë¦¬ëŠ” ë‹¤ë¥¸ ë§ì€ ë°”ì´ì˜¤ì œì•½ ê¸°ì—…ë“¤ê³¼ëŠ” ë§¤ìš° ë‹¤ë¥¸ ë§¤ì¶œì´ì´ìµë¥ (gross margin)ì„ ê°€ì§„ íšŒì‚¬ì—ì„œ ì¶œë°œí•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ í˜ì‹ ì ì¸ ì œí’ˆì„ ì¶œì‹œí•  ë•Œë§ˆë‹¤ ìš°ë¦¬ì˜ ë§¤ì¶œì´ì´ìµë¥ ì´ ë³€í™”í•˜ê³ , ì´ëŠ” EBITDAì™€ ì£¼ë‹¹ìˆœì´ìµ(EPS), ê·¸ë¦¬ê³  í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí•˜ëŠ” ëŠ¥ë ¥ì„ ê·¼ë³¸ì ìœ¼ë¡œ ë³€í™”ì‹œí‚µë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë ¸ë“¯ì´, ì´ëŸ¬í•œ ì œí’ˆë“¤ì´ ì–´ë–¤ ì‹ìœ¼ë¡œë“  ê°€ì¹˜ë¥¼ í¬ê¸°í•˜ëŠ” ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. í…Œë°”ì˜ ê´€ì ì—ì„œ ë´ë„ ê·¸ë ‡ìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì‹¤ì œë¡œ ì´ ì—¬ì •ì„ ì‹œì‘í•˜ëŠ” ì§€ì ì´ ì–´ë””ì¸ì§€ë¥¼ ê³ ë ¤í•˜ë©´ ë§ì´ì£ . ë˜ í•œ ê°€ì§€ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì ì€, ìš°ë¦¬ê°€ ë§¤ìš° ì§§ì€ ê¸°ê°„ ë™ì•ˆ ì´ë ‡ê²Œ ë§ì€ ì œí’ˆë“¤ì„ ì¶œì‹œí•˜ê³  ìˆë‹¤ëŠ” ê²ƒì´ë©°, ë°”ë¡œ ì´ê²ƒì´ ìš°ë¦¬ê°€ ì§‘ì¤‘í•˜ê³  ìˆëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” 5ë…„ ë‚´ì— 4ê°œ ì œí’ˆì„ ì¶œì‹œí•  ìˆ˜ ìˆëŠ” ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì ì  ë” ë§ì€ ì ì‘ì¦ì„ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ íŒŒì´í”„ë¼ì¸ì˜ í•µì‹¬ì€ ì‹œì¥ì— ì‹ ì†í•˜ê²Œ ì§„ì…í•˜ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ê²°ì½” ê°€ì¹˜ë¥¼ í¬ê¸°í•˜ëŠ” ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì˜¤íˆë ¤ ìš°ë¦¬ê°€ ì›€ì§ì´ëŠ” ì†ë„ ë•ë¶„ì— ê°€ì¹˜ë¥¼ ê°€ì†í™”í•˜ê³  ìˆë‹¤ê³  ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  TL1A ìœ ì§€ìš”ë²• ë°ì´í„°ì˜ í•µì‹¬ê³¼ ìš°ë¦¬ì˜ ê¸°ëŒ€ì¹˜ì— ê´€í•´ì„œëŠ” Ericì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ê·¸ í›„ì— ì œê°€ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eric Hughes: Executive VP of Global R&D and Chief Medical Officer Sure. Yes. Thanks, Ash, for the question regarding what we anticipate from the maintenance data of TL1A. So I'd start off by saying what's the history we've been telling with regard to duvakitug at Teva. We started by saying that we found in our in vitro work that we had the most potent antibody, the most selective antibody and the one that probably has the lowest antidrug antibodies. I think it's about 3% to 5% we saw in our Phase II study. So with that, we went into our Phase II program that we executed very well at speed. And then we came up with the highest reported numbers for both ulcerative colitis in Crohn's disease in 2 very well-controlled and run studies. So the in vitro translated into a very good result in Phase II. So if you translate that into what we anticipate in the maintenance, if you think that we have the most potent, the most selective, the lowest antidrug antibodies and that we can execute the study well, I would hope that when we lock the database, we see great results. So I'm bullish on it. Hopefully, that comes true, but we'll see what the data shows.</td><td>**Eric Hughes:** ë„¤, ì• ì‰¬, TL1Aì˜ ìœ ì§€ìš”ë²• ë°ì´í„°ì— ëŒ€í•œ ê¸°ëŒ€ì— ê´€í•œ ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € í…Œë°”ì—ì„œ ë‘ë°”í‚¤íˆ¬ë§™ì— ëŒ€í•´ ìš°ë¦¬ê°€ ì–´ë–¤ ì´ì•¼ê¸°ë¥¼ í•´ì™”ëŠ”ì§€ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹œí—˜ê´€ ì—°êµ¬(in vitro)ì—ì„œ ê°€ì¥ ê°•ë ¥í•œ í•­ì²´, ê°€ì¥ ì„ íƒì ì¸ í•­ì²´, ê·¸ë¦¬ê³  ì•„ë§ˆë„ í•­ì•½ë¬¼í•­ì²´(antidrug antibodies)ê°€ ê°€ì¥ ë‚®ì€ í•­ì²´ë¥¼ ë°œê²¬í–ˆë‹¤ëŠ” ê²ƒë¶€í„° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. 2ìƒ ì„ìƒì‹œí—˜ì—ì„œ ì•½ 3~5% ì •ë„ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ ë°”íƒ•ìœ¼ë¡œ 2ìƒ í”„ë¡œê·¸ë¨ì„ ì‹ ì†í•˜ê²Œ ë§¤ìš° ì˜ ì‹¤í–‰í–ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ê³¼ í¬ë¡ ë³‘ ëª¨ë‘ì—ì„œ ê°€ì¥ ë†’ì€ ìˆ˜ì¹˜ë¥¼ ë³´ê³ í–ˆê³ , ì´ëŠ” ë§¤ìš° ì˜ í†µì œë˜ê³  ì§„í–‰ëœ ë‘ ì—°êµ¬ì—ì„œ ë‚˜ì˜¨ ê²°ê³¼ì…ë‹ˆë‹¤. ì¦‰, ì‹œí—˜ê´€ ì—°êµ¬ ê²°ê³¼ê°€ 2ìƒì—ì„œ ë§¤ìš° ì¢‹ì€ ê²°ê³¼ë¡œ ì´ì–´ì§„ ê²ƒì…ë‹ˆë‹¤. ìœ ì§€ìš”ë²•ìœ¼ë¡œ ì „í™˜í–ˆì„ ë•Œ ì–´ë–¤ ê²°ê³¼ë¥¼ ê¸°ëŒ€í•˜ëŠ”ì§€ ë§ì”€ë“œë¦¬ìë©´, ì €í¬ê°€ ê°€ì¥ ê°•ë ¥í•˜ê³ , ê°€ì¥ ì„ íƒì ì´ë©°, í•­ì•½ë¬¼í•­ì²´(antidrug antibodies)ê°€ ê°€ì¥ ë‚®ì€ ì•½ë¬¼ì„ ë³´ìœ í•˜ê³  ìˆê³ , ì„ìƒì‹œí—˜ì„ ì˜ ìˆ˜í–‰í•  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•œë‹¤ë©´, ë°ì´í„°ë² ì´ìŠ¤ë¥¼ ì ê¸ˆ(lock)í•  ë•Œ í›Œë¥­í•œ ê²°ê³¼ë¥¼ ë³¼ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €ëŠ” ë‚™ê´€ì ì…ë‹ˆë‹¤. ê·¸ë ‡ê²Œ ë˜ê¸°ë¥¼ ë°”ë¼ì§€ë§Œ, ë°ì´í„°ê°€ ì–´ë–»ê²Œ ë‚˜ì˜¤ëŠ”ì§€ ì§€ì¼œë´ì•¼ê² ì£ .</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks, Eric. We stand by the fact that we have and we believe we have the best TL1A.</td><td>**Richard Francis:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Eric. ì €í¬ëŠ” ìµœê³ ì˜ TL1Aë¥¼ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ì‚¬ì‹¤ì„ í™•ì‹ í•˜ë©°, ì•ìœ¼ë¡œë„ ì´ ì…ì¥ì„ ê²¬ì§€í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Jason Gerberry of Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ ì œì´ìŠ¨ ê±°ë² ë¦¬ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jason Gerberry: BofA Securities, Research Division One for Eli, just I didn't catch this, but can you talk about in 2026 guide, sort of what's the gross margin outlook versus the OpEx spend ratio? I think the latter would be in that 27% to 28% range you guys have talked about historically, but I just wanted to make sure that, that was confirmed from a modeling perspective. And then just for my follow-up, on vitiligo, I was trying to maybe understand kind of what we're going to get with this upcoming Phase Ib. Will we get VASI75 scores through the full evaluable period? Are you expecting most of these 30-plus patients to make it through the full evaluable period? Just kind of wondering how robust that data will be.</td><td>**Jason Gerberry:** 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ì—˜ë¦¬ì—ê²Œ ì§ˆë¬¸ í•˜ë‚˜ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì œê°€ ë†“ì¹œ ë¶€ë¶„ì´ ìˆëŠ”ë°, ë§¤ì¶œì´ì´ìµë¥  ì „ë§ê³¼ ì˜ì—…ë¹„ìš© ë¹„ìœ¨ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì˜ì—…ë¹„ìš© ë¹„ìœ¨ì€ ì—¬ëŸ¬ë¶„ì´ ì—­ì‚¬ì ìœ¼ë¡œ ë§ì”€í•˜ì‹  27%ì—ì„œ 28% ë²”ìœ„ì¼ ê²ƒìœ¼ë¡œ ìƒê°í•˜ëŠ”ë°, ëª¨ë¸ë§ ê´€ì ì—ì„œ ì´ ë¶€ë¶„ì´ ë§ëŠ”ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  í›„ì† ì§ˆë¬¸ìœ¼ë¡œ ë°±ë°˜ì¦ ê´€ë ¨í•´ì„œìš”, ë‹¤ê°€ì˜¤ëŠ” 1bìƒ ì„ìƒì—ì„œ ì–´ë–¤ ê²°ê³¼ë¥¼ ì–»ê²Œ ë ì§€ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì „ì²´ í‰ê°€ ê¸°ê°„ ë™ì•ˆ VASI75 ì ìˆ˜ë¥¼ ë°›ê²Œ ë˜ë‚˜ìš”? 30ëª… ì´ìƒì˜ í™˜ìë“¤ ëŒ€ë¶€ë¶„ì´ ì „ì²´ í‰ê°€ ê¸°ê°„ì„ ì™„ë£Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œë‚˜ìš”? ê·¸ ë°ì´í„°ê°€ ì–¼ë§ˆë‚˜ ê²¬ê³ í• ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks, Jason. Thanks for the question. So over to you, Eli, on the gross margin.</td><td>**Richard Francis:** ê°ì‚¬í•©ë‹ˆë‹¤, Jason. ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ê·¸ëŸ¼ ë§¤ì¶œì´ì´ìµë¥ (gross margin)ì— ëŒ€í•´ì„œëŠ” Eliê°€ ë‹µë³€í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eliyahu Kalif: Executive VP & CFO Jason, thanks for the question. So on gross margin, we end up the year, if we exclude the 2 milestone payments at a 54.7% gross margin. We are looking to be in the range of 54.5% to 55.5% in 2026. In terms of the OpEx, there are kind of mainly 2 dynamics there. First of all, -- and as I mentioned in my prepared remarks, we're going to see a bit higher OpEx, still in the range between 27% to 28% in the first half versus the second half just because of the revenue dynamics during the year. But there is also another element inside the OpEx, we're going to see more reduction in our G&A and actually shifting that reduction in between R&D and sales and marketing and able to stabilize it at the range of 27% to 28%. So this one didn't change versus our prior communication.</td><td>**Eliyahu Kalif:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥ (gross margin)ë¶€í„° ë§ì”€ë“œë¦¬ë©´, 2ê±´ì˜ ë§ˆì¼ìŠ¤í†¤ ì§€ê¸‰ì„ ì œì™¸í•˜ê³  ì—°ë§ ê¸°ì¤€ 54.7%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” 54.5%ì—ì„œ 55.5% ë²”ìœ„ë¥¼ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìš´ì˜ë¹„ìš©(OpEx) ê´€ë ¨í•´ì„œëŠ” ì£¼ë¡œ ë‘ ê°€ì§€ ìš”ì¸ì´ ì‘ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ì„  ì œê°€ ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ì—°ì¤‘ ë§¤ì¶œ ë³€ë™ì„±ìœ¼ë¡œ ì¸í•´ ìƒë°˜ê¸°ì— ìš´ì˜ë¹„ìš©ì´ ë‹¤ì†Œ ë†’ì•„ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ê·¸ë˜ë„ ì—¬ì „íˆ 27%ì—ì„œ 28% ë²”ìœ„ ë‚´ì—ì„œ ìœ ì§€ë  ê²ƒì´ë©°, ì´ëŠ” í•˜ë°˜ê¸° ëŒ€ë¹„ ë†’ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. <br><br>ë˜ ë‹¤ë¥¸ ìš”ì†Œë¡œëŠ” ìš´ì˜ë¹„ìš© ë‚´ë¶€ êµ¬ì¡° ë³€í™”ê°€ ìˆìŠµë‹ˆë‹¤. ì¼ë°˜ê´€ë¦¬ë¹„(G&A)ë¥¼ ë” ì¤„ì´ê³ , ê·¸ ê°ì†Œë¶„ì„ ì—°êµ¬ê°œë°œ(R&D)ê³¼ ì˜ì—… ë° ë§ˆì¼€íŒ… ë¶€ë¬¸ìœ¼ë¡œ ì¬ë°°ì¹˜í•  ê³„íšì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì „ì²´ ìš´ì˜ë¹„ìš©ì„ 27%ì—ì„œ 28% ë²”ìœ„ë¡œ ì•ˆì •í™”ì‹œí‚¬ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ì´ì „ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ê³¼ ë³€ë™ì‚¬í•­ì´ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Yes. And the thing I'd add on to that, Jason, is gross margin is a really exciting story for us because as you see, as we continue to grow our innovative portfolio, we continue to launch products, that gross margin will just keep going up. It's just going to be a question of how much, but it will keep going up because of the fact that we're changing our portfolio so dramatically. Now with regard to the vitiligo data, I'll hand over to Eric.</td><td>**Richard Francis:** ë„¤, ì œì´ìŠ¨, ê±°ê¸°ì— ë§ë¶™ì´ìë©´ ë§¤ì¶œì´ì´ìµë¥ ì€ ìš°ë¦¬ì—ê²Œ ì •ë§ í¥ë¯¸ë¡œìš´ ìŠ¤í† ë¦¬ì…ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ í˜ì‹ ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê³„ì† ì„±ì¥ì‹œí‚¤ê³  ì œí’ˆì„ ì§€ì†ì ìœ¼ë¡œ ì¶œì‹œí•˜ë©´ì„œ ë§¤ì¶œì´ì´ìµë¥ ì€ ê³„ì† ìƒìŠ¹í•  ê²ƒì…ë‹ˆë‹¤. ì–¼ë§ˆë‚˜ ì˜¤ë¥¼ì§€ì˜ ë¬¸ì œì¼ ë¿, í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì´ë ‡ê²Œ ê·¹ì ìœ¼ë¡œ ë³€í™”ì‹œí‚¤ê³  ìˆê¸° ë•Œë¬¸ì— ê³„ì† ìƒìŠ¹í•  ê²ƒì…ë‹ˆë‹¤. ë°±ë°˜ì¦ ë°ì´í„°ì— ê´€í•´ì„œëŠ” ì—ë¦­ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eric Hughes: Executive VP of Global R&D and Chief Medical Officer Yes. Thank you, Jason, for the question. So the data that we're going to be presenting in the first half of 2026 is a single-arm study for patients with vitiligo. It's about 38 patients in total. It will have the traditional and known endpoints for this field, which is facial VASI and total VASI. So it will be easily comparable to other treatments out there. And that reminds me the important thing here is that there are limited treatments for vitiligo today. There's one approved, which is a topical that only covers 10% of your body. And ones that are in development are the ones that what we need, things that are systemic in treatment, not only the face, but the entire body, more than just 10%. So one of the exciting things we think about when we talk about our anti-IL-15 program in vitiligo is this has the potential to be a once subcutaneous shot every 3 months. So a quarterly shot potentially to treat a systemic disease. So we're looking forward to that. You'll -- I think you'll get data that we'll be able to compare it to other treatments out there in development and approved.</td><td>**Eric Hughes:** ë„¤, Jason, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 2026ë…„ ìƒë°˜ê¸°ì— ë°œí‘œí•  ì˜ˆì •ì¸ ë°ì´í„°ëŠ” ë°±ë°˜ì¦ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ë‹¨ì¼êµ° ì—°êµ¬ì…ë‹ˆë‹¤. ì´ 38ëª…ì˜ í™˜ìê°€ ì°¸ì—¬í•˜ë©°, ì´ ë¶„ì•¼ì—ì„œ ì „í†µì ìœ¼ë¡œ ì‚¬ìš©ë˜ëŠ” ì˜ ì•Œë ¤ì§„ í‰ê°€ì§€í‘œì¸ ì•ˆë©´ VASI(Vitiligo Area Scoring Index)ì™€ ì „ì‹  VASIë¥¼ ì‚¬ìš©í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¤ë¥¸ ì¹˜ë£Œë²•ë“¤ê³¼ ì‰½ê²Œ ë¹„êµê°€ ê°€ëŠ¥í•  ê²ƒì…ë‹ˆë‹¤.<br><br>ì—¬ê¸°ì„œ ì¤‘ìš”í•œ ì ì€ í˜„ì¬ ë°±ë°˜ì¦ ì¹˜ë£Œì œê°€ ë§¤ìš° ì œí•œì ì´ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ìŠ¹ì¸ëœ ì¹˜ë£Œì œëŠ” í•˜ë‚˜ë¿ì¸ë°, ì²´í‘œë©´ì ì˜ 10%ë§Œ ì»¤ë²„í•  ìˆ˜ ìˆëŠ” êµ­ì†Œ ë„í¬ì œì…ë‹ˆë‹¤. í˜„ì¬ ê°œë°œ ì¤‘ì¸ ì¹˜ë£Œì œë“¤ì€ ìš°ë¦¬ì—ê²Œ í•„ìš”í•œ ê²ƒ, ì¦‰ ì–¼êµ´ë¿ë§Œ ì•„ë‹ˆë¼ ì „ì‹ ì„ ì¹˜ë£Œí•  ìˆ˜ ìˆëŠ” ì „ì‹  ì¹˜ë£Œì œì´ë©°, ë‹¨ìˆœíˆ 10%ê°€ ì•„ë‹Œ ê·¸ ì´ìƒì„ ì¹˜ë£Œí•  ìˆ˜ ìˆëŠ” ê²ƒë“¤ì…ë‹ˆë‹¤. ë°±ë°˜ì¦ì— ëŒ€í•œ í•­IL-15 í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë•Œ ê°€ì¥ í¥ë¯¸ë¡œìš´ ì  ì¤‘ í•˜ë‚˜ëŠ” 3ê°œì›”ë§ˆë‹¤ í•œ ë²ˆì”© í”¼í•˜ì£¼ì‚¬ë¡œ íˆ¬ì—¬í•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì…ë‹ˆë‹¤. ì¦‰, ì „ì‹  ì§ˆí™˜ì„ ì¹˜ë£Œí•˜ê¸° ìœ„í•´ ë¶„ê¸°ë³„ë¡œ í•œ ë²ˆë§Œ íˆ¬ì—¬í•˜ë©´ ë˜ëŠ” ê²ƒì´ì£ . ì´ ë¶€ë¶„ì„ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ ë°ì´í„°ë¥¼ í†µí•´ í˜„ì¬ ê°œë°œ ì¤‘ì´ê±°ë‚˜ ìŠ¹ì¸ëœ ë‹¤ë¥¸ ì¹˜ë£Œì œë“¤ê³¼ ë¹„êµí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Chris Schott of JPMorgan.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPëª¨ê±´ì˜ í¬ë¦¬ìŠ¤ ì‡¼íŠ¸ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division Just sticking on IL-15. On the development time lines in vitiligo, can you just elaborate what exactly you need for that 2031 pathway versus '34? And I guess, is there a similar opportunity in celiac there as well? And if I can just do a really quick one, just coming back to AUSTEDO. I think you were talking about roughly $100 million benefit in 4Q, and it sounds like that's between rebate and inventory. Just when we think about destocking in 1Q, can you just clarify how much of that was inventory and how much was kind of this reversal of rebates?</td><td>**Christopher Schott:** ë°±ë°˜ì¦ì—ì„œì˜ ê°œë°œ ì¼ì •ê³¼ ê´€ë ¨í•´ì„œ, 2031ë…„ ê²½ë¡œì™€ 2034ë…„ ê²½ë¡œì˜ ì°¨ì´ì ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 2031ë…„ ê²½ë¡œë¥¼ ìœ„í•´ì„œëŠ” íŠ¹ì • ì„ìƒ ë°ì´í„°ì™€ ê·œì œ ìš”ê±´ë“¤ì„ ì¶©ì¡±í•´ì•¼ í•˜ëŠ”ë°, ì´ëŠ” ë³´ë‹¤ ì‹ ì†í•œ ìŠ¹ì¸ ê²½ë¡œë¥¼ í™œìš©í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë°˜ë©´ 2034ë…„ ê²½ë¡œëŠ” ë³´ë‹¤ ì „í†µì ì¸ ê°œë°œ í”„ë¡œê·¸ë¨ì„ ë”°ë¥´ê²Œ ë©ë‹ˆë‹¤. ì…€ë¦¬ì•…ë³‘ì˜ ê²½ìš°ì—ë„ ìœ ì‚¬í•œ ê¸°íšŒê°€ ìˆì„ ìˆ˜ ìˆì§€ë§Œ, ê° ì ì‘ì¦ë§ˆë‹¤ ê·œì œ ìš”ê±´ê³¼ ì„ìƒ ê°œë°œ ê³„íšì´ ë‹¤ë¦…ë‹ˆë‹¤.<br><br>AUSTEDO ê´€ë ¨ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, 4ë¶„ê¸°ì— ì•½ 1ì–µ ë‹¬ëŸ¬ì˜ ê¸ì •ì  íš¨ê³¼ê°€ ìˆì—ˆë‹¤ê³  ë§ì”€ë“œë ¸ëŠ”ë°, ì´ëŠ” ë¦¬ë² ì´íŠ¸ì™€ ì¬ê³  íš¨ê³¼ê°€ ë³µí•©ì ìœ¼ë¡œ ì‘ìš©í•œ ê²ƒì…ë‹ˆë‹¤. 1ë¶„ê¸° ì¬ê³  ì¡°ì •ê³¼ ê´€ë ¨í•´ì„œ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, 1ì–µ ë‹¬ëŸ¬ ì¤‘ ì¬ê³  íš¨ê³¼ì™€ ë¦¬ë² ì´íŠ¸ ë°˜ì „ íš¨ê³¼ì˜ ë¹„ì¤‘ì„ ëª…í™•íˆ êµ¬ë¶„í•˜ìë©´, ì¬ê³  ê´€ë ¨ ë¶€ë¶„ì´ ìƒë‹¹ ë¶€ë¶„ì„ ì°¨ì§€í–ˆê³ , ë‚˜ë¨¸ì§€ê°€ ë¦¬ë² ì´íŠ¸ ì¡°ì •ì— ë”°ë¥¸ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. 1ë¶„ê¸°ì—ëŠ” ì´ëŸ¬í•œ ì¬ê³  íš¨ê³¼ê°€ ì •ìƒí™”ë˜ë©´ì„œ ì¼ë¶€ ì—­íš¨ê³¼ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks for the question, Chris. Eric, do you want to start with the anti-IL-15, vitiligo and celiac?</td><td>**Richard Francis:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Chris. Eric, anti-IL-15, ë°±ë°˜ì¦, ê·¸ë¦¬ê³  ì…€ë¦¬ì•…ë³‘ì— ëŒ€í•´ ë¨¼ì € ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Eric Hughes: Executive VP of Global R&D and Chief Medical Officer Sure. So thank you for the question on IL-15. So just to start off with IL-15 is it's a key cytokine in a number of different indications I mentioned before. We're working on vitiligo and celiac. I'm excited by both the potential for alopecia areata, atopic dermatitis or eosinophilic esophagitis. They're all interesting and important for this cytokine. For vitiligo, we're particularly excited because this is a program that we can move quickly. It has precedents for the regulatory endpoint. It's an endpoint that you can easily measure. You see the results. So that makes it a little bit more easy. And there's an unmet medical need here. We need systemic therapies, as I mentioned before. So we're thinking out of the box at Teva, we are accelerating this program in a clever pathway of a Phase II and Phase III study that we can work very quickly with the regulators. So the potential for a once quarterly dose subcutaneous shot is very exciting for us.</td><td>**Eric Hughes:** ë„¤, IL-15ì— ëŒ€í•œ ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € IL-15ëŠ” ì œê°€ ì•ì„œ ì–¸ê¸‰í•œ ì—¬ëŸ¬ ì ì‘ì¦ì—ì„œ í•µì‹¬ì ì¸ ì‚¬ì´í† ì¹´ì¸ì…ë‹ˆë‹¤. í˜„ì¬ ë°±ë°˜ì¦ê³¼ ì…€ë¦¬ì•…ë³‘ì— ëŒ€í•´ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì›í˜• íƒˆëª¨ì¦, ì•„í† í”¼ í”¼ë¶€ì—¼, í˜¸ì‚°êµ¬ì„± ì‹ë„ì—¼ì— ëŒ€í•œ ê°€ëŠ¥ì„±ë„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì‚¬ì´í† ì¹´ì¸ê³¼ ê´€ë ¨í•´ì„œ ëª¨ë‘ í¥ë¯¸ë¡­ê³  ì¤‘ìš”í•œ ì ì‘ì¦ë“¤ì…ë‹ˆë‹¤. ë°±ë°˜ì¦ì˜ ê²½ìš° íŠ¹íˆ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. ì´ í”„ë¡œê·¸ë¨ì€ ë¹ ë¥´ê²Œ ì§„í–‰í•  ìˆ˜ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·œì œ ìŠ¹ì¸ì„ ìœ„í•œ í‰ê°€ë³€ìˆ˜(endpoint)ì— ì„ ë¡€ê°€ ìˆê³ , ì¸¡ì •ì´ ìš©ì´í•œ í‰ê°€ë³€ìˆ˜ì…ë‹ˆë‹¤. ê²°ê³¼ë¥¼ ì§ì ‘ í™•ì¸í•  ìˆ˜ ìˆì–´ì„œ ë¹„êµì  ìˆ˜ì›”í•œ í¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸°ì—ëŠ” ì¶©ì¡±ë˜ì§€ ì•Šì€ ì˜ë£Œì  í•„ìš”(unmet medical need)ê°€ ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì „ì‹  ì¹˜ë£Œì œê°€ í•„ìš”í•œ ìƒí™©ì…ë‹ˆë‹¤. <response><br><br>ë”°ë¼ì„œ í…Œë°”ì—ì„œëŠ” ê¸°ì¡´ì˜ í‹€ì„ ë²—ì–´ë‚œ ì‚¬ê³ ë¥¼ í•˜ê³  ìˆìœ¼ë©°, 2ìƒê³¼ 3ìƒ ì„ìƒì‹œí—˜ì„ ì˜ë¦¬í•œ ë°©ì‹ìœ¼ë¡œ ì§„í–‰í•˜ì—¬ ê·œì œ ë‹¹êµ­ê³¼ ì‹ ì†í•˜ê²Œ í˜‘ë ¥í•  ìˆ˜ ìˆë„ë¡ ì´ í”„ë¡œê·¸ë¨ì„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë¶„ê¸°ë‹¹ 1íšŒ í”¼í•˜ ì£¼ì‚¬ íˆ¬ì—¬ ê°€ëŠ¥ì„±ì€ ì €í¬ì—ê²Œ ë§¤ìš° í¥ë¯¸ë¡œìš´ ê¸°íšŒì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks, Eric. And then on the AUSTEDO question, Chris, the way to think about that $100 million is the vast majority, the vast majority pretty much was the inventory. So that's why, obviously, we have a lot of confidence about 2026 in our numbers. So hopefully, that helps, Chris.</td><td>**Richard Francis:** ê°ì‚¬í•©ë‹ˆë‹¤, Eric. ê·¸ë¦¬ê³  AUSTEDO ê´€ë ¨ ì§ˆë¬¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, Chris, ê·¸ 1ì–µ ë‹¬ëŸ¬ë¥¼ ì´í•´í•˜ì‹œëŠ” ë°©ë²•ì€ ëŒ€ë¶€ë¶„ì´, ê±°ì˜ ëŒ€ë¶€ë¶„ì´ ì¬ê³ ì˜€ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ë¶„ëª…íˆ ì €í¬ê°€ 2026ë…„ ì‹¤ì ì— ëŒ€í•´ ìƒë‹¹í•œ í™•ì‹ ì„ ê°€ì§€ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ë„ì›€ì´ ë˜ì…¨ê¸°ë¥¼ ë°”ëë‹ˆë‹¤, Chris.</td></tr>
<tr><td>Operator: Our next question comes from Umer Raffat of Evercore ISI .</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì—ë²„ì½”ì–´ ISIì˜ ìš°ë¨¸ ë¼íŒŸ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Umer Raffat: Evercore ISI Institutional Equities, Research Division If I look at the delta versus consensus this quarter, it looks like it's driven by sales and marketing when I take out the one-timer impact of the milestone. And coincidentally, I feel like this is probably the highest sales and marketing spend quarter we've seen in the last 3 years or so. So I'm curious why that is, especially because it's happening in the middle of the transformation that's underway, number one. Secondly, for '26 guidance, is it fair to say that the Royalty Pharma $75 million payment for Phase IIb is embedded within the EBITDA? And is there any other milestones that are baked into the EBITDA guidance as well from TL1A or anything else? And then finally, on vitiligo, OPZELURA obviously has not necessarily done too well, but as Eric pointed out, has limited coverage. But is it fair to say that on the scores like OPZELURA showing about 30% facial VASI75 score, you would want to be tracking meaningfully north considering Royalty Pharma is all excited and they're not funding celiac only doing vitiligo. I'm just curious about your overall take on expectations.</td><td>**Umer Raffat:** ì´ë²ˆ ë¶„ê¸° ì»¨ì„¼ì„œìŠ¤ ëŒ€ë¹„ ì°¨ì´ë¥¼ ë³´ë©´, ë§ˆì¼ìŠ¤í†¤ì˜ ì¼íšŒì„± ì˜í–¥ì„ ì œì™¸í–ˆì„ ë•Œ íŒë§¤ ë° ë§ˆì¼€íŒ… ë¶€ë¬¸ì—ì„œ ë°œìƒí•œ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê³µêµë¡­ê²Œë„ ì´ë²ˆ ë¶„ê¸°ê°€ ì§€ë‚œ 3ë…„ ì •ë„ ì¤‘ì—ì„œ íŒë§¤ ë° ë§ˆì¼€íŒ… ì§€ì¶œì´ ê°€ì¥ ë†’ì•˜ë˜ ë¶„ê¸°ì¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ì´ìœ ê°€ ê¶ê¸ˆí•œë°, íŠ¹íˆ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ì „í™˜ ê³¼ì •ì˜ í•œê°€ìš´ë°ì„œ ì´ëŸ° ì¼ì´ ë°œìƒí•˜ê³  ìˆë‹¤ëŠ” ì ì´ ì²« ë²ˆì§¸ ì§ˆë¬¸ì…ë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ë¡œ, 26ë…„ ê°€ì´ë˜ìŠ¤ì™€ ê´€ë ¨í•´ì„œ, Royalty Pharmaì˜ Phase IIb ê´€ë ¨ 7,500ë§Œ ë‹¬ëŸ¬ ì§€ê¸‰ì´ EBITDAì— í¬í•¨ë˜ì–´ ìˆë‹¤ê³  ë´ë„ ë˜ëŠ”ì§€ìš”? ê·¸ë¦¬ê³  TL1Aë‚˜ ë‹¤ë¥¸ í•­ëª©ì—ì„œ ë°œìƒí•˜ëŠ” ì¶”ê°€ ë§ˆì¼ìŠ¤í†¤ì´ EBITDA ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆëŠ” ê²ƒì´ ìˆëŠ”ì§€ë„ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ë°±ë°˜ì¦ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. OPZELURAê°€ ì‹¤ì ì´ ê·¸ë‹¤ì§€ ì¢‹ì§€ ì•Šì€ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, Ericì´ ì§€ì í•˜ì‹  ê²ƒì²˜ëŸ¼ ë³´í—˜ ì»¤ë²„ë¦¬ì§€ê°€ ì œí•œì ì´ê¸´ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ OPZELURAê°€ ì•ˆë©´ VASI75 ì ìˆ˜ì—ì„œ ì•½ 30%ë¥¼ ë³´ì´ê³  ìˆëŠ” ìƒí™©ì—ì„œ, ê·€ì‚¬ëŠ” ì´ë³´ë‹¤ ì˜ë¯¸ ìˆê²Œ ë†’ì€ ìˆ˜ì¹˜ë¥¼ ëª©í‘œë¡œ í•˜ê³  ê³„ì‹  ê±´ê°€ìš”? íŠ¹íˆ Royalty Pharmaê°€ ìƒë‹¹íˆ ê¸°ëŒ€ë¥¼ í•˜ê³  ìˆê³ , ì…€ë¦¬ì•…ë³‘ì´ ì•„ë‹Œ ë°±ë°˜ì¦ë§Œ í€ë”©í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ë§ì…ë‹ˆë‹¤. ì „ë°˜ì ì¸ ê¸°ëŒ€ì¹˜ì— ëŒ€í•œ ê²¬í•´ê°€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Umer, thanks for the questions. You got a few into that one question there. So thanks for that. On the sales and marketing and the OpEx, I'll hand that to Eli to talk about.</td><td>**Richard Francis:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì—¬ëŸ¬ ì§ˆë¬¸ì„ í•œ ë²ˆì— í•˜ì…¨ë„¤ìš”. ì˜ì—… ë° ë§ˆì¼€íŒ…ê³¼ ìš´ì˜ë¹„ìš©(OpEx) ê´€ë ¨í•´ì„œëŠ” Eliì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eliyahu Kalif: Executive VP & CFO Okay. Umer. So first of all, about the question about Royalty Pharma, out of the $75 million, the way that we're viewing, it's actually going to spread over '26 and '27 with 1/3 out of the $75 million going to happen in '26. It's more kind of backloaded for '26 year. And that's the only thing that's embedded there. We don't have any other, I would say, assumptions in our EBITDA related to TL1A milestones or anything like that. As far as related to the sales and marketing, if you actually back out the higher revenue due to the milestone, you get to kind of a 15.4% on sales and marketing. But going forward, next year, we're going to see that one actually 16%, and why? Because we are keeping investing in our growth engine, which is AUSTEDO and actually heading to next year, building kind of investment into our olanzapine launch. So we're going to see that one increasing. But all in all, the whole bucket going to be, from a dollar perspective, really kind of flat, but also from a percentage perspective due to the fact that you will see our transformation program going to impact the G&A, as I mentioned to Jason, and that's kind of a reduction in G&A going to split in between the R&D investment and into the sales and marketing.</td><td>**Eliyahu Kalif:** ë„¤, Umer. ë¨¼ì € Royalty Pharma ê´€ë ¨ ì§ˆë¬¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, 7,500ë§Œ ë‹¬ëŸ¬ ì¤‘ì—ì„œ ì‹¤ì œë¡œëŠ” 26ë…„ê³¼ 27ë…„ì— ê±¸ì³ ë¶„ì‚°ë  ì˜ˆì •ì…ë‹ˆë‹¤. 7,500ë§Œ ë‹¬ëŸ¬ ì¤‘ 1/3ì´ 26ë…„ì— ë°œìƒí•  ê²ƒì´ê³ , 26ë…„ë„ì—ëŠ” í›„ë°˜ë¶€ì— ë” ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ê²ƒë§Œ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. TL1A ë§ˆì¼ìŠ¤í†¤ì´ë‚˜ ê·¸ ì™¸ ë‹¤ë¥¸ ê°€ì •ë“¤ì€ EBITDAì— í¬í•¨í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. <br><br>íŒë§¤ ë° ë§ˆì¼€íŒ… ë¹„ìš© ê´€ë ¨í•´ì„œëŠ”, ë§ˆì¼ìŠ¤í†¤ìœ¼ë¡œ ì¸í•œ ë†’ì€ ë§¤ì¶œì„ ì œì™¸í•˜ë©´ ì•½ 15.4% ìˆ˜ì¤€ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë‚´ë…„ì—ëŠ” 16%ë¡œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì´ìœ ëŠ”ìš”? ì„±ì¥ ë™ë ¥ì¸ AUSTEDOì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•˜ê³  ìˆê³ , ì‹¤ì œë¡œ ë‚´ë…„ì„ í–¥í•´ ì˜¬ë€ìí•€ ì¶œì‹œë¥¼ ìœ„í•œ íˆ¬ìë„ ì¤€ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì€ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ì²´ì ìœ¼ë¡œ ë³´ë©´, ê¸ˆì•¡ ì¸¡ë©´ì—ì„œëŠ” ê±°ì˜ ë³€ë™ì´ ì—†ì„ ê²ƒì´ê³ , ë¹„ìœ¨ ì¸¡ë©´ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì œì´ìŠ¨ì—ê²Œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìš°ë¦¬ì˜ í˜ì‹  í”„ë¡œê·¸ë¨ì´ ì¼ë°˜ê´€ë¦¬ë¹„ì— ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¼ë°˜ê´€ë¦¬ë¹„ ì ˆê°ë¶„ì´ R&D íˆ¬ìì™€ ì˜ì—… ë° ë§ˆì¼€íŒ… ë¶€ë¬¸ìœ¼ë¡œ ë‚˜ë‰˜ì–´ ì¬ë°°ë¶„ë  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks, Eli. And look, one thing I'll just add on to the back of that before I hand it over to Eric. If you think about the guidance for this year, the EBITDA range, I think, is showing the value of the programs we put in place, the value of driving our innovative portfolio, the fact that when we talk about our transformation program, it was $700 million of net savings after investing in our growth drivers. And so we've allowed ourselves to make sure that we can drive this innovative portfolio, which helps drive that EBITDA, but at the same time, our efficiency programs help also drive the EBITDA. So I think we're very pleased and proud of the fact that our EBITDA starts with a 5 in front of it, which I think is important. But we're very mindful of how we spend our money and where we allocate our capital. When it comes to vitiligo, I'll hand that over to Eric.</td><td>**Richard Francis:** ê°ì‚¬í•©ë‹ˆë‹¤, Eli. ê·¸ë¦¬ê³  Ericì—ê²Œ ë„˜ê¸°ê¸° ì „ì— í•œ ê°€ì§€ë§Œ ë§ë¶™ì´ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ ê°€ì´ë˜ìŠ¤, íŠ¹íˆ EBITDA ë²”ìœ„ë¥¼ ë³´ì‹œë©´, ìš°ë¦¬ê°€ ì‹œí–‰í•œ í”„ë¡œê·¸ë¨ë“¤ì˜ ê°€ì¹˜, í˜ì‹ ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì¶”ì§„í•˜ëŠ” ê°€ì¹˜ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì „í™˜ í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë•Œ, ì„±ì¥ ë™ë ¥ì— íˆ¬ìí•œ í›„ 7ì–µ ë‹¬ëŸ¬ì˜ ìˆœ ì ˆê°ì•¡ì„ ë‹¬ì„±í–ˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì´ í˜ì‹ ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì¶”ì§„í•  ìˆ˜ ìˆë„ë¡ í–ˆê³ , ì´ê²ƒì´ EBITDA ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ë™ì‹œì—, ìš°ë¦¬ì˜ íš¨ìœ¨ì„± í”„ë¡œê·¸ë¨ ì—­ì‹œ EBITDA ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ EBITDAê°€ 5ë¡œ ì‹œì‘í•œë‹¤ëŠ” ì ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìë¶€ì‹¬ì„ ëŠë¼ê³  ìˆìœ¼ë©°, ì´ëŠ” ì¤‘ìš”í•œ ì˜ë¯¸ë¥¼ ê°–ëŠ”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ìê¸ˆì„ ì–´ë–»ê²Œ ì‚¬ìš©í•˜ê³  ìë³¸ì„ ì–´ë””ì— ë°°ë¶„í• ì§€ì— ëŒ€í•´ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°±ë°˜ì¦ ê´€ë ¨í•´ì„œëŠ” Ericì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eric Hughes: Executive VP of Global R&D and Chief Medical Officer Thank you, Umer, for the question. So when it comes to what data we've seen with the topical out there today and what's in development, I always want to be competitive on any endpoint what you talk about. So hopefully, when we lock the database and get that results, we can show that we're competitive against what's available. But again, let's focus again what patients need. They need systemic therapy that's conveniently given. So it's almost inappropriate to compare it to a topical on 10% of your body. But certainly, we hope to be competitive.</td><td>**Eric Hughes:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Umer. í˜„ì¬ ì‹œì¥ì— ë‚˜ì™€ ìˆê±°ë‚˜ ê°œë°œ ì¤‘ì¸ êµ­ì†Œ ì¹˜ë£Œì œ ë°ì´í„°ì™€ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ìë©´, ì €ëŠ” ì–´ë–¤ ì—”ë“œí¬ì¸íŠ¸(endpoint)ì—ì„œë“  ê²½ìŸë ¥ì„ ê°–ì¶”ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë°ì´í„°ë² ì´ìŠ¤ë¥¼ ì ê·¸ê³  ê²°ê³¼ë¥¼ í™•ë³´í•˜ë©´, í˜„ì¬ ì´ìš© ê°€ëŠ¥í•œ ì¹˜ë£Œì œë“¤ê³¼ ë¹„êµí•´ì„œ ê²½ìŸë ¥ì´ ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ë“œë¦´ ìˆ˜ ìˆê¸°ë¥¼ ë°”ëë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¤ì‹œ í•œë²ˆ í™˜ìë“¤ì´ ì‹¤ì œë¡œ í•„ìš”ë¡œ í•˜ëŠ” ê²ƒì— ì§‘ì¤‘í•´ì•¼ í•©ë‹ˆë‹¤. í™˜ìë“¤ì€ í¸ë¦¬í•˜ê²Œ íˆ¬ì—¬í•  ìˆ˜ ìˆëŠ” ì „ì‹  ì¹˜ë£Œì œ(systemic therapy)ê°€ í•„ìš”í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì²´í‘œë©´ì˜ 10%ë§Œ ì¹˜ë£Œí•˜ëŠ” êµ­ì†Œ ì¹˜ë£Œì œì™€ ë¹„êµí•˜ëŠ” ê²ƒì€ ì‚¬ì‹¤ìƒ ì ì ˆí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ” ê²½ìŸë ¥ì„ ê°–ì¶”ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Les Sulewski of Truist.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Truistì˜ Les Sulewskië¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Leszek Sulewski: Truist Securities, Inc., Research Division Congrats on the progress. I just wanted to focus on the biosimilars side. So what's the launch cadence and expected profitability profile, particularly given the U.S. channel and PBM dynamics? And then what are the prerequisites for targeting the 10 new products beyond 2028? And you've previously evaluated or mentioned reevaluating BD within the space. So what type of, whether it's in-licensing, co-development or tuck-ins fits your leverage and margin profile today? And has that bar changed given the latest policy dynamics?</td><td>**Leszek Sulewski:** ì§„ì „ ìƒí™©ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ë¶€ë¬¸ì— ì§‘ì¤‘í•´ì„œ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. íŠ¹íˆ ë¯¸êµ­ ìœ í†µ ì±„ë„ê³¼ PBM ì—­í•™ì„ ê³ ë ¤í–ˆì„ ë•Œ, ì¶œì‹œ ì¼ì •ê³¼ ì˜ˆìƒ ìˆ˜ìµì„± í”„ë¡œí•„ì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”? ê·¸ë¦¬ê³  2028ë…„ ì´í›„ 10ê°œì˜ ì‹ ì œí’ˆì„ ëª©í‘œë¡œ í•˜ê¸° ìœ„í•œ ì „ì œ ì¡°ê±´ì€ ë¬´ì—‡ì¸ê°€ìš”? ì´ì „ì— ì´ ë¶„ì•¼ì—ì„œ BDë¥¼ í‰ê°€í•˜ê±°ë‚˜ ì¬í‰ê°€í•œë‹¤ê³  ì–¸ê¸‰í•˜ì…¨ëŠ”ë°, í˜„ì¬ ê·€ì‚¬ì˜ ë ˆë²„ë¦¬ì§€ì™€ ë§ˆì§„ í”„ë¡œí•„ì— ë§ëŠ” ì¸ë¼ì´ì„¼ì‹±, ê³µë™ ê°œë°œ ë˜ëŠ” ì†Œê·œëª¨ ì¸ìˆ˜ ì¤‘ ì–´ë–¤ ìœ í˜•ì´ ì í•©í•œê°€ìš”? ê·¸ë¦¬ê³  ìµœê·¼ ì •ì±… ë³€í™”ë¥¼ ê³ ë ¤í•  ë•Œ ê·¸ ê¸°ì¤€ì´ ë‹¬ë¼ì¡Œë‚˜ìš”?</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks for the questions. So talking about biosimilars, yes, it's an exciting time. And I think the fact that we built the second largest portfolio and continue to add to it in such a short space of time is a testament to the prioritization we put behind it. But to sort of give you a bit of specifics and -- when we talk about -- we have 10 in the market now, we have 6 to launch between now and '27. Those 6 -- majority of those will be across both U.S. and Europe, which is important because we haven't actually had a presence in Europe of any significance. And we know that market is a market with quicker uptake, more predictability and some very clear returns. So excited about that. And to name just a few, we have biosimilar Prolia, biosimilar Xgeva, biosimilar Simponi, biosimilar Eylea and biosimilar Xolair. So we have a lot coming through of those markets and most of those are in both. I think it's Simponi that's just in the U.S. Now you highlighted the 10. And you sort of -- in your question, it sounded like we had targeted 10. No, we have 10. They are in our pipeline. But we're just going to add to that. So we have 10, which is why I said we can start launching '28 onwards, but we are continually adding to that. And the final part of your question is doing this through partnerships, how does that work out in gross margin. So we are going to continue doing it through partnerships, and it still is attractive from a gross margin point of view with the right partnership. It's still accretive to our business, our generics business significantly. So that's how we do it. And you'll probably start to see some deals coming through already in the first half of this year as we already build out this portfolio beyond the '26. So -- and then the final thing I'll add on that, this biosimilar portfolio is coming through thick and fast, and that's going to really help us drive the generics business going forward, both in Europe and in the U.S. But thanks for your question.</td><td>**Richard Francis:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë°”ì´ì˜¤ì‹œë°€ëŸ¬ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì •ë§ í¥ë¯¸ì§„ì§„í•œ ì‹œê¸°ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì´ë ‡ê²Œ ì§§ì€ ì‹œê°„ ì•ˆì— ì—…ê³„ ë‘ ë²ˆì§¸ë¡œ í° í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í•˜ê³  ê³„ì† í™•ì¥í•˜ê³  ìˆë‹¤ëŠ” ì‚¬ì‹¤ ìì²´ê°€ ìš°ë¦¬ê°€ ì´ ë¶„ì•¼ì— ì–¼ë§ˆë‚˜ ìš°ì„ ìˆœìœ„ë¥¼ ë‘ê³  ìˆëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ì‹œì¥ì— 10ê°œ ì œí’ˆì´ ë‚˜ì™€ ìˆê³ , ì§€ê¸ˆë¶€í„° 2027ë…„ê¹Œì§€ 6ê°œë¥¼ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ 6ê°œ ì œí’ˆ ì¤‘ ëŒ€ë¶€ë¶„ì€ ë¯¸êµ­ê³¼ ìœ ëŸ½ ì–‘ìª½ ì‹œì¥ì—ì„œ ì¶œì‹œë  ê²ƒì¸ë°, ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ì˜ë¯¸ë¥¼ ê°–ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ìš°ë¦¬ê°€ ìœ ëŸ½ì—ì„œ ì˜ë¯¸ ìˆëŠ” ì…ì§€ë¥¼ ê°€ì ¸ë³¸ ì ì´ ì‚¬ì‹¤ìƒ ì—†ì—ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ìœ ëŸ½ ì‹œì¥ì´ ë” ë¹ ë¥¸ ë„ì…ë¥ ê³¼ ë” ë†’ì€ ì˜ˆì¸¡ê°€ëŠ¥ì„±, ê·¸ë¦¬ê³  ë§¤ìš° ëª…í™•í•œ ìˆ˜ìµì„ ì œê³µí•˜ëŠ” ì‹œì¥ì´ë¼ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì— ëŒ€í•´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. ëª‡ ê°€ì§€ë§Œ ë§ì”€ë“œë¦¬ë©´, í”„ë¡¤ë¦¬ì•„ ë°”ì´ì˜¤ì‹œë°€ëŸ¬, ì—‘ìŠ¤ì§€ë°” ë°”ì´ì˜¤ì‹œë°€ëŸ¬, ì‹¬í¬ë‹ˆ ë°”ì´ì˜¤ì‹œë°€ëŸ¬, ì•„ì¼ë¦¬ì•„ ë°”ì´ì˜¤ì‹œë°€ëŸ¬, ê·¸ë¦¬ê³  ì¡¸ë ˆì–´ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ê°€ ìˆìŠµë‹ˆë‹¤. ì´ë“¤ ì‹œì¥ì—ì„œ ë§ì€ ì œí’ˆë“¤ì´ ë‚˜ì˜¬ ì˜ˆì •ì´ê³ , ëŒ€ë¶€ë¶„ì€ ì–‘ìª½ ì‹œì¥ ëª¨ë‘ì— í•´ë‹¹ë©ë‹ˆë‹¤. ì‹¬í¬ë‹ˆë§Œ ë¯¸êµ­ ì‹œì¥ì—ë§Œ í•´ë‹¹ë˜ëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. <br><br>10ê°œë¥¼ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°, ì§ˆë¬¸í•˜ì‹¤ ë•Œ ë§ˆì¹˜ ì €í¬ê°€ 10ê°œë¥¼ ëª©í‘œë¡œ í•œ ê²ƒì²˜ëŸ¼ ë“¤ë ¸ìŠµë‹ˆë‹¤. ì•„ë‹™ë‹ˆë‹¤, ì €í¬ëŠ” ì´ë¯¸ 10ê°œë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ í˜„ì¬ íŒŒì´í”„ë¼ì¸ì— ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ê¸°ì— ê³„ì† ì¶”ê°€í•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ 10ê°œë¥¼ ë³´ìœ í•˜ê³  ìˆê³ , ì´ê²ƒì´ ì œê°€ 2028ë…„ë¶€í„° ì¶œì‹œë¥¼ ì‹œì‘í•  ìˆ˜ ìˆë‹¤ê³  ë§ì”€ë“œë¦° ì´ìœ ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ì†ì ìœ¼ë¡œ ì¶”ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì§ˆë¬¸ì˜ ë§ˆì§€ë§‰ ë¶€ë¶„ì¸ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ ì§„í–‰í•˜ëŠ” ê²ƒì´ ë§¤ì¶œì´ì´ìµë¥ (gross margin)ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ì§€ì— ëŒ€í•´ì„œëŠ”, íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ ê³„ì† ì¶”ì§„í•  ì˜ˆì •ì´ë©°, ì ì ˆí•œ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•œë‹¤ë©´ ë§¤ì¶œì´ì´ìµë¥ (gross margin) ê´€ì ì—ì„œ ì—¬ì „íˆ ë§¤ë ¥ì ì…ë‹ˆë‹¤. ìš°ë¦¬ ì œë„¤ë¦­ ì‚¬ì—…ì— ì—¬ì „íˆ ìƒë‹¹í•œ ê¸ì •ì  ê¸°ì—¬ë¥¼ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ì˜ ë°©ì‹ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë§ˆë„ ì˜¬í•´ ìƒë°˜ê¸°ë¶€í„° ì´ë¯¸ ëª‡ëª‡ ê±°ë˜ë“¤ì´ ë‚˜ì˜¤ëŠ” ê²ƒì„ ë³´ì‹œê²Œ ë  ê²ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¯¸ 26ë…„ ì´í›„ë¥¼ ëŒ€ë¹„í•´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ í•œ ê°€ì§€ ë§ë¶™ì´ìë©´, ë°”ì´ì˜¤ì‹œë°€ëŸ¬ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ë¹ ë¥´ê²Œ í™•ëŒ€ë˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ìœ ëŸ½ê³¼ ë¯¸êµ­ ëª¨ë‘ì—ì„œ ì œë„¤ë¦­ ì‚¬ì—…ì„ ì„±ì¥ì‹œí‚¤ëŠ” ë° í° ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Stevo: Senior Vice President of Investor Relations & Competitive Intelligence Les, could you repeat your BD question, please?</td><td>**Christopher Stevo:** ë ˆìŠ¤, BD ê´€ë ¨ ì§ˆë¬¸ì„ ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Leszek Sulewski: Truist Securities, Inc., Research Division Essentially, I just wanted to get a sense of if there's a potential for you to kind of dive a little bit deeper via BD within the space, if there's anything available out there via partnerships that you've previously had and essentially what's your strategy for that space?</td><td>**Leszek Sulewski:** <Korean><br><br>ê¸°ë³¸ì ìœ¼ë¡œ ì œê°€ ì•Œê³  ì‹¶ì€ ê²ƒì€, ì´ ë¶„ì•¼ì—ì„œ BDë¥¼ í†µí•´ ì¢€ ë” ê¹Šì´ ë“¤ì–´ê°ˆ ê°€ëŠ¥ì„±ì´ ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ì´ì „ì— ë§ºì—ˆë˜ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ í™œìš© ê°€ëŠ¥í•œ ê²ƒì´ ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ë³¸ì§ˆì ìœ¼ë¡œ ì´ ë¶„ì•¼ì— ëŒ€í•œ ê·€ì‚¬ì˜ ì „ëµì´ ë¬´ì—‡ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br></Korean></td></tr>
<tr><td>Christopher Stevo: Senior Vice President of Investor Relations & Competitive Intelligence Sorry, are you asking about biosimilars?</td><td>**Christopher Stevo:** ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ, ë°”ì´ì˜¤ì‹œë°€ëŸ¬ì— ëŒ€í•´ ì§ˆë¬¸í•˜ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Richard Francis: President, CEO & Director Yes. So that's what I thought. So that's -- I think I answered that question, Les. We'll continue to do the partnerships. Some of those we already have good, big partnerships with companies that we think we can have the potential to expand those, whether that's mAbxience, whether that's Samsung. So I think we're looking at expanding. But also we have other companies that have approached us to be their partner because obviously, the performance we've had in the U.S. has been impressive. We have the fastest-growing biosimilar Humira. We have a very fast-growing business now in the U.S. So I think people are seeing that. But yes, it will be through partnerships, the majority of it.</td><td>**Richard Francis:** ë„¤, ì œ ìƒê°ì´ ë§ì•˜ë„¤ìš”. ë ˆìŠ¤, ê·¸ ì§ˆë¬¸ì— ëŒ€í•´ì„œëŠ” ë‹µë³€ì„ ë“œë¦° ê²ƒ ê°™ìŠµë‹ˆë‹¤. íŒŒíŠ¸ë„ˆì‹­ì€ ê³„ì† ì¶”ì§„í•  ê²ƒì…ë‹ˆë‹¤. ì´ë¯¸ ìš°ë¦¬ê°€ í™•ì¥ ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ë³´ëŠ” íšŒì‚¬ë“¤ê³¼ ì¢‹ì€ ëŒ€í˜• íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºê³  ìˆìŠµë‹ˆë‹¤. mAbxienceë“  ì‚¼ì„±ì´ë“  ë§ì´ì£ . ê·¸ë˜ì„œ í™•ì¥ì„ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë‹¤ë¥¸ íšŒì‚¬ë“¤ë„ ìš°ë¦¬ì—ê²Œ íŒŒíŠ¸ë„ˆê°€ ë˜ê³  ì‹¶ë‹¤ê³  ì ‘ê·¼í•´ ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ìš°ë¦¬ê°€ ë³´ì—¬ì¤€ ì„±ê³¼ê°€ ì¸ìƒì ì´ì—ˆê¸° ë•Œë¬¸ì´ì£ . ìš°ë¦¬ëŠ” ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ë°”ì´ì˜¤ì‹œë°€ëŸ¬ íœ´ë¯¸ë¼ë¥¼ ë³´ìœ í•˜ê³  ìˆê³ , í˜„ì¬ ë¯¸êµ­ì—ì„œ ë§¤ìš° ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì‚¬ì—…ì„ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ëŒë“¤ì´ ê·¸ê±¸ ë³´ê³  ìˆëŠ” ê±°ì£ . í•˜ì§€ë§Œ ë„¤, ëŒ€ë¶€ë¶„ì€ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ ì´ë£¨ì–´ì§ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Dennis Ding of Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì œí”„ë¦¬ìŠ¤ì˜ ë°ë‹ˆìŠ¤ ë”©ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Yuchen Ding: Jefferies LLC, Research Division I had 2, if I may. Number one, sort of a big picture question on R&D. What is your R&D philosophy at Teva? And I guess how much derisking do you think we'll get around the R&D platform from the data readouts this year? I'm also curious what else could be planned for 2027 as you advance some of these newer drugs forward? And then number two, just a question around BD. I'm curious as you transition to a novel biopharma company, if your BD philosophy has changed at all and if Teva might be interested in doing acquisitions in, let's say, the classic biotech space rather than what's historically been spec pharma.</td><td>**Yuchen Ding:** ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” R&Dì— ê´€í•œ í° ê·¸ë¦¼ì˜ ì§ˆë¬¸ì…ë‹ˆë‹¤. Tevaì˜ R&D ì² í•™ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì˜¬í•´ ë°ì´í„° ê²°ê³¼ ë°œí‘œë¥¼ í†µí•´ R&D í”Œë«í¼ì˜ ë¦¬ìŠ¤í¬ê°€ ì–¼ë§ˆë‚˜ í•´ì†Œë  ê²ƒìœ¼ë¡œ ë³´ì‹­ë‹ˆê¹Œ? ë˜í•œ ì´ëŸ¬í•œ ì‹ ì•½ë“¤ì„ ì§„ì „ì‹œí‚¤ë©´ì„œ 2027ë…„ì— ì¶”ê°€ë¡œ ê³„íšëœ ê²ƒì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ì‚¬ì—…ê°œë°œ(BD)ì— ê´€í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤. í˜ì‹  ë°”ì´ì˜¤ì œì•½ íšŒì‚¬ë¡œ ì „í™˜í•˜ë©´ì„œ BD ì² í•™ì— ë³€í™”ê°€ ìˆì—ˆëŠ”ì§€, ê·¸ë¦¬ê³  Tevaê°€ ê¸°ì¡´ì˜ ìŠ¤í˜ì…œí‹° ì œì•½ì´ ì•„ë‹Œ ì „í†µì ì¸ ë°”ì´ì˜¤í… ë¶„ì•¼ì—ì„œ ì¸ìˆ˜í•©ë³‘ì— ê´€ì‹¬ì´ ìˆìœ¼ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks, Dennis. Thanks for the question. I'll tag team that with Eric and maybe start on the philosophy of R&D or maybe we call it the strategy.</td><td>**Richard Francis:** ê°ì‚¬í•©ë‹ˆë‹¤, Dennis. ì§ˆë¬¸ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. Ericê³¼ í•¨ê»˜ ë‹µë³€ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € R&D ì² í•™, ë˜ëŠ” ì „ëµì´ë¼ê³  í•  ìˆ˜ ìˆëŠ” ë¶€ë¶„ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eric Hughes: Executive VP of Global R&D and Chief Medical Officer Yes. No, thank you for the question, Dennis. And this is a very important question. And I think that the philosophy in the way that we operate at Teva is we are ruthlessly driven by data. We have, first and foremost, a pipeline in Phase III and Phase II that's relatively derisked. I think emrusolmin is probably the lowest on the probability of success. But when you think about our programs, we use known science, we combine it in a way that will execute well and quickly with regulatory approvals. And that's based and driven solely on data. One of the things I've noticed and been able to achieve here at Teva is when we see data, we pivot and we move forward with it. That's something I hadn't been able to do in my career in other places. So speed and execution driven by data with this philosophy of known science and derisked assets is how we will move forward. I think that's baked into every one of our programs at this point.</td><td>**Eric Hughes:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Dennis. ì´ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤. í…Œë°”ì—ì„œ ìš°ë¦¬ê°€ ìš´ì˜í•˜ëŠ” ì² í•™ê³¼ ë°©ì‹ì€ ì² ì €í•˜ê²Œ ë°ì´í„°ì— ì˜í•´ ì›€ì§ì¸ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ì„  3ìƒê³¼ 2ìƒ íŒŒì´í”„ë¼ì¸ì€ ìƒëŒ€ì ìœ¼ë¡œ ìœ„í—˜ì´ ì œê±°ëœ ìƒíƒœì…ë‹ˆë‹¤. emrusolminì´ ì•„ë§ˆë„ ì„±ê³µ í™•ë¥ ì´ ê°€ì¥ ë‚®ì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ í”„ë¡œê·¸ë¨ë“¤ì„ ë³´ë©´, ìš°ë¦¬ëŠ” ê²€ì¦ëœ ê³¼í•™ì„ í™œìš©í•˜ê³ , ì´ë¥¼ ê·œì œ ìŠ¹ì¸ì„ ì‹ ì†í•˜ê³  íš¨ê³¼ì ìœ¼ë¡œ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ë°©ì‹ìœ¼ë¡œ ê²°í•©í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ì „ì ìœ¼ë¡œ ë°ì´í„°ì— ê¸°ë°˜í•˜ê³  ë°ì´í„°ì— ì˜í•´ ì¶”ì§„ë©ë‹ˆë‹¤.<br><br>ì œê°€ í…Œë°”ì—ì„œ ì£¼ëª©í•˜ê³  ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆë˜ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ”, ë°ì´í„°ë¥¼ ë³´ë©´ ì¦‰ì‹œ ë°©í–¥ì„ ì „í™˜í•˜ê³  ê·¸ê²ƒì„ ê°€ì§€ê³  ì•ìœ¼ë¡œ ë‚˜ì•„ê°„ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ê²ƒì€ ì œê°€ ë‹¤ë¥¸ ê³³ì—ì„œì˜ ê²½ë ¥ ë™ì•ˆì—ëŠ” í•  ìˆ˜ ì—†ì—ˆë˜ ê²ƒì…ë‹ˆë‹¤. <response><br><br>ì†ë„ì™€ ì‹¤í–‰ë ¥ì„ ë°ì´í„°ë¡œ ë’·ë°›ì¹¨í•˜ê³ , ê²€ì¦ëœ ê³¼í•™ê³¼ ë¦¬ìŠ¤í¬ê°€ ì œê±°ëœ ìì‚°ì´ë¼ëŠ” ì² í•™ì„ ë°”íƒ•ìœ¼ë¡œ ë‚˜ì•„ê°ˆ ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì ‘ê·¼ ë°©ì‹ì´ í˜„ì¬ ìš°ë¦¬ì˜ ëª¨ë“  í”„ë¡œê·¸ë¨ì— ë‚´ì¬ë˜ì–´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Richard Francis: President, CEO & Director Thanks, Eric. And then to move on to your next question, you said what about BD and as we pivot into a biopharma company. So firstly, thank you for the recognition that we are pivoting. And I think we pivoted. But anyway, we'll keep showing that with the pipeline as it comes out. But yes, we are actively looking at BD. We think we have a commercial powerhouse of the team. I think you've seen that with the results of AUSTEDO, UZEDY and AJOVY. And so we want to add to that team. Now that said, we have, as Eric highlighted, a really exciting pipeline. So the organic growth we have coming through is impressive. So we're not desperate to do BD. We don't have to. At the same time, it fits into our TA areas of CNS neurology and immunology, then I think it's very synergistic, and it makes a lot of sense. So we are very active in that. What is interesting, I think, within the last year to 18 months, the amount of approaches we've had has significantly increased. And I think that's because they see Teva as a partner both from an R&D perspective, the speed which we move things through the clinic is exciting, but also primarily because of the commercial capability and muscle we have and the focus we give assets when we have an asset, whether it's in development, we focus and we move it quickly, whether it's in the market, we focus and we actually drive sales. So I think we'll hopefully be able to talk about some things going forward, but we are very disciplined in our capital allocation, and we think it's the right asset at the right time at the right price, we'll definitely do it. But because of the pipeline we have that's coming through, we can stick to that in a very disciplined way, and we will because going back to that fourth pillar of the Pivot to Growth strategy, it's about focused capital allocation, making sure we give a good return on that in the short, medium and long term and create value for shareholders. So thanks for your question, Dennis. And I think with that, I think that is the final question. We went over a bit, but I think we did start a couple of minutes late. So thank you for your questions and your interest in Teva, and I look forward to following this up later with our Q1 results. Thank you.</td><td>**Richard Francis:** ê°ì‚¬í•©ë‹ˆë‹¤, Eric. ë‹¤ìŒ ì§ˆë¬¸ì¸ ë°”ì´ì˜¤íŒŒë§ˆ ê¸°ì—…ìœ¼ë¡œì˜ ì „í™˜ê³¼ ê´€ë ¨í•œ BDì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì €í¬ê°€ ì „í™˜í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ì¸ì •í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì‚¬ì‹¤ ì €í¬ëŠ” ì´ë¯¸ ì „í™˜í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤ë§Œ, ì•ìœ¼ë¡œ ë‚˜ì˜¬ íŒŒì´í”„ë¼ì¸ì„ í†µí•´ ê³„ì† ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>ë„¤, ì €í¬ëŠ” ì ê·¹ì ìœ¼ë¡œ BDë¥¼ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê°•ë ¥í•œ ìƒì—…í™” ì¡°ì§ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. AUSTEDO, UZEDY, AJOVYì˜ ì‹¤ì ì„ í†µí•´ ì´ë¯¸ í™•ì¸í•˜ì…¨ì„ ê²ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ì¡°ì§ì— ë” ë§ì€ ì œí’ˆì„ ì¶”ê°€í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. <br><br>ë‹¤ë§Œ Ericì´ ê°•ì¡°í–ˆë“¯ì´, ì €í¬ëŠ” ë§¤ìš° í¥ë¯¸ë¡œìš´ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‚´ë¶€ì ìœ¼ë¡œ ì°½ì¶œë˜ëŠ” ì„±ì¥ ë™ë ¥ì´ ì¸ìƒì ì…ë‹ˆë‹¤. ë”°ë¼ì„œ BDë¥¼ ë°˜ë“œì‹œ í•´ì•¼ í•˜ëŠ” ì ˆë°•í•œ ìƒí™©ì€ ì•„ë‹™ë‹ˆë‹¤. ê¼­ í•„ìš”í•œ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ë™ì‹œì— ìš°ë¦¬ì˜ ì¹˜ë£Œ ì˜ì—­ì¸ ì¤‘ì¶”ì‹ ê²½ê³„(CNS) ì‹ ê²½í•™ê³¼ ë©´ì—­í•™ì— ë¶€í•©í•œë‹¤ë©´ ë§¤ìš° ì‹œë„ˆì§€ê°€ ìˆê³  ì¶©ë¶„íˆ ì˜ë¯¸ê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì´ ë¶€ë¶„ì—ì„œ ë§¤ìš° ì ê·¹ì ìœ¼ë¡œ ì›€ì§ì´ê³  ìˆìŠµë‹ˆë‹¤. í¥ë¯¸ë¡œìš´ ì ì€ ì§€ë‚œ 1ë…„ì—ì„œ 1ë…„ ë°˜ ì‚¬ì´ì— ìš°ë¦¬ì—ê²Œ ë“¤ì–´ì˜¤ëŠ” ì œì•ˆì´ í¬ê²Œ ì¦ê°€í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” í…Œë°”ë¥¼ íŒŒíŠ¸ë„ˆë¡œ ë³´ëŠ” ì‹œê°ì´ ìƒê²¼ê¸° ë•Œë¬¸ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. R&D ê´€ì ì—ì„œ ìš°ë¦¬ê°€ ì„ìƒì„ ì§„í–‰í•˜ëŠ” ì†ë„ê°€ ë§¤ë ¥ì ì´ê¸°ë„ í•˜ì§€ë§Œ, ë¬´ì—‡ë³´ë‹¤ ìš°ë¦¬ê°€ ë³´ìœ í•œ ìƒì—…í™” ì—­ëŸ‰ê³¼ í˜, ê·¸ë¦¬ê³  ìì‚°ì— ëŒ€í•œ ì§‘ì¤‘ë ¥ ë•Œë¬¸ì…ë‹ˆë‹¤. ê°œë°œ ë‹¨ê³„ì— ìˆë“  ì‹œì¥ì— ì¶œì‹œë˜ì–´ ìˆë“ , ìš°ë¦¬ëŠ” ìì‚°ì„ í™•ë³´í•˜ë©´ ì§‘ì¤‘í•´ì„œ ë¹ ë¥´ê²Œ ì›€ì§ì´ê³ , ì‹œì¥ì—ì„œëŠ” ì§‘ì¤‘í•´ì„œ ì‹¤ì œë¡œ ë§¤ì¶œì„ ê²¬ì¸í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ê°€ì§€ ì‚¬í•­ë“¤ì— ëŒ€í•´ ë§ì”€ë“œë¦´ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤ë§Œ, ì €í¬ëŠ” ìë³¸ ë°°ë¶„ì— ìˆì–´ ë§¤ìš° ì—„ê²©í•œ ì›ì¹™ì„ ê³ ìˆ˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì ì ˆí•œ ì‹œê¸°ì— ì ì ˆí•œ ê°€ê²©ìœ¼ë¡œ ì ì ˆí•œ ìì‚°ì„ í™•ë³´í•  ìˆ˜ ìˆë‹¤ë©´ ë¶„ëª…íˆ ì‹¤í–‰í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ íŒŒì´í”„ë¼ì¸ì´ ìˆê¸° ë•Œë¬¸ì—, ì €í¬ëŠ” ë§¤ìš° ê·œìœ¨ ìˆëŠ” ë°©ì‹ìœ¼ë¡œ ì´ë¥¼ ê³ ìˆ˜í•  ìˆ˜ ìˆê³  ë˜ ê·¸ë ‡ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì„±ì¥ ì „í™˜ ì „ëµ(Pivot to Growth strategy)ì˜ ë„¤ ë²ˆì§¸ ì¶•ì¸ ì§‘ì¤‘ì  ìë³¸ ë°°ë¶„ìœ¼ë¡œ ëŒì•„ê°€ëŠ” ê²ƒì´ë©°, ë‹¨ê¸°, ì¤‘ê¸°, ì¥ê¸°ì ìœ¼ë¡œ ì¢‹ì€ ìˆ˜ìµì„ ì°½ì¶œí•˜ê³  ì£¼ì£¼ ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Dennis. ì´ê²ƒìœ¼ë¡œ ë§ˆì§€ë§‰ ì§ˆë¬¸ì´ì—ˆë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì‹œê°„ì„ ì¡°ê¸ˆ ì´ˆê³¼í–ˆì§€ë§Œ, ì‹œì‘ë„ ëª‡ ë¶„ ëŠ¦ì—ˆìœ¼ë‹ˆ ì–‘í•´ ë¶€íƒë“œë¦½ë‹ˆë‹¤. <budget><br><br>ì§ˆë¬¸ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦¬ê³  Tevaì— ê´€ì‹¬ ê°€ì ¸ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 1ë¶„ê¸° ì‹¤ì  ë°œí‘œ ë•Œ ë‹¤ì‹œ ëµ™ê¸°ë¥¼ ê¸°ëŒ€í•˜ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br></budget></td></tr>
<tr><td>Operator: Thank you all for joining today's call. You may now disconnect your lines.</td><td>**Operator:** ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Teva Pharmaceutical ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì„±ê³¼ ë° ê°€ì´ë˜ìŠ¤<br>- **AUSTEDO 2026ë…„ ê°€ì´ë˜ìŠ¤**: ì¬ê³  ì¶•ì  íš¨ê³¼($100M, ëŒ€ë¶€ë¶„ ì¬ê³  ìš”ì¸) ì œì™¸ ì‹œ 11~18% ì„±ì¥ ì˜ˆìƒ, 2027ë…„ $2.5B ëª©í‘œ ìœ ì§€<br>- **2026ë…„ ì „ë§**: ë§¤ì¶œì´ì´ìµë¥  54.5~55.5%, ì˜ì—…ë¹„ìš© ë¹„ìœ¨ 27~28% ìœ ì§€, EBITDAëŠ” 5ë¡œ ì‹œì‘í•˜ëŠ” ìˆ˜ì¤€ ë‹¬ì„±<br>- **TRx ì„±ì¥ ëª¨ë©˜í…€**: AUSTEDO XR ì‹ ê·œ ì²˜ë°© 60% ì°¨ì§€, ë°€ë¦¬ê·¸ë¨ ê¸°ì¤€ 19% ì„±ì¥, UZEDYëŠ” ê°•ë ¥í•œ TRx ì„±ì¥ì„¸ ì§€ì†<br><br>## íŒŒì´í”„ë¼ì¸ ë° R&D ì „ëµ<br>- **ì™¸ë¶€ ê²€ì¦ ì™„ë£Œ**: 5ê°œ ì£¼ìš” í”„ë¡œê·¸ë¨ ì¤‘ 4ê°œê°€ ì™¸ë¶€ íŒŒíŠ¸ë„ˆì‹­ ì²´ê²° (Sanofi, Royalty Pharma, Abingworth ë“±)<br>- **TL1A í•­ì²´(duvakitug)**: ìµœê³  íš¨ëŠ¥ ë° ì„ íƒì„±, ë‚®ì€ í•­ì•½ë¬¼í•­ì²´(3~5%) ë³´ìœ , 2026ë…„ ìƒë°˜ê¸° ìœ ì§€ìš”ë²• ë°ì´í„° ê³µê°œ ì˜ˆì •<br>- **IL-15 í•­ì²´**: ë°±ë°˜ì¦ 1bìƒ ê²°ê³¼ 2026ë…„ ìƒë°˜ê¸° ë°œí‘œ, 3ê°œì›” 1íšŒ í”¼í•˜ì£¼ì‚¬ë¡œ ì „ì‹  ì¹˜ë£Œ ê°€ëŠ¥ì„±, 2031ë…„ ì¶œì‹œ ê²½ë¡œ ì¶”ì§„ ì¤‘<br><br>## ê²½ì˜ì§„ í†¤ ë° ì „ëµì  ë°©í–¥<br>- **ìì‹ ê° í‘œì¶œ**: "ì„¸ê³„ì  ìˆ˜ì¤€ì˜</p>
    <hr style="margin:50px 0;">
    
</body></html>